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Studies have shown an increasing use of herbal medicines alongside conventional drugs by 
patients in their disease management especially for chronic diseases, with the attendant risks 
of herb-drug interactions. In order to forestall this, adequate information about the 
pharmacological and toxicological profile of herbal medicines and how these would in turn 
affect the bioavailability of the co-administered drug is required.  
To evaluate potential herb-drug interactions that could occur in diabetes management in 
Nigeria- (a) An assessment of available data on the pharmacological and toxicological 
effects of plants used in diabetes management was conducted as a means of mapping those 
with identified potential risks for herb-drug interactions; (b) A field work study was carried 
out in different localities in Nigeria to identify potential pharmacokinetic interactions based 
on the prescription drugs and herbal medicines co-administered by diabetic patients; and (c) 
Experimental analysis of plant samples collected during the field work was done to assess 
their effects on known cell detoxification mechanisms and pharmacokinetic parameters.  
The results of the research have confirmed the continued use of a wide range of medicinal 
plants in diabetes management, many of which have not been thoroughly investigated. In 
addition, 50% of diabetic patients visiting healthcare facilities in Nigeria routinely manage 
their diabetes or existing co-morbidities with herbal medicines alongside prescription drugs. 
Even more worrying is the frequent use of unlabeled herbal preparations which would 
constitute a huge challenge in the proper identification of herb-drug interactions when they 
occur. Based on previously available data and the experimental results of this research, a 
number of these herbal medicines have been identified as having overlapping interactions 
with prescription drugs. There is therefore a need for better regulation of herbal medicine 
use alongside pharmacovigilance monitoring in Nigeria in order to forestall the occurrence 
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1 GENERAL INTRODUCTION 
  
 1.1 HISTORY OF THE USE OF HERBAL MEDICINE AND THE 
INCIDENCE OF HERB-DRUG INTERACTIONS 
The findings from excavations of skeletons from the Neanderthal period indicates that 
knowledge of the medicinal properties of plants dates to as far back as approximately 60,000 
years ago (Solecki, 1975). Written records have also shown that physicians of the ancient 
world utilized botanical medicines for their disease management. These have been 
mentioned in several medical works of historical significance including the Sushrita 




 centuries; the Egyptian 
medical manuscript Ebers Papyrus, a comprehensive compendium of drugs and 
prophylactics derived from animal, plant and mineral sources written about 552 B.C; and 
Chinese medical texts written as early as 3000 years B.C. (Oubré et al., 1997). 
Herbal medicine practice continued to flourish until the 17
th
 century. In the 18
th
 century, its 
use began to decline in favour of the more ‘scientific’ pharmacological remedies (Trevelyan, 
1993). In the early 1800’s, Friedrich Sertűrner isolated the first pharmacologically active 
pure compound, morphine from seeds of the opium poppy plant Papaver somniferum L. 
(Hamilton and Baskett, 2000, Li and Vederas, 2009). Soon after, many herbal-derived 
medicines such as cinchona and digitalis as well as synthetic derivatives of plant-based 
drugs like aspirin were introduced into modern medicine (Saklani and Kutty, 2008).  
For digitalis in particular, Withering transformed it from a family recipe for dropsy 
containing more than twenty substances to a modern drug, after recognising the plant’s slim 
margin of safety as well as the importance of dose (Withering, 1785, Goldman, 2001). This 
recognition of the ease of producing more active and safer drugs from pure compounds 
drove the preference for pharmaceutical companies as sources of medicines for healthcare 
(Rates, 2001). In the early 19
th
 century, scientific methods became more advanced and 
preferred, and the practice of traditional botanical healing was gradually being dismissed as 
‘quackery’ (Winslow and Kroll, 1998). 
The practice of herbal medicine in many countries is based on traditional knowledge of plant 
use by local communities and passed on through several generations, either through oral or 
written forms, and recently through the study of ethnopharmacology (Houghton, 1995). 
Although a large number of conventional drugs are based on herbal medicines, the main 
difference between the two is that the latter contains a large number of chemicals (consisting 
of both primary and secondary metabolites) rather than a single pharmacologically active 
substance, which act on one another to moderate, oppose or enhance an effect (Edwards et 
al., 2012).  
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Different pharmaceutical tragedies in the 1950’s such as the use of thalidomide during 
pregnancy coupled with advances in scientific knowledge about natural products and its 
perceived lack of side effects rekindled consumers’ interest in herbal medicines (Brantley et 
al., 2014). For Africa in particular, economic circumstances made imported techniques and 
drugs less accessible, thereby pressurizing the authorities to consider the possibility of 
utilising the hitherto abandoned traditional medicine to improve the health situation. As a 
result, the African regional committee of the World Health Assembly in its twenty-sixth 
session in 1976 passed a resolution inviting member states to ‘take appropriate steps to 
ensure the use of essential drugs and medicinal plants of the traditional pharmacopoeia so as 
to meet the basic needs of communities and ensure the development of the African 
Pharmaceutical industry’ (Bannerman et al., 1983). This formed part of the basis for 
recommendations by the World Health Organization for the use of traditional plant 
medicines in fulfilling the unmet needs of modern healthcare systems (He et al., 2010, 
Trevelyan, 1993).  
Unfortunately, this perceived lack of side effects for herbal medicines compared to 
conventional drugs led to a generalization by the lay public that ‘natural means safe’ 
(Markowitz and Zhu, 2012). Numerous plant-derived products containing biologically active 
phytochemicals became available in different forms for use worldwide. This range from 
non-standardized preparations of plant-derived raw materials to extracts from different plant 
sources available either in encapsulated forms, as tablets or as beverages and tinctures. Some 
extracts have also been included as ingredients in sports/nutrition drinks, powders and 
‘energy’ bars. The fallout of the proliferation of herbal medicine use was that patients began 
to co-administer them alongside their prescription drugs in a bid to obtain the maximal 
therapeutic benefit, often without informing their healthcare practitioners (Bruno and Ellis, 
2005); thereby giving rise to incidences of herb-drug interactions (HDIs). 
HDIs are either pharmacodynamic (PD) or pharmacokinetic (PK) in nature.  For the former, 
this occurs when co-administered herbs and conventional medicines enhance or negate each 
other’s effects as a result of similar or disparate pharmacological activity respectively. PK 
interactions on the other hand arise from the ability of the herb to modulate the absorption, 
distribution, metabolism and/or excretion (ADME) of the drug. Changes in drug absorption 
may be mediated through modulation of intestinal uptake and efflux transporters, while 
changes in metabolism and excretion occur through the modulation of hepatic/renal uptake 
and efflux transporters and/or through inhibition/induction of metabolising enzymes. Altered 
drug distribution as a result of protein binding displacement by herbs has not yet been 
reported (de Lima Toccafondo Vieira and Huang, 2012). 
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Prior to the emergence of reports of clinically relevant HDIs between St John’s Wort 
(Hypericum perforatum L.) and drugs such as digoxin, warfarin, protease inhibitors and oral 
contraceptives; very few herb-drug interactions were documented (Williamson, 2003).  The 
generalization that ‘natural means safe’ soon gave way to the notion that the example of St 
John’s Wort was possibly only the ‘tip of the iceberg’ given the widespread use of herbal 
medicines alongside prescription drugs. This resulted in increased efforts to screen 
numerous herbal medicinal products for potential drug interactions primarily those used by 
‘at risk’ populations such as the elderly and those patients more likely to be on more than 
one prescription drug (‘poly-pharmacy’) (Markowitz and Zhu, 2012).  
Pharmacodynamic herb-drug interactions require a basic pharmacological knowledge about 
the herb and drug, but this is often lacking for the herb. If this information is available 
however, PD HDIs can be more easily predicted and therefore monitored. When herbal 
medicines are known to be pharmacologically active in a particular disease context for 
which other prescription medicines are being taken, caution should be applied with 
monitoring by healthcare practitioners to decipher when this might result in clinically 
relevant HDIs. Synergistic or additive therapeutic efficacy may lead to unfavourable 
toxicities and complicate the dosage regimen of long term medications; while antagonistic 
interactions will result in decreased efficacy and therapeutic failure (Hu et al., 2005).  
In instances of synergistic interactions, these might require an adjustment of the dose of the 
prescription drug. Examples of improved glycaemic control have been shown with the co-
administration of Momordica charantia L. (Karela) with chlopropramide, with suggestions 
of a dose reduction for the latter (Aslam and Stockley, 1979, Leatherdale et al., 1981). This 
is often beneficial as patients especially those taking herbal medicines would be more open 
to the possibility of a dose adjustment with the concurrent use of their herbal medicines. 
However, it is important to note that due to variability in plant sources and contents, the 
pharmacological activity due to the herb may not always be consistent hence the importance 
of strict regulations for standardized herbal medicines. Evidence of a number of identified 
pharmacodynamic HDIs of commonly used herbal medicines with different clinically 
relevant drugs have so far been published (Izzo and Ernst, 2009, Hu et al., 2005, 
Williamson, 2003, Fugh-Berman and Ernst, 2001). 
Pharmacokinetic HDIs are the more difficult to deduce and have so far been the most 
commonly identified and documented form of clinically-relevant HDIs (de Lima 
Toccafondo Vieira and Huang, 2012, Delgoda and Westlake, 2004). The interactions of 
herbs with different pharmacokinetic parameters (transporters and metabolising enzymes) 
are however often not the cause for concern. Given that plants have always been a rich 
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source of food and medicines to man, the expression and activity of the multiplicity of 
transporters and metabolising enzymes present in humans have been phylogenetically 
shaped by man’s exposure to these phytochemicals (Gurley, 2012). It could therefore be 
argued that the synthetic medications themselves are the sources of interference since the 
human pharmacokinetic system has already been pre-conditioned to work with secondary 
products of natural origin (Butterweck et al., 2004). Thus, in the presence of these herbs, 
these interferences result in HDIs. 
The evaluation of these interferences/interactions of new drug entities with different 
pharmacokinetic parameters is actually a crucial aspect of pre-clinical drug discovery, 
ultimately responsible for determining the final clinical success of a drug candidate. This is 
because the ADME properties of drugs need to be pre-determined to ensure acceptable 
clinical efficacy and safety prior to a drug being approved for use (Li, 2001). The 
information is also required for predicting contraindications in drug prescribing by 
healthcare practitioners, thereby avoiding any clinically relevant drug-drug interactions 
(DDIs).  
The biggest challenge in the identification of potential HDIs is that herbal medicines are not 
subject to the same ‘rigid’ pre-clinical or clinical assessments and regulations as those 
carried out with new drug entities (Zhou et al., 2010b). Many herbal medicines are treated as 
‘food supplements’ even though they should not necessarily be regarded as such 
(Williamson, 2003). As a result, potential risks of HDIs are not identified and/or flagged up 
prior to its wide circulation to the unsuspecting public. 
In Europe, efforts have been made to ensure better monitoring of all herbal medicines in 
circulation, either through the issuance of a full product licence (PL), which requires 
sufficient evidence of safety, quality and efficacy, including full clinical trial data; or the 
issuance of a traditional herbal registration (THR) under the Traditional Herbal Medicinal 
Products Directive (2004/24/EC). THRs are issued to herbal medicines indicated for 
relatively minor, self-limiting conditions. For a THR registration to be granted, evidence of 
traditional use of at least thirty years, (fifteen years in the EU), with acceptable levels of 
quality and safety is sufficient and supersedes the need for results of clinical trials (Cox and 
Roche, 2004).  
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1.2 EXPERIMENTAL TARGETS FOR EVALUATING 
PHARMACOKINETIC HERB-DRUG INTERACTIONS 
Herbal medicines share the same drug metabolizing enzymes and drug transporters with 
several clinically important drugs. Thus, current methods for evaluating the 
pharmacokinetics of pharmaceutical drugs have been adapted for the evaluation of herbal 
medicines (Na et al., 2011); and in so doing are useful for predicting potential herb-drug 
interactions. 
More than 400 drug transporters are responsible for the uptake and efflux of drugs, with high 
expression in the epithelia of the intestine, liver, kidney and the blood brain barrier (BBB). 
These exist in two major super families- the Adenosine triphosphate-binding cassette (ABC) 
and the solute carrier (SLC). Seven of these transporters have compelling evidence of their 
involvement in drug absorption and disposition as well as drug interactions. These include 
P-glycoprotein (P-gp), breast cancer resistance protein (BCRP), OAT1, OAT3, OATP1B1 
and OATP1B3 from the organic anion transporter family and OCT2 from the organic cation 
transporter family (Giacomini et al., 2010, Ho and Kim, 2005). Of all the identified HDIs 
involving transporters, P-gp has been the most implicated, thus more focus will be given to 
this transporter in this thesis. 
Drug metabolism has always been a key aspect of drug development as enzymatic 
biotransformation is the principal route for the elimination of most drugs from the body. It is 
also necessary for the activation of some pro-drugs to pharmacologically active entities. The 
metabolising enzymes are divided into two- phase I metabolising enzymes and phase II 
metabolising enzymes. Phase I metabolism comprises metabolic oxidation, reduction and 
hydrolysis, which are catalysed by cytochromes P (CYP) 450s, flavin-containing 
monoxygenases, monoamine oxidase, carboxylesterase, amidase, epoxide hydrolase and 
peroxidase. The CYPs are made up of approximately seventy members in eighteen families 
and are the most important of all the enzymes, catalysing mainly oxidative reactions 
(Pelkonen et al., 2005).  
Phase II metabolism which often follows phase I metabolism, comprises various conjugation 
reactions whereby hydrophilic species are added to the drug molecule to promote 
elimination. These include- glucuronidation catalysed by uridine diphosphoglucuronosyl 
transferases (UGTs), sulfation catalysed by sulfotransferases (SULTs) and glutathione 
conjugation catalysed by glutathione-S-transferases (GSTs). These enzymes are responsible 
for the transfer of sugars, sulfates and sulfhydryls respectively to a wide variety of 
substrates. Methylation and acetylation are also phase II metabolic pathways of elimination 
for some drugs (Gurley, 2012, Markowitz and Zhu, 2012). 
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1.2.1 Herb-Drug interactions involving P-glycoprotein 
P-gp (also known as MDR1; multi-drug resistant protein or ABCB1) is a member of the 
human family of ABC transporters. This family of transporters play a major role in the 
defence of the body against carcinogens and toxins. They do this by the active efflux of 
substrates against their concentration gradient through the hydrolysis of adenosine 
triphosphate (ATP) (Li et al., 2010).  
P-gp is a 170kDa surface glycoprotein and was first observed in cultured cells, which when 
exposed to increasing concentrations of cytotoxic drugs developed resistance to their 
cytotoxic effects (Juliano and Ling, 1976). It was later shown to be present in low levels in 
most tissues but much higher amounts are found on epithelial cells with excretory roles such 
as those of the small intestine as well as many cultured cells of mammalian origin. Its role in 
the intestinal epithelium is the extrusion of certain xenobiotics from the blood to the 
intestinal lumen as well as to prevent drugs in the lumen from entering the bloodstream, 
ultimately resulting in decreased absorption & decreased oral bioavailability (Sharom, 
2011). While intestinal P-gp limits the absorption of xenobiotics, liver and kidney P-gp (and 
indeed other transporters) facilitate their elimination through biliary and urinary excretion 
respectively (Gurley, 2012). 
Due to its localization and function, P-gp interacts with a wide range of structurally diverse 
compounds which are non-polar or weakly amphipatic, including natural products. These 
compounds interact either as P-gp substrates and/or modulators of P-gp activity (inhibitors, 
sensitizers or reversers). There is also an overlap of substrates of P-gp and other drug 
transporters, such as the multidrug resistance associated proteins (MRPs) and the BCRP. 
Blockade of P-gp or disruption of the MDR1 gene facilitates accumulation of these 
substrates within previously resistant cells, leading to increased sensitivity to these drugs 
(Zhou et al., 2004).  
In the small intestine, interactions with P-gp are important in determining the bioavailability 
& subsequent oral dosing of the drug, either singly or in combination with other drugs. It 
also helps in identifying drugs that would be contraindicated, since a co-administration may 
bring about altered plasma concentration levels. ‘Too low’ plasma levels could result in 
decreased efficacy or no efficacy, while ‘too high’ levels could result in increased toxicity.  
Various herbal medicines have been shown to interact with P-gp, some of which have been 
attributed to the presence of identified secondary plant metabolites in the plant. One of such 
plant metabolites is curcumin, a natural polyphenol found in the rhizomes of Curcuma longa 
L. also known as turmeric, a popular spice used in many Asian dishes. It has also been 
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isolated from other Curcuma species except Curcuma zedoaria (Christm.) Roscoe (Hou et 
al., 2008). Curcumin dose-dependently decreased the P-gp mediated efflux and increased the 
cellular accumulation of Rhodamine-123 (Rh-123), a known P-gp substrate in vitro, in both 
primary cultures of rat hepatocytes and in a P-gp over-expressing cell line, KB-V1 cells. 
Western blot analysis showed that this was partly due to decreased expression of protein 
levels of P-gp resulting in the development of an increased resistance to curcumin; as well as 
a direct interaction of curcumin with P-gp (Zhou et al., 2004).  
Similar modulation of P-gp function has been shown in vitro with other metabolites of 
curcumin such as demethoxycurcumin and bisdemethoxycurcumin (Ampasavate et al., 
2010); as well as tetrahydrocurcumin (THC), the main metabolite of curcumin in vivo. THC 
inhibited the function of P-gp and subsequently increased the accumulation of rhodamine 
and calcein-AM in KB-V1 cells but not in wild type cells.  It also showed similar inhibitory 
effects on other ABC drug transporters- multidrug resistance protein 1 (MRP1 or ABCC1) 
and mitoxantrone resistance protein (MXR or ABCG2) (Limtrakul et al., 2007).  
Surprisingly, while curcumin has an inhibitory effect on P-gp, the administration of 
methanol extracts of Curcuma species (C. longa, C. aromatic and C. zedoaria) had the                                                                                                                                                                                        
opposite effect. They all increased Rh-123 efflux dose dependently; as well as enhanced the 
net efflux of [
3
H]-digoxin, another well-known P-gp substrate in Caco-2 monolayers. This 
opposing effect of the curcuma drugs is however not attributed to curcumin since C. 
zedoaria is not known to contain curcumin but showed similar effects with the other 
Curcuma species (Hou et al., 2008). 
Several in vivo studies have been carried out to evaluate the in vitro                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    
P-gp modulatory effects of curcumin. In rats given an oral dose of 60mg/kg of curcumin for 
four days, there was decreased expression of protein levels of P-gp in the small intestine, 
with increased P-gp levels in the liver, while those of the kidney remain unchanged based on 
western blot analysis. Other studies have also shown that decreased P-gp expression levels 
in the small intestine often results in a compensatory over-expression in other organs as seen 
with the liver. Similarly, the pharmacokinetics of 30mg/kg celiprolol (a beta blocker and 
also a P-gp substrate) was also affected with the co-administration of curcumin. The peak 
plasma drug concentration (Cmax) and the area under the concentration time curve (AUC) 
levels were increased, while the systemic clearance was reduced. Similar effects were not 
seen in rats which were pre-administered curcumin only 30mins prior to the administration 
of the celiprolol, indicating that the effect was due to curcumin’s modulation of P-gp 
expression levels (Zhang et al., 2007).  
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The absence of a compensatory effect on the plasma concentration levels of celiprolol 
despite increased P-gp expression in the liver might be because there are no known 
metabolites for the drug (Hartmann et al., 1990), thus only the effects of the increased P-gp 
levels in the small intestine were evidenced in the drug’s bioavailability. Similar increased 
bioavailability has been shown with etoposide, another P-gp substrate when administered 
orally but not with that administered intravenously (Lee et al., 2011); thereby confirming 
curcumin’s modulation of the intestinal absorption of the two drugs due to its inhibitory 
effect on the P-gp efflux pump in the small intestine. 
Paradoxically, when the effect of the P-gp modulatory effects of curcumin was investigated 
in twelve healthy volunteers administered 300mg/day curcumin for six days prior to the oral 
administration of 50mg talinolol (a beta-blocker and another P-gp substrate) on the seventh 
day, decreased bioavailability of talinolol indicated by decreased Cmax and AUC levels; and 
increased renal clearance were observed as opposed to the increased bioavailability seen in 
the experiments with rats.  The authors suggest that this might either be as a result of the up-
regulation of other ABC transporters, since talinolol is also known to be a substrate of 
MRP2 or due to an extensive metabolism of curcumin to other metabolites of unknown P-gp 
effect (Juan et al., 2007). Similar in vivo studies have not been carried out with Curcuma 
drugs to find out what the effects and subsequent clinical implication might be when herbal 
medicines containing whole extracts of Curcuma species containing both curcumin and 
other opposing P-gp modulatory constituents present are co-administered with prescription 
drugs. 
Garlic (Allium sativum L.) is another medicinally used herb that has shown low to moderate 
P-gp inhibtory effects based on the evaluation of various garlic products in vitro (Foster et 
al., 2001). However, decreased bioavailability of the protease inhibitors saquinavir and 
ritonavir were observed with the co-administration of garlic in humans. This might be due to 
the inhibitory effects of garlic on CYP3A4 as both drugs are known substrates of both P-gp 
and CYP3A4 (Zhou et al., 2004). Other herbs that have shown P-gp modulatory effects 
include green tea (Camellia sinensis (L.) Kuntze), grapefruit juice (Citrus paradisi Macfad.), 
milk thistle (Silybum marianum (L.) Gaertn.) piperine from Piper nigrum L. and Piper 
longum L. species and St John’s Wort (SJW). The clinical significance of these interactions 
on the pharmacokinetics of various pharmaceutically important drugs as well as the 
constituents responsible for these interactions have been identified for some of them (He et 
al., 2010, Colalto, 2010, Hu et al., 2005, Zhou et al., 2004, Williamson, 2003). 
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1.2.2 Herb-drug interactions involving Cytochrome P450 enzymes 
Cytochrome enzymes are membrane-bound proteins found in the endoplasmic reticulum of 
hepatocytes and mucousal cells of the gastrointestinal tract (GIT), indicating that the liver 
and the GIT play major roles in drug metabolism. Only a few specific isoforms- CYP1A1/2, 
CYP2A6, CYP2B6, CYP2C8/9/19, CYP2D6, CYP2E1 and CYP3A4/5 from three families 
are however responsible for the bulk of phase 1 metabolism. CYP3A4 is the most important 
as it metabolises around 50% of pharmaceutical drugs in use. Inter-individual variation in 
the expression of CYPs is common, with expression subject to genetic and environmental 
factors. There is also evidence of genetic polymorphisms for CYP1A2, CYP2A6, CYP2D6, 
CYP2C9, CYP2C19 and CYP3A resulting in variations in the functional activity of the 
CYPs in those individuals (Na et al., 2011).  
Due to the interaction of a plethora of drugs with various cytochrome P450 enzymes, the 
potential pharmacological and toxicological impact of early screening for CYP enzyme 
activity has long been a part of the process of drug development (Delgoda and Westlake, 
2004). In fact, the FDA guidance for drug interactions with drug metabolising enzymes were 
developed long before those for interactions with drug transporters (Giacomini et al., 2010). 
Various specific drug probes for the different clinically important CYP enzymes such as the 
benzodiazepine midazolam for CYP3A4, have been selected for their use in experimental 
evaluations of drug interactions; with guidelines on the degree of variations that should be 
considered ‘clinically significant’ (Gurley, 2012). 
Interactions with CYP enzymes can either occur through an inhibition (either reversible or 
irreversible) or an induction of the enzyme. The competitive mechanism of reversible 
inhibition results in an almost immediate response; while mechanism-based or irreversible 
inhibition is characterised by a time- and concentration- dependent blockade. The effect of 
the latter can sometimes persist even after the herbal medicine is withdrawn, since the 
recovery of the enzyme activity will depend on its replacement by a newly synthesized one 
(Gurley, 2012, de Lima Toccafondo Vieira and Huang, 2012). When components of herbal 
medicines inhibit CYPs, they decrease the metabolic clearance of a co-administered drug 
that is a substrate of the inhibited pathway; while the reverse is the case for induction of 
CYPs.  Induction of CYPs is a slow and regulated process often requiring transcriptional 
gene activation (Na et al., 2011). 
There is overlapping tissue distribution of CYP3A4 and P-gp, as well as a broad spectrum of 
drugs that interact with both proteins either as substrates, inhibitors or inducers (Zhou et al., 
2007). The expression of both proteins has also been shown to be co-ordinately regulated by 
nuclear receptors, one of which is the pregnane X receptor (PXR), otherwise known as the 
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steroid and xenobiotics sensing receptor (SXR). In fact, it has been hypothesized that P-gp 
and CYP3A4 found in the villus of the small intestine act together to limit the absorption of 
many xenobiotics (Zhang and Lim, 2008). It therefore appears that dual substrates for 
CYP3A4 and P‑gp would have a much higher potential for clinically relevant HDIs (de 
Lima Toccafondo Vieira and Huang, 2012).  
A review of all preclinical and clinical evidence relating to drug interactions with St John’s 
wort has shown that the herb is able to jointly induce the activity of both CYP3A4 and P-gp, 
possibly through the activation of PXR. This inducing effect of components of the herb form  
the basis for its interaction with many clinically relevant drugs such as cyclosporine, 
hormonal contraceptives, anticoagulants and anti-HIV drugs with consequences of treatment 
failure in many cases, especially for drugs which are substrates of both proteins such as 
cyclosporin. There is also some evidence that the herb has can also modulate the activity of 
other CYP enzymes such as CYP2C19. These results are in contrast to the potent inhibitory 
effects previously shown by SJW in in-vitro studies suggesting that components of SJW 
might actually be CYP substrates rather than CYP inhibitors (Mannel, 2004). Garlic is 
another herb that has shown modulation of both CYP3A4 and P-gp activity (Allium sativum 
L.) (Gallicano et al., 2003, Piscitelli et al., 2002).  
Individual constituents of herbal medicines have sometimes been evaluated independently as 
modulators of both P-gp and CYP3A4 activity. In a study carried out with eight 
phytochemical constituents from six commonly consumed herbal spices, only two of the 
spice components- curcumin and 6-gingerol from Zingiber officinale Roscoe showed 
modulatory effects on both P-gp and CYP3A4; although the other spice components 
produced some form of modulatory effect of CYP3A4 activity but not P-gp (Zhang and Lim, 
2008). In addition to CYP3A4 modulatory effects, a number of herbal medicines have 
shown interactions with other CYP enzymes based on in vitro and/or in vivo data, with some 
of them showing modulatory effects of more than one CYP enzyme. Various extensive 
reviews covering this subject have so far been published with some of them identifying 
herbal constituents responsible for these modulatory effects (Brantley et al., 2014, Na et al., 
2011, He et al., 2010, Delgoda and Westlake, 2004, Zhou et al., 2003, Ioannides, 2002).  
In some cases, the constituents are ubiquitous in a number of herbal medicines or found in 
food drugs that are consumed in large amounts for dietary purposes such as the polyphenols 
gallic acid, catechin and quercetin; indole-3-carbinol found in broccoli and other cruciferous 
vegetables identified as an up-regulator of CYP1A2 activity and bergamottin and its 
derivatives found in grapefruit and other citrus fruits and identified as a potent inhibitor of 
CYP3A4 (Ioannides, 2002). These have raised a number of questions about the significance 
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of extrapolating these modulatory effects of the different herbal medicines to 
pharmacokinetic HDIs since these will often be all too frequently identified given the 
overlap in their disposition pathways.  
Although more often regarded as negative, some HDIs actually result in beneficial effects in 
humans. For instance, CYP2E1 catalyzes the activation of certain nitrosamines and other 
environmental carcinogens. Thus, inhibition of this enzyme could minimize the deleterious 
effects of these carcinogens. It is thought to be one of the mechanisms by which diets rich in 
sulphur-containing plant constituents such as isothiocyanates and allyl sulphides in garlic 
have chemopreventive properties (Gurley, 2012). 
Given the various complications encountered in the prediction of HDIs, various authors have 
recommended that results of pharmacokinetic interactions of herbal medicines or their 
components should not be evaluated in themselves. On the other hand, they should always 
be interpreted in the context of co-administered prescription drugs with sufficient 
information about the bioavailability of the herb itself; and then backed up by evidence from 
clinical studies (Markowitz and Zhu, 2012, Na et al., 2011, He et al., 2010). 
1.2.3 Herb-drug interactions involving Phase II metabolising enzymes 
Human UGTs represent a super-family of endoplasmic reticulum-bound enzymes that 
catalyze glucuronidation. Of all human UGTs, just 10 specific enzymes from two families 
(UGT1A and 2B) catalyze the bulk of all xenobiotics’ conjugations, utilizing glucuronic acid 
as the donor sugar (Gurley, 2012). The liver and the intestine are the main sites for UGT 
glucuronidation, with a majority of the enzymes expressed in the liver. Glucuronidation 
accounts for approximately 35% of all drugs metabolized by phase II enzymes (He et al., 
2010, Na et al., 2011).  
The SULT super-family are cytosolic enzymes that catalyze the sulfation of a multitude of 
xenobiotics, therapeutic drugs, bile acids, peptides, lipids, hormones and neurotransmitters. 
Only members of the SULT 1 & 2 family particularly SULT1A are primarily involved in the 
sulfation of xenobiotics. They catalyze the addition of sulfates to hydroxyl and monoamine 
groups on phenolic-type molecules (He et al., 2010). Although sulfation like most 
conjugation reactions generally renders a substrate less toxic, it has also been shown to 
activate certain plant-derived procarcinogens such as safrole, thereby resulting in a more 
toxic product (Gurley, 2012).  
GSTs catalyze the nucleophilic addition of a sulfhydryl group (glutathione) to electrophilic 
substrates. Most GSTs are soluble cytosolic enzymes, which in mammalian species are 
divided into four families- alpha (α),  mu (µ), pi (π) and theta (θ); in addition to a small 
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family of microsomal GSTs and one identified mitochondrial GST (GST kappa) (Eaton and 
Bammler, 1999). Many carcinogens such as the epoxides are reportedly detoxified by GSTs. 
Activation of the enzyme by inducers promote their elimination from the body thereby 
playing a role in chemoprevention. GST inhibitors on the other hand promote the 
cytotoxicity of anti-neoplastic agents when co-administered, thereby playing a role in 
overcoming tumour-induced drug resistance (Mukanganyama et al., 2002, Hatono et al., 
1996). Asides the detoxification of exogenous chemicals, another important role of GST is 
in the detoxification of endogenous products of lipid peroxidation. This underlies its role in 
protecting the body against oxidative stress (Eaton and Bammler, 1999). 
Many phytochemicals are themselves conjugated by the various phase 2 enzymes. 
Glucuronidation and sulfation have been identified as the main elimination pathway for 
silymarin, a mixture of polyphenolic flavonoids extracted from milk thistle (Silybum 
marianum (L.) Gaertn.). The glucuronide conjugates account for 55% of the total plasma 
concentration, while the sulfates account for 28% (Wen et al., 2008). Asides being a 
substrate, it has also been shown to inhibit UGT 1A1, 1A6, 1A9, 2B7 and 2B15 as well as 
some members of the CYP family; with UGT 1A1 being the most inhibited of all the 
metabolising enzymes. Although UGT 1A1 and 1A9 are involved in the metabolic 
disposition of the anti-cancer drug irinotecan, co-administration with milk thistle did not 
however affect its pharmacokinetics in a clinical study carried out in six volunteers (van Erp 
et al., 2005). This is thought to be as a result of the poor bioavailability of silymarin partly 
due to its extensive pre-systemic metabolism (Gurley et al., 2012). 
Finally, some nuclear receptors such as the PXR and the CAR (constitutive androstane 
receptor) regulate the expression of some of the phase 2 metabolising enzymes. Herbal 
medicines that activate either of these receptors can therefore bring about an induction of 
these enzymes resulting in increased metabolic clearance. Hyperforin from SJW and 
glucosinolates from cruciferous vegetables (after in vivo conversion to isothiocyanates) have 
been found to induce the activity of various GSTs and UGTs (Gurley et al., 2012). 
1.3 PREDICTION OF HERB DRUG INTERACTIONS AND ITS 
IMPLICATION IN DISEASE MANAGEMENT 
By their very nature of being composed of plant-based chemicals and thus identified by the 
human body as xenobiotics, all herbal medicines undergo some form of pharmacokinetic 
interaction with one or more of the different transporters or metabolising enzymes that 
constitute the ADME system. The varied nature of these pharmacokinetic interactions 
undergone by herbal medicines and their constituents indicate that prediction of herb-drug 
interactions can only best be done in the context of the co-administered prescription drug. 
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The same herbal medicine can be utilized to produce a beneficial effect on the one hand or a 
detrimental effect on the other.  
For example, a number of plant-based GST inhibitors or inhibitors of ABC transporters have 
been proposed as chemo-modulators to enhance the cytotoxic effect of anti-cancer drugs due 
to their relatively non-toxic nature (Hayeshi et al., 2007, Hayeshi et al., 2004, Wu et al., 
2011). Prolonged inhibition of these pharmacokinetic parameters can unfortunately bring 
about increased toxicity if they interfere with the elimination of other toxic xenobiotics that 
may be present in the body at the same time. Given that most herbal remedies are 
administered orally in a chronic regimen, the possibility of such prolonged effects should be 
anticipated.  
It is therefore necessary to understand the absorption and disposition pharmacokinetics of 
herbal medicines as a prerequisite for predicting potential interactions when co-administered 
with prescription drugs; but also for the purposes of estimating the bioavailability of the 
‘active’ constituents for which the herbal medicine is being taken in the first instance 
(Brantley et al., 2014).  
The majority of drug interaction studies are in vitro largely due to its high throughput nature 
and substantially reduced costs relative to in vivo studies (Markowitz and Zhu, 2012). In 
vitro studies also provide mechanistic information about potential interactions. However, the 
use of ‘non-therapeutically’ relevant concentrations and the inability to incorporate the true 
biological fate of the test compound in the assay setup are limitations to their use for the 
accurate prediction of HDIs (Venkataramanan et al., 2006).  
In vivo interaction studies are usually necessary to provide evidence of the clinical 
importance of previously obtained in vitro results. Animal studies give important 
information on HDIs, but interspecies variations in the substrate specificity, catalytic 
features and amino acid sequences of the proteins may cause difficulty in extrapolating 
animal data to humans. Therefore, it may be difficult to predict accurately the effects of 
herbal preparations in humans based on animal studies, and human studies are usually 
required to confirm HDIs (Zhou et al., 2003).  
When carrying out in vivo studies involving herbal medicines, regulatory agencies 
recommend the identification of one or more marker compounds (‘stated ingredients’), 
which is then used for monitoring the quality, safety and efficacy of the herbal product in 
clinical studies (Cox and Roche, 2004). In many cases, these marker compound(s) are 
responsible for some of its known biological effects (Markowitz and Zhu, 2012). An 
assessment of the phytochemical bioavailability of the marker compounds in biological 
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fluids would in turn provide evidence of exposure. However, one limitation of this approach 
is that herbal medicines are a complex mixture of multiple ingredients, many of which 
remain unidentified and/or uncharacterised. Even if these ‘other’ constituents do not 
contribute to the biological effect of the herb, they may still affect its pharmacokinetics and 
should therefore be monitored.  
Evaluation of the clinical evidence of most identified pharmacokinetic herb-drug 
interactions have shown that only a small percentage of in vitro identified HDIs produce a 
significant clinical effect. One very good example is with milk thistle whereby despite 
substantial evidence for interactions with transporter proteins, phase 1 and phase 2 
metabolising enzymes, a significant clinical effect was only identified with CYP2C9 
(Brantley et al., 2014, Hermann and von Richter, 2012).  
“Nonetheless, in vitro studies still provide much value for identifying specific herbal 
medicines that may potentially pose an interaction risk and thus serve as a ‘signal’ that in 
vivo studies may be warranted to confirm clinical relevance” (Markowitz and Zhu, 2012). In 
addition, it raises an alert to healthcare practitioners thereby encouraging better clinical 
monitoring (Williamson et al., 2013). It could also provide a mechanistic understanding of 
the potential herb interaction which enables clinicians make predictions of other drugs that 
may be similarly affected, especially those with low therapeutic indices. Such clinical 
studies of drug interactions with herbal medicines should not be arbitrarily carried out with 
just any therapeutic drug but in the context of the therapeutic use for which it is meant 
and/or in the presence of drugs that are likely to be co-administered by the patient alongside 
herbal medicines. 
It is important to note that the assessment and interpretation of the clinical evidence of HDIs 
is in itself fraught with certain limitations. There is very often large variability in the 
phytochemical content of different herbal preparations of the same botanical specie due to 
variability in source, cultivation practices and extraction procedures. It is therefore important 
to carry out such studies with products whose components have been quantitatively and 
qualitatively analysed; as well as to make sure that the interaction effect(s) seen is not due to 
any adulterants or contaminants. 
Many clinical studies have been identified as having a somewhat ‘flawed’ study design- in 
that they are carried out in healthy human volunteers as opposed to compromised subjects 
without the use of positive reference controls to confirm the magnitude of any observed 
interaction. Inter-individual variability in the expression of some of these pharmacokinetic 
parameters as well as genetic variation in drug response due to the existence of 
polymorphisms can also have a profound effect on the pharmacokinetic profile of the drug 
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(Gurley, 2012, Venkataramanan et al., 2006). All these factors should therefore be 
considered when proposing interpretations of any clinically observed HDI.  
In this regard, there is a strong advocate for the pharmacovigilance of herbal medicines post-
registration to identify previously unidentified or unrecognised risks. Periodic safety update 
reports (PSUR) are requested at defined time points by regulation bodies such as the UK’s 
MHRA (Medical and healthcare products regulatory agency). Registration licence holders 
are expected to provide a critical evaluation of the risks and benefits of the product in light 
of whatever new information that may have become available in the interim since 
registration. 
1.4 DIABETES MANAGEMENT IN NIGERIA AND THE RISK OF HERB-
DRUG INTERACTIONS 
1.4.1 Overview of Diabetes 
Diabetes mellitus is a chronic metabolic disorder of  multiple aetiology. It is characterized 
by uncontrolled high blood glucose levels and disturbances of carbohydrate, protein and fat 
metabolism. This is either as a result of insufficient endogenous insulin production by the 
beta cells of the islets of the pancreas, or impaired insulin secretion and/or action. The 
former condition is known as Type-1 diabetes, while the latter is known as Type-2 diabetes.  
In type-1 patients, there is destruction of the beta-cells such that insulin production is 
compromised. This is often due to an auto-immune disorder indicated by the presence of 
insulin antibodies in these individuals. Some other type-1 patients are regarded as 
‘idiopathic’, wherein the cause of beta cell destruction is unknown (WHO, 1999). So far, the 
highest risk factor identified for type-1 diabetes is a genetic predisposition. Epigenetic and 
environmental factors have also been implicated as being contributory to its onset (Todd, 
2010). Administration of exogenous insulin for blood glucose metabolism is mandatory for 
the survival of type-1 patients, due to this lack of, or insufficient insulin production. 
Type-2 diabetes is the more common form of diabetes with an estimated occurrence in 
almost 90-95% of diabetic patients (ADA, 2011). Although the exact pathophysiology is still 
unclear, it is increasingly evident that there are various factors which initially predispose 
individuals to beta cell dysfunction and decreased insulin sensitivity of the peripheral 
tissues. These in turn, lead to impaired glucose tolerance and subsequently to the 
development of type-2 diabetes. The factors that have so far been identified are genetic 
predisposition, age, physical inactivity, obesity or body-fat distribution and diet. In most 
cases, beta cell dysfunction and/or decreased insulin sensitivity would have been present for 
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several years before hyperglycaemia begins to manifest in the patient (Kahn, 2003, Scheen, 
2003). 
There are also other specific but less common types of diabetes, which do not fit into the 
criteria for either type-1 or type-2 diabetes but are characterised by high blood glucose 
levels. These include drug-induced or chemical-induced diabetes, diabetes caused by 
diseases of the exocrine pancreas (such as cystic fibrosis) or by infections, and gestational 
diabetes (Mayfield, 1998). 
Clinical symptoms of diabetes include- frequent urination, frequent thirst, increased hunger, 
weight loss and fatigue. In addition to high blood glucose levels, there are usually high 
levels of glucose in the urine (glucosuria). Ketoacidosis is present only in severe cases of 
diabetes often in type-1 diabetes, which may lead to a diabetic coma and death if not treated. 
The long term effect of diabetes is the progressive development of diabetes-related vascular 
complications (WHO, 1999). 
Various studies have identified increased oxidative stress as the link between diabetes and 
vascular complications. There is often a mitochondrial overproduction of reactive oxygen 
species (ROS) in specific cell types during glucose oxidation due to high blood glucose 
levels. These ROS cause tissue damage by activating certain intracellular pathways, 
resulting in vascular diseases such as atherosclerosis, cardiomyopathy, diabetic foot 
syndrome, retinopathy, nephropathy and diabetic neuropathy. Insulin resistance is also a risk 
factor for cardiovascular diseases due to the increased release of free fatty acids from stored 
triglycerides. Oxidation of these free fatty acids results in increased production of ROS 
(Giacco and Brownlee, 2010, Maritim et al., 2003). These vascular diseases are the common 
causes of mortality & morbidity amongst type-2 diabetic patients. 
1.4.2 Current Therapeutic Options in the Management of Type-2 Diabetes 
The prevalence of type 2 diabetes has been increasing in the last decade due to increase in 
the various identified risk factors, provoked by urbanisation and the resultant lifestyle 
changes (Guariguata et al., 2014). To mitigate this, the main therapeutic goal in the current 
treatment of type-2 diabetes is the maintenance of patient’s glycaemic levels as close to the 
non-diabetic range as possible with the aid of pharmacotherapeutic drugs, both to improve 
symptoms of diabetes as well as prevent diabetes-related complications. This is in addition 
to the implementation of lifestyle modifications including increased physical activity and 
diet adjustment to a low-fat diet, of which no more than 10% should be saturated fatty acids 
(Nyenwe et al., 2011).  
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A fasting plasma glucose (FPG) concentration  of ≥ 7mmol/L (126mg/dL) or ≥ 11.1mmol/L 
(200mg/dL)  2 hours after the intake of the equivalent of 75g glucose (also known as the oral 
glucose tolerance test or OGTT); or a glycated haemoglobin value (HbA1c) of ≥ 6.5% is a 
confirmatory diagnosis for diabetes. Individuals with FPG levels between 6.1-6.9mmol/L 
(110-125mg/dL) are classified as having impaired fasting glucose (IFG); while those with 
OGTT values between 7.8-11mmol/L (140-200mg/dL) have impaired glucose tolerance 
(IGT). These two groups of people have glucose levels outside the normal range and have a 
higher risk (10 times more than normal patients) of developing clinical diabetes (ADA, 
2011, WHO). 
The complexity of type-2 diabetes presupposes that different classes of drugs can act as anti-
diabetic agents. The choice of drug is therefore determined by the medical needs of the 
patient, the potency of the agent, the side effect profile of the drug, its ease of administration 
and cost-effectiveness. As monotherapy, most of these drugs (except insulin) only reduce 
HbA1c levels by 0.5% to 2%. For a patient with HbA1c of 8.5%, a single agent is therefore 
unlikely to achieve the therapeutic goal (Nyenwe et al., 2011). In many cases, patients are 
often on a ‘combination therapy’ of either two (or more) different types of anti-diabetic 
drugs or the anti-diabetic medication alongside another medication addressing the other 
existing risk factor(s) or vascular complication.  
Current drugs used in diabetes management can be categorized into three groups (Chehade 
and Mooradian, 2000, Sheehan, 2003). Drugs in the first group increase endogenous insulin 
availability. These include the sulfonylureas (SURs) such as glibenclamide, the glinides, 
insulin analogues, glucagon-like peptide 1 (GLP-1) agonists and dipeptidyl peptidase-IV 
(DPP-IV) inhibitors. The first two members of this group act on the sulfonylurea receptor in 
the pancreas to promote insulin secretion; with the SURs becoming increasingly popular and 
recommended as additional treatment for patients with HbA1c levels ≥ 7% (Nathan et al., 
2006). 
Glucagon-like peptide 1 (GLP-1) is a naturally occurring, rapidly degraded peptide secreted 
from the walls of the small intestine which stimulates insulin secretion. It also slows down 
gastric motility and gastric secretion. Because of its overall benefit in diabetic patients, 
exenatide a synthetic GLP-1 agonist has been developed for the management of type-2 
diabetes. However, it is only available as an injectable which limits its use. GLP-1 is 
degraded by the dipeptidyl peptidase-4 enzyme (DPP-4). Orally administered DPP-4 
inhibitors have been developed for the management of type-2 diabetes, but their modest 
reduction in HbA1c levels has made its use unpopular (White and Campbell, 2008). 
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The second group of drugs enhance the sensitivity of insulin. This includes the 
thiazolidinediones and the biguanide metformin. Biguanides are derivatives of galegine, a 
guanidine isolated from Galega officinalis L. also known as goat’s rue or French lilac. The 
plant is used in the treatment of people with diabetes in Europe. Due to the toxic effects 
associated with galegine, a structural modification was introduced which led to the 
development of metformin (dimethyl biguanide) (Figure 1.1); with the synthetic analogue 
having improved efficacy, less toxicity and better tolerability (Bailey and Day, 2004). 
Metformin increases the sensitivity of the liver and peripheral tissues to insulin by 
modulating insulin’s signalling pathway, thereby resulting in decreased gluconeogenesis in 
the liver as well as increased glucose uptake by peripheral tissues. It has also been shown to 
be beneficial for other cardiovascular risk factors due to its ability to decrease blood pressure 
and improve plasma lipid profiles (Goodarzi and Bryer-Ash, 2005). It is currently the most 
popular oral anti-diabetic medication in most parts of the world and is recommended as first 
line treatment especially when initiating chemotherapy in newly diagnosed patients (Nathan 
et al., 2006). 
 
Figure 1.1: Structural modification of Galegine from Galega officinalis to the type-2 anti-
diabetic drug Metformin 
 
Thiazolidinediones are direct stimulators of the ‘gamma’ member of the peroxisome 
proliferator-activated nuclear receptors (PPARɣ). Upon activation, these nuclear receptors 
stimulate the expression of genes responsible for lipid metabolism resulting in decreased 
levels of free fatty acids as well as increased carbohydrate metabolism (Hannele Yki-
Järvinen, 2004). By improving the action of insulin, this group of drugs help to decrease 
insulin resistance in peripheral tissues. Thiazolidinediones are however taken with caution 
by patients who have existing cardiovascular problems as rosiglitazone is thought to increase 
the risk of ischemic heart failure in such patients (Kaul et al., 2010).  
The last group of drugs are those that decrease the patient’s need for insulin. Prominent 
amongst this group are the alpha glucosidase inhibitors, acarbose & miglitol. They inhibit 
Galegine Metformin
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the alpha glucosidase enzymes present in the brush border of the small intestine, which are 
responsible for the breakdown of polysaccharides to monosaccharides. This action decreases 
the rate of absorption of polysaccharides, thereby reducing postprandial glucose levels. All 
the above mentioned drugs are orally administered and more commonly used by diabetic 
patients due to their ease of administration.  
The administration of recombinant human insulin to decrease blood glucose levels in type-2 
diabetic patients is not considered to be the first line of treatment, despite being the most 
effective since it is only available as injectables. This makes it more cumbersome and less 
amenable to use by patients. However, when other alternatives do not bring about significant 
blood glucose reduction in the patient, insulin is considered either as a monotherapy, or in 
addition to an existing oral anti-diabetic drug (Nathan et al., 2006).  
1.4.3 Clinical Management of Diabetes in Nigeria 
The International Diabetes federation (IDF) estimates that the prevalence of diabetes in 
Nigeria for adults (aged 20-79 years) is expected to rise from 5.0% of its population in 2013 
to 5.5% in 2035 (Guariguata et al., 2014). A study carried out in the city of Port-Harcourt 
(one of the coastal cities in Nigeria) in 2000 gave a prevalence of 7.9% (Nyenwe et al., 
2003). This high rate, which is greater than the IDF estimated prevalence may be as a result 
of the survey being conducted in adults ≥ 40years. The middle aged years (between the ages 
of 35 and 65) have repeatedly been shown to be the most common age bracket for diabetic 
patients in Nigeria as well as globally (Guariguata et al., 2014, Okoro et al., 2002).  
Studies have also showed that the prevalence of diabetes is higher in urban areas than in 
rural areas and that a high percentage of diabetic patients are undiagnosed and/or 
asymptomatic. In addition, the greater percentage of the diabetic population in Nigeria are 
type-2 patients, which constitute more than 80% of diabetic hospital admissions and more 
than 50% of total hospital admissions. More importantly, type 2 diabetes in Nigeria has a 
high mortality rate of over 30% mainly due to diabetic foot ulcers (DFU); with ignorance, 
late diagnosis and poor glycaemic control identified as some of the reasons for the high 
mortality rate (Chijioke et al., 2010, Ogbera et al., 2007).  
A case study carried out at the University of Ilorin teaching hospital located in the south-
west of Nigeria showed that the quality of care of diabetic patients receiving treatment in 
hospital facilities currently falls below the recommended minimum international standards 
(Okoro et al., 2002). The reason for this non-adherence to recommended guidelines by 
hospitals in Nigeria may not be too far-fetched. Average percentage contribution by the 
government to the total health expenditure is less than 30% (less than 2% of GDP is 
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allocated to health); while the remaining 70% are ‘out-of-pocket’ expenses borne by the 
patients themselves or their family members in subsidized public hospitals (WHO, 2000). 
This greater percentage of health costs being borne by the patient is very likely a huge 
financial burden for a chronic disease like diabetes. Studies have shown that direct payments 
by patients prevent many people from seeking care in the first place, and that improving 
universal health coverage requires systems that raise funds through alternative forms of pre-
payment such as taxes and/or insurance (Evans and Etienne, 2010). 
There is limited access to healthcare for most patients in Nigeria, characterized by a high 
doctor to patient ratio (Kengne et al., 2005). In addition, distance and costs of healthcare 
have been identified as significant determinants to the choice of healthcare and often act as 
deterrents to healthcare access (Amaghionyeodiwe, 2008). Many patients would rather 
purchase their drugs from local pharmacies so as to eliminate the costs of consultation fees 
and the time ‘wasted’ in visiting health facilities due to long delays. This practice increases 
the risk of cardiovascular complications as routine blood glucose levels aren’t determined. 
Patients are therefore unaware if adequate glycaemic control is being achieved with their 
current therapy. As a result, there is a high incidence of diabetic complications and 
hyperglycaemic emergencies amongst diabetic patients in healthcare facilities in Nigeria 
(Gill et al., 2009, Ogbera et al., 2007, Ogbera et al., 2009).  
The aim of physicians when prescribing existing pharmacological agents is to bring about a 
more intensive blood glucose control such that HbA1c levels are less than 7%. To achieve 
this, patients often have to constantly be on medications. Given that most diabetic patients 
are unable to achieve adequate glycaemic control on monotherapy, polytherapy is more 
common. In a study carried out in a diabetic clinic in Ibadan Nigeria, over 80% of type 2 
diabetic patients were prescribed a combination therapy of metformin and a sulphonylurea to 
achieve adequate glycaemic control. The average number of drugs prescribed per day 
increased to an average of four in the presence of other vascular complications. Anti-
hypertensives, anti-coagulants & anti-lipidaemics were the medications commonly taken by 
such patients (Enwere et al., 2006). 
The combined costs of these drugs can bring undue financial strain on the patient in the long 
term given the already existing unstable economic environment of most developing 
countries. A situation whereby the monthly cost of glibenclamide therapy is equivalent to 
more than a week’s wages would therefore be very unfavourable for the patient (Beran and 
Yudkin, 2006). Various studies have showed that the need for chronic intake of a large 
number of drugs with their attendant side effects, in addition to the high cost of purchase 
have been identified as the reasons for non-adherence to diabetes therapy. As a result of this, 
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patients often have recourse to alternative forms of therapy such as herbal medicines (Adisa 
et al., 2009, Yusuff et al., 2008, Enwere et al., 2006).  
A recent study evaluating how treatment burden affects the benefits of glycaemic treatment 
showed that the patient’s view of the burden of the specific treatment being considered for 
the disease management, and not necessarily the intensity of the treatment greatly 
determines the overall glycaemic control achieved. It therefore advocates for shared decision 
making whereby patients’ preferences are specifically considered prior to implementing a 
particular glycaemic treatment (Vijan et al., 2014). It should not be overlooked that some of 
these patients’ preferences might involve the concurrent use of herbal medicines. Healthcare 
practitioners should therefore be aware of this and be open to options whereby maximal 
therapeutic benefit to the patient can still be achieved. 
1.4.4 Potential Risks of Herb-Drug Interactions amongst Diabetic Patients  
The use of herbal medicines as part of traditional medicine practice continues to play an 
important role in healthcare for a large number of the population of developing countries, 
particularly those living in rural areas. This is primarily because such areas are often 
severely under-provided with western-type healthcare, thereby bringing about a greater 
dependence on the more-accessible but also more culturally acceptable traditional medicine 
for their disease management (Alves and Rosa, 2007, Bodeker and Kronenberg, 2002, Stock, 
1983).  
Studies have however now shown an increasing use of herbal medicines and indeed other 
forms of complementary and alternative medicine (CAM) in urban areas. Suggestions as to 
the reasons for this include- ‘that this could either be as a result of increased rural-urban 
migration’; or ‘a means for patients to supplement the high costs of conventional medicines 
with the ‘relatively’ cheaper traditional alternative’; or ‘simply because of a dissatisfaction 
with conventional therapy’ (van Andel and Westers, 2010, Saydah and Eberhardt, 2006).  
Surprisingly, a large subgroup of patients who use herbal medicines do not necessarily do so 
based on cost-considerations or at the expense of modern healthcare delivery. On the other 
hand, these patients prefer the autonomy of being in control of their disease management as 
well as the ability to make treatment decisions; and are willing to try out alternative 
therapies alongside (Garrow and Egede, 2006, Astin, 1998). Some of the reasons that have 
been given by patients for their concomitant use of herbs and pharmaceutical drugs include: 
‘a desire for a more holistic approach to healthcare; a belief that this will produce a better 
outcome; a desire for safer, more natural treatments at lower costs; and a need for a larger 
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number of healthcare options than that offered by biomedicine’ (Jonas, 2002, Picking et al., 
2011).  
The presence of chronic diseases including arthritis, cancer, cardiovascular diseases and 
diabetes represent key disease areas where the use of CAM have been shown to be 
increasingly prevalent. In a study carried out in Malaysia amongst patients with chronic 
diseases wherein 60% used CAM for their disease management, over 70% of the patients 
were diabetic (Hasan et al., 2009). This high prevalence is unfortunately accompanied by 
poor communication between patients and clinicians. For instance, diabetic patients in the 
US have been identified as the least likely to inform their healthcare practitioners of their 
herb use (Saydah and Eberhardt, 2006).  
The average worldwide prevalence for the use of CAM alongside conventional medicines 
amongst diabetes patients has been estimated as 45.5%. This reduces to approximately 30% 
when looking only at the use of biological based therapies (the use of natural products as 
opposed to other mind and body practices) (Chang et al., 2007).  Given that this prevalence 
rate is based on studies carried out in only nine countries, most of which are developed ones, 
this is quite possibly an underestimation. Developing countries like Mexico and India have 
already shown prevalence rates of over 60% (Argaez-Lopez et al., 2003, Kumar et al., 2006). 
Furthermore, the prevalence of diabetes is estimated to increase globally, and at an even 
higher rate in developing countries (Guariguata et al., 2014). This implies that the worldwide 
prevalence of herbal medicine users amongst diabetic patients is also very likely to increase.  
In Nigeria, the prevalence of concomitant use of herbal medicines alongside conventional 
drugs in diabetes management is about the same as the estimated worldwide prevalence rate. 
A study carried out amongst diabetic patients in Lagos gave a prevalence of 46% for the use 
of CAM alongside prescription drugs, most of which were herbal medicines (Ogbera et al., 
2010). This high prevalence is seen in urban areas which have relatively better access to 
modern healthcare facilities, possibly due to high healthcare costs.  Another study carried 
out to estimate herbal use in all the geo-political zones of Nigeria, encompassing both urban 
and rural areas showed that 41% of respondents use herbal medicines either singly or in 
combination with conventional medicines as their treatment choice (Osemene et al., 2011).  
One of the main challenges of diabetes management is that despite existing 
pharmacotherapy, attaining adequate glycaemic control especially in type-2 diabetic patients 
is really difficult due to a steady decline in beta cell function (Robertson et al., 2004, 
Wallace and Matthews, 2000). Poor glycaemic control increases the risk of diabetic related 
complications ensuing in more complex treatment plans which the patients have to deal with 
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for a long time. This characteristic of diabetes lends itself as a condition whose patients are 
likely to seek out alternative forms of treatment (Chang et al., 2007).  
In clinical practice, the use of two or more drugs by patients with chronic diseases or those 
with co-morbid conditions pose a risk of drug-drug interactions which physicians take into 
serious consideration while prescribing an appropriate therapeutic regimen for the patient. 
Herbal medicines also pose a similar risk since they are primarily plant-derived, biologically 
active chemical constituents. The chronic nature of diabetes means that the concurrent use of 
herbal medicines together with prescribed drugs could result in undesirable herb-drug 
interactions. Unfortunately, the use of herbal medicines is still not very well regulated as 
most times these are self-prescribed by the patients themselves. As a result, healthcare 
practitioners are unable to provide informed advice to their patients when prescribing to 
forestall unwanted HDIs. 
Now that it has become apparent that herb use is more widespread than previously thought, 
more focus has been given to evaluating various herbal medicines for possible HDIs. Some 
studies have focused on evaluating the pharmacodynamic interactions between herbs and 
drugs taken for the same ailment. It is often assumed that the co-administration of a herb and 
a drug both having the same therapeutic benefit will result in an additive effect, but this is 
not always the case. For example, when extracts of pawpaw (Carica papaya L.) leaves 
known for its hypoglycaemic effects (Maniyar and Bhixavatimath, 2012) were co-
administered with glimepiride, rather than the expected enhanced hypoglycaemic effect, the 
leaves decreased the hypoglycaemic effect of the glimepiride due to a decrease in its onset of 
action, while it produced an enhanced hypoglycaemic effect with metformin (Fakeye et al., 
2007). Similarly, the water soluble fractions of okro (Abelmoschus esculentus (L.) Moench) 
significantly decreased the in vivo absorption of metformin resulting in a loss of its 
hypoglycaemic effect (Khatun et al., 2011).  
An enhanced hypoglycaemic effect should therefore not always be assumed by patients and 
physicians alike, as there may be other underlying interactions that may negate this expected 
effect as shown with okro. A true assessment can however only be possible when in vivo 
experimental studies are carried out or active therapeutic monitoring of patients’ blood 
glucose levels. These are unfortunately beyond the scope of this current PhD research. 
Limited information about the pharmacokinetic profile and potential risks of herb-drug 
interaction of most herbal medicines makes pharmacokinetic HDIs more difficult to predict. 
Consequently, efforts have been channelled towards investigating the effects of different 
herbal extracts on known pharmacokinetic parameters. Individual studies involving 
medicinal plants used in Nigeria, and indeed in West Africa are however limited (Oga et al., 
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2012, Agbonon et al., 2010, Appiah-Opong et al., 2008, Deferme et al., 2003). Various 
reviews of the scientific literature have shown that although pharmacokinetic data involving 
herbal remedies have significantly increased in recent years, many of these have focused 
only on a small number of commonly used herbal products; while for the majority of herbal 
medicines used in traditional medicine, data on their disposition and biological fate in 
humans is lacking (He et al., 2010).  
Efforts have also been made to collate existing information about herbal medicines as a 
guide to healthcare practitioners, and as a means of forestalling potentially clinically relevant 
herb-drug interactions (Joint Formulary Committee, 2014, Williamson et al., 2013, Ulbricht 
et al., 2008). Despite a higher prevalence of herb use in Africa, similar resources collating 
information about commonly used herbal medicines, particularly those that are indigenous to 
African countries as a guide for healthcare practitioners are far less common. Only one 
review covering thirty-five plants was identified (Cordier and Steenkamp, 2011).   
Medicinal plants used in diabetes management in Nigeria are utilised in various forms 
(Figure 1.2) - either as food vegetables incorporated as part of one’s diet; as crude herbal 
preparations; or as manufactured herbal medicinal products, which are more commonly 
found in pharmacy stores. The herbal preparations and manufactured herbal medicinal 
products are often multi-component mixtures of two or more plants most likely to produce a 
‘synergistic effect’.  
Crude herbal preparations are the most commonly utilized form of herbal medicine (Fakeye 
et al., 2009, Olisa and Oyelola, 2009). These are often prepared by a traditional medicine 
practitioner (TMP). Sometimes, patients purchase plant parts from various herbal markets 
based on recommendation by the herb seller, friends or family which they then prepare by 
themselves. Common methods of preparation include maceration with aqueous or alcoholic 
solution, infusion, decoction and the direct use of powdered plant parts sometimes sprinkled 
on food.  
The expertise acquired by traditional medicine practitioners by prolonged use is such that 
they are often aware of the right method of preparation and/or the right dosage to avoid the 
harmful effects of herbal medicines. This expertise is however on the premise that these 
herbal medicines are being used by themselves for the disease management and not 
alongside conventional medicines. Thus, there is very little awareness of the risks of herb-
drug interactions. These risks are further heightened in patients who self-medicate herbal 
medicines based on recommendations by friends and/or family with the preconception that 
‘herbal medicines are natural and hence safe’. 






Figure 1.2: Various forms in which medicinal plants are utilised as herbal medicines in Nigeria. 
(a) Ocimum gratissimum and Vernonia amygdalina are two anti-diabetic medicinal plants 
commonly used as food vegetables and often grown in home gardens; (b) Crude herbal 
preparations prepared by herbalists themselves or sold in herbal shops and/or markets, often 
comprising unidentified constituents. 
 
Manufactured herbal medicinal products are powdered plant extracts in capsules or 
compressed as tablets as well as liquid preparations containing a specified dose. These are 
the only forms of herbal medicine that are currently subject to regulation in Nigeria by the 
National Agency for Food and Drug Administration and Control (NAFDAC). A registration 
status renders to the product a permit for it to be sold and distributed outside the locality of 
production. The quantitative list of ingredients either by their botanical names or common 
names, evidence of efficacy and safety, as well as the indications and contraindications of 
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to manufactured herbal medicinal products for a period of two years, which precludes the 
need for rigorous assessment of good manufacturing practices or laboratory evaluations of 
efficacy. A full registration licence is then given after a reassessment of the safety of the 
product based on post market surveillance and laboratory evaluations of safety and efficacy 
(NAFDAC, 2005).  
The absence of an extensive regulatory framework encompassing most of the herbal 
medicines utilised in Nigeria means that the current system is ill-suited for 
pharmacovigilance monitoring to help the identification of some of the unwanted effects that 
may be encountered during disease management. There is therefore a need for an 
experimental evaluation of the potential for herb-drug interactions for these anti-diabetic 
plants so that their use in diabetes management can be properly harnessed by the population. 
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1.5 AIM OF THESIS 
The complexity of diabetes and the current therapeutic options available for its management, 
coupled with the associated treatment burden due to healthcare costs identifies it as a disease 
with a very high risk for concomitant use of herbal medicines particularly in developing 
countries like Nigeria. Unfortunately, adequate information about the pharmacological and 
toxicological profile of most of the herbal medicines used in diabetes management that 
would enable the prediction and/or identification of potential herb-drug interactions is 
lacking. In addition, there is the absence of an appropriate regulatory framework for the use 
of herbal medicines that would ensure pharmacovigilance monitoring, identification and 
reporting of these herb-drug interactions if and when encountered by healthcare 
practitioners. 
In a bid to address some of these identified problems, the aim of this PhD research is the 
evaluation of medicinal plants used in diabetes management in Nigeria for possible herb-
drug interactions. 
1.5.1 Research strategy 
To achieve this, the research for this thesis was carried out in three parts: 
- An assessment of available data on the pharmacology and toxicology of herbs 
traditionally used for diabetes management in Nigeria and theoretical predictions of 
herb-drug interactions that their use may pose. A review collating the results of this 
assessment and its implications in disease management has now been published 
(Ezuruike and Prieto, 2014). 
- A field work study carried out in different locations of Nigeria with the aim of 
identifying medicinal plants that are commonly used by diabetic patients in their 
disease management; and an assessment of the potential risks of pharmacokinetic 
herb-drug interactions amongst a cohort of diabetic patients in two urban cities in 
Nigeria based on their co-administered prescription drugs. 
- Experimental evaluation of the effects of some medicinal plants collected during the 
field work on different cell detoxification mechanisms and pharmacokinetic 
parameters; as a means of identifying potential herb-drug interactions. 
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2 CRITICAL ASSESSMENT OF PHARMACOLOGICAL AND 
TOXICOLOGICAL DATA FOR MEDICINAL PLANTS USED 
IN DIABETES MANAGEMENT IN NIGERIA 
 
Parts of this chapter have been accepted for publication as: 
Ezuruike UF, Prieto JM. 
The use of plants in the traditional management of diabetes in Nigeria: pharmacological and 
toxicological considerations. 
Journal of Ethnopharmacology 2014 Sep 11; 155(2):857-924.  
DOI: 10.1016/j.jep.2014.05.055.  
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2.1  INTRODUCTION 
A number of ethnobotanical surveys have been carried out in different parts of Nigeria to 
identify plants used in the traditional management of diabetes (Soladoye et al., 2012, 
Gbolade, 2009, Etuk and Mohammed, 2009, Abo et al., 2008). These surveys have 
highlighted not only the dependence of a large percentage of the Nigerian population on 
herbal medicines, but also the use of a large number of plants from diverse plant families. 
Various reviews have also highlighted the traditional use of a wide range of medicinal plants 
in diabetes management in other parts of the world (Andrade-Cetto and Heinrich, 2005, 
Grover et al., 2002, Marles and Farnsworth, 1995, Bailey and Day, 1989, Bever, 1980). 
Although a lot of these medicinal plants have been shown to possess a number of beneficial 
therapeutic effects, they could also be harmful, depending on the dose administered or the 
method of preparation. Pharmacological and/or toxicological evidence available for these 
medicinal plants are ‘scattered’ in various publications, which are sometimes not readily 
available or accessible to patients, healthcare practitioners and researchers to make a 
thorough assessment of their beneficial and toxic effects in diabetes management.  
This chapter, therefore, aims to provide Nigerian healthcare professionals with a useful 
resource to enable a thorough assessment of the pharmacological and toxicological profile of 
plants used in diabetes management so as to ensure better advice and safer use. 
2.2 METHOD 
Information about medicinal plants traditionally used in the management of diabetes in 
Nigeria was obtained from published papers and texts on ethnobotanical studies; as well as 
those investigating the effect of plant(s) used in diabetes management, in which the place of 
use and/or sample collection was identified as Nigeria. A literature search of electronic 
databases such as Google Scholar, Pubmed and Scopus up to 2013 was carried out using 
‘Diabetes’ and ‘Nigeria’ as keywords for the primary searches; and then ‘Plant name- 
accepted or synonyms’, ‘Constituents’, ‘Drug interaction’ and/or ‘Toxicity’ for the 
secondary searches.  
In order to highlight medicinal plants traditionally used in diabetes management with the 
potential for integration into the healthcare system, not all identified plants were included. 
Only those with (1) more than one reference to its use in diabetes management in Nigeria 
based on ethnobotanical studies were retained; and/or (2) experimental evidence in one or 
more diabetes experimental models validating its activity. This analysis is therefore not 
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exhaustive for all the plants reportedly used traditionally for diabetes management in 
Nigeria. 
2.3 RESULTS AND DISCUSSION 
Data for one hundred and fifteen plants traditionally used in diabetes management in Nigeria 
were obtained; either from previously conducted ethnobotanical studies (Igoli et al., 2004, 
Igoli et al., 2005, Aiyeloja and Bello, Okoli et al., 2007, Abo et al., 2008, Ajibesin et al., 
2008, Olowokudejo et al., 2008, Etuk and Mohammed, Gbolade, Ogbonnia and Anyakora, 
Lawal et al., 2010); or from primary research papers. These are tabulated according to their 
accepted Latin Name (based on www.plantlist.org). Synonyms are included for plants which 
were not identified with their accepted names in the primary research paper. For each of the 
identified plants, the family name, common name(s), identified region of use in diabetes 
management, experimental evidence of activity (where available), other medicinal uses, 
plant part(s) used, traditional method(s) of preparation, identified active constituent(s), other 
relevant phytochemical constituents, as well as data on interaction and toxicity studies are 
included (Table 1; Appendix 1). 
Out of the 115 plants, only twelve of them have no experimental evaluation of their blood 
sugar reducing effects, either in vivo or in vitro. In selecting studies to be included, priority 
was given to investigations carried out with samples collected in Nigeria. Certain 
publications were not included if the study design of the experimental evidence wasn’t 
appropriate enough for validating the effect of the plant, such as the absence of a suitable 
control or the use of improper doses.  
Two-thirds of the identified plants with experimental evidence for their biological activity 
involved samples collected from Nigeria. For the remaining one-third, although the studies 
were not carried out with plant samples sourced from within Nigeria, these were still 
included, as the available experimental evidence could provide some information validating 
their use in diabetes management in Nigeria. However, possible chemical variability would 
need to be taken into consideration. The ethnobotanical research investigating the local 
knowledge and geographical distribution of Moringa oleifera Lam. in Nigeria (Popoola and 
Obembe, 2013) provides a rationale for including information from studies carried out in 
different countries, as some of these locally available plants could have been initially 
sourced from elsewhere.  
In-vitro experimental studies as well as phytochemical studies carried out on the plant 
species regardless of the source of the plant samples were also included. These together 
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could provide more insight into the biological activity(s) of the plant, which would in turn 
help to promote a more rational use of the plant in diabetes management, either in the 
presence or absence of other co-morbidities. For completeness, reports on the antioxidant 
properties of many of the identified plants have been included as this has become a popular 
parameter in assessing the beneficial effects of a plant in diabetes management. 
2.3.1 Assessment of the Preclinical Pharmacological Evidence 
2.3.1.1 In vivo hypoglycaemic activity 
Reducing blood sugar levels is the classical clinical target in all forms of diabetes. Thus, the 
in vivo sugar lowering effect of putative hypoglycaemic plants is therefore a premise to infer 
their potential clinical efficacy.  In vivo validation also provides an indication of the relative 
toxicity of the plant. Although most herbal medicines have a long history of traditional use, 
only their experimental validation at known doses may give a clearer idea about its safety 
and efficacy, in line with the objectives of the WHO traditional medicine strategy (WHO, 
2013).  
Ninety six out of the one hundred and fifteen plants have been evaluated in various in vivo 
animal models of diabetes, mostly using alloxan and/or streptozotocin (STZ)-induced 
diabetic animals, which are the most frequently used animal diabetes models worldwide 
(Fröde and Medeiros, 2008). These chemical agents are cytotoxic to the β-cells of the 
pancreatic islets, generating a state of insulin deficiency (akin to type-1 diabetes) with 
subsequent hyperglycaemia (Szkudelski, 2001). Other in vivo models used include 
spontaneous diabetic animal models obtained as a result of one or more genetic mutations- 
such as obese zucker fatty rats, db/db mice and KK-A
y
 mice; as well as the use of high 
glucose or fructose-fed animals. This latter group better simulate the development of 
diabetes from insulin resistance as is more commonly found in patients with type-2 diabetes 
(Srinivasan and Ramarao, 2007).  
Although most plants were only evaluated experimentally in a type-1 diabetes model, some 
of these have been shown to be effective hypoglycaemic agents in type-2 diabetes patients, 
such as extracts of Bridelia ferruginea Benth. Daily administration of an infusion of its 
leaves to type-2 diabetic patients previously on insulin injections for eight weeks resulted in 
a significant decrease in their blood sugar levels (Iwu, 1983). 
Only two out of the 96 plant species evaluated in vivo were ineffective in their experimental 
model of study, namely Zea mays L. (Suzuki et al., 2005) and Cucumeropsis mannii Naudin 
(Teugwa et al., 2013). Despite its identified in vitro PPARα and ɣ agonist activities and α-
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glucosidase inhibitory effects (Lee et al., 2010), extracts of Zea mays failed to produce a 
significant hypoglycaemic effect in vivo (Rau et al., 2006). This could be due to the absence 
of the bioactive constituent(s) responsible for the hypoglycaemic effects or their availability 
in very low amounts as a result of chemical variability in the samples investigated. 
Nonetheless, the complete absence of an in-vivo hypoglycaemic effect would not necessarily 
preclude its use in the clinical management of diabetes, which also takes into account the 
presence of co-morbid conditions. In this regard, Zea mays could also provide protection 
against diabetic nephropathy, as it has been shown to improve kidney parameters in vivo 
(Suzuki et al., 2005).  
In the case of Cucumeropsis mannii, its traditional use involves the ingestion of its ashes or 
its juice (Gbolade, 2009). This may indicate that its use is based on its oligo-elements and/or 
vitamins and not necessarily on secondary plant metabolites. The supplementation of 
elements such as chromium, magnesium and vanadium is actively explored in the treatment 
of diabetes (Anderson et al., 1997; Halberstam et al., 1996; Rodríguez-Morán and Guerrero-
Romero, 2003); some of which have been identified in the seeds of Cucumeropsis mannii 
(Badifu and Ogunsua 1991). 
2.3.1.2 In vitro pharmacological evidence  
It is recommended that in vitro experiments are carried out to ascertain the mechanism of 
action for the plant. Certain plants produce hypoglycaemia as a side effect of their in vivo 
toxicity (Marles and Farnsworth, 1995). There is also the risk that the hypoglycaemic effect 
is being mediated –at least in part- through an unwanted physical mechanism, rather than a 
physiological one, such as was observed with Gymnema sylvestre (Retz.) R. Br. Ex Sm 
(Persaud et al., 1999). This immediately eliminates the potential use of such plant as a 
therapeutic hypoglycaemic agent. In addition, due to the ethical considerations surrounding 
animal use (Festing and Wilkinson, 2007), it is advised that validation experiments are 
‘replaced’ with non-animal models where possible. 
Over one-third of the plants have been studied for their in vitro effects in models that could 
possibly explain some or all of their mechanism of action. Twenty-nine plants have 
inhibitory effects against either -amylase or -glucosidase enzymes; five plants have 
agonist activity on the PPARγ receptor; whose activation enhances glucose metabolism; four 
plants increase insulin release from pancreatic cells; five plants increase glucose uptake in 
muscles or liver; while two plants increased the expression of the glucose transporter 
GLUT4, which in turn increases glucose uptake into muscles and adipose tissues. Two 
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plants were identified as potential DPP-IV inhibitors; while six plants were identified as 
aldose reductase inhibitors (Figure 2.1). 
 
Figure 2.1: Proposed molecular mechanisms of hypoglycaemic effects for the selected species. 
 
In vitro experiments are often designed to ‘reflect’ the mechanism of existing drugs used in 
diabetes management. Plants that possess alpha amylase or alpha glucosidase inhibitory 
effects reflect the action of acarbose; PPARγ agonist activity reflect the thiazolidinediones, 
while aldose reductase inhibitors are potential agents for preventing diabetic complications 
like the drug epalrestat.  Thus with this identified mechanisms, researchers and healthcare 
professional alike can immediately identify the potential therapeutic benefit of the plant. 
This information could contribute to a more rational therapeutic regimen for diabetes 
patients, possibly benefitting from a synergistic effect with herbal remedies. 
The disadvantage of the molecular approach for experimental validation of plant activity is 
that the biological assays only explore known targets and do not take into account extracts 
that might be acting on unknown targets, possibly through innovative mechanisms.  In 
addition, herbal medicines are often complex mixtures of various phytochemicals which 
may work synergistically to achieve a desired therapeutic outcome (Williamson, 2001). In 
such cases, a single end-point in vitro biological assay will not be sufficient in evaluating the 
clinical effect of the plant.  
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As an example, the methanol extract of the root and stem of Gongronema latifolium Benth. 
produced a greater anti-hyperglycaemic effect in glucose loaded rats than each of its 
fractions, possibly indicating a synergistic –if not additive- effect of its constituents even 
though some of the fractions of the whole extract possessed hyperglycaemic effects. In 
addition, a number of triterpenes (α & β-amyrin cinnamate, lupenyl cinnamate, lupenyl 
acetate) possessing in vitro insulin stimulating effects were isolated from only one of the 
active fractions further confirming the synergistic activity of phytoconstituents of herbal 
medicines (Adebajo et al., 2013).  
There is also a holistic approach in the herbal management of diabetes such that plants 
which are not hypoglycaemic themselves may be included in multi-component preparations 
because of their benefits in co-morbid conditions. Thus, in vitro studies might not 
immediately indicate the beneficial effect of the plant. A good example is the use of the 
aphrodisiac plant Mondia whiteii (Hook.f.) Skeels (Quasie et al., 2010). Despite not showing 
in vitro hypoglycaemic effect (Etoundi et al., 2010), it is commonly included in multi-
component preparations for diabetes management in men since erectile dysfunction is a 
common complication of the illness (personal communication during field work). This 
however does not preclude any in vivo activity which is yet to be evaluated.  
2.3.1.3 Bioactive compounds 
Many plant secondary metabolites have been associated with specific beneficial effects in 
diabetes, which might account for the threrapeutic effect of the herbal drug (Qi et al., 2010). 
Thus, apart from a bioguided fractionation, the biologically active agent of a plant can also 
be hypothesised by evaluating the phytochemical constituents that have previously been 
isolated. These can thereafter be confirmed in specific pharmacologic experiments. 
Over forty compounds have been identified from twenty three antidiabetic plants, either 
through an activity guided fractionation or in silico studies as the bioactive constituents 
responsible for some or all of the plants’ beneficial effects in diabetes. Some of these 
constituents are species-specific such as the alkaloid mahanimbine from Murraya koenigii 
(L.) Spreng (Dineshkumar et al., 2010); while others are known to be present in many plants 
like the alkaloid trigonelline, which is responsible for the hypoglycaemic effect of Abrus 
precatorius L. (Monago and Nwodo, 2010) and Trigonella foenum-graecum L. (fenugreek), 
a plant whose use in diabetes management is popular across India and Europe (Bailey and 
Day, 1989).  
These compounds are classified according to similar chemical features as follows: 
compounds containing nitrogen (1-9) (Figure 2.2), terpenes (10-16) (Figure 2.3), phenolic 
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compounds (17-33) (Figures 2.4) and compounds containing hydroxyl groups including 
sugars (34-40) (Figure 2.5). 
2.3.1.3.1 Nitrogen containing compounds 
A number of alkaloidal and non-alkaloidal active principles from plants used in diabetes 
management have been reported. Some of these were isolated from samples not collected 
from Nigeria such as hypoglycin A (1) and B (2) - from the fruit of Blighia sapida 
K.D.Koenig., which produced hypoglycaemic effects in rabbits, monkeys rats and mice but 
not in cats, dogs and pigeons (Chen et al., 1957).  
Murraya koenigii leaves are used traditionally in Indian Ayurvedic system to treat diabetes. 
Mahanimbine (5) isolated from Indian plant samples decreased blood glucose levels in STZ-
induced diabetic rats and also produced a dose-dependent α-amylase and α-glucosidase 
inhibitory effect (Dineshkumar et al., 2010). Its cellular mechanism of action is also thought 
to be mediated by an increase in glucose utilization in 3T3-L1 cells (Dinesh Kumar et al., 
2013). On the other hand, mahanimbine and other related carbazole alkaloids isolated from 
plant samples from Nigeria decreased the glucose-mediated insulin release from INS-1 cells 
when compared to control, suggesting that its enhanced glucose uptake is not due to 
increased insulin release (Adebajo et al., 2005). 
The alkaloid trigonelline (4) isolated from the seeds of Abrus precatorius (L.) collected from 
the eastern part of Nigeria decreased blood glucose levels in alloxan-induced diabetic rats as 
well as reduced the activity of glucose-6-phosphatase and glycogen phosphorylase, two 
enzymes important for glucose production (Monago and Nwodo, 2010).   
Akuammicine (3) isolated from the chloroform extract of the seeds of Picralima nitida 
(Stapf) T.Durand and H.Durand stimulated glucose uptake in 3T3-L1 adipocytes (Shittu et 
al., 2010). It is also present in plants of the genus Alstonia such as A. boonei De Wild. and A. 
Congensis Engl. and would probably contribute to their blood glucose lowering activity. 
Ajmaline (6) and isosandwichine (7) from Rauvolfia vomitoria Afzel. were identified as 
DPP-IV inhibitors using an in silico approach (Guasch et al., 2012). 
Garlic and onions are commonly used as part of the diet in many Nigerian households and 
the hypoglycaemic effect of plant samples collected from Nigeria have also been studied 
(Eyo et al., 2011). This hypoglycaemic effect is possibly due to the presence of S-
methylcysteine sulfoxide (8) (SMCS) in onions and S-allylcysteine sulfoxide (9) (SACS) in 
garlic, which have been isolated from Indian plant samples and have been shown to improve 
Chapter Two-Critical Assessment of Pharmacological and Toxicological data 
51 
 
glucose tolerance in alloxan-induced diabetic rats (Sheela et al., 1995). Clinical studies in 
humans have shown that the supplementation of garlic to diabetic patients in combination 
with hypoglycaemic drugs improves glycaemic control in addition to the reduction of 
cardiovascular risk (Sobenin et al., 2008). Although they both contain nitrogen, SMCS and 
SACS are primarily classed as sulphur containing compounds. 
 
Figure 2.2: Nitrogen containing active principles from plants used in diabetes management. 
  
2.3.1.3.2 Terpenes 
A number of terpenes have been isolated as bioactive constituents in plants used for diabetes 
management (Figure 3). The leaves of Gongronema latifolium, otherwise known as ‘utazi’ 
or ‘madu-maro’ in Ibo and Yoruba respectively is commonly used as a food vegetable and is 
widely recognised for its traditional use in diabetes management. Lupenyl cinnamate (15), 
lupenyl acetate and α- & β-amyrin cinnamates (16) isolated from the combined root and 
stems of locally obtained samples have recently been identified as some of the bioactive 
compounds, possessing both anti-hyperglycaemic effects in glucose-fasted rats as well as 
insulin stimulating effects in INS-1 cells (Adebajo et al., 2013).  
Foetidin from the whole plant and the unripe fruits of Momordica foetida collected in 
Nigeria also decreased blood glucose levels of normal fasted, but not alloxan-induced rats at 
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Acetylenic glucosides (10) and (11) isolated from Bidens pilosa decreased blood glucose 
levels in the murine type 2 diabetes model C57BL/Ks-db/db mice (Ubillas et al., 2000); and 
inhibited the spontaneous development of diabetes in non-obese diabetic (NOD) mice by 
modulating the differentiation of T-helper cells (Chang et al., 2004).  
The monoterpenes myrcene (12), citral (13) and geraniol (14) found in Cymbopogon citratus 
were identified as aldose reductase inhibitors using in-silico docking methods (Vyshali et al., 
2011). They are also components of the essential oil of many medicinal plants used in 
Nigeria as shown in Table 1 (Appendix 1). This preliminary information warrants further in 
vitro and in vivo studies involving plant samples from Nigeria known to contain these 
compounds, given that the beneficial effect of the essential oil of Cymbopogon citratus in 
the amelioration of glycaemia, insulinaemia & lipid dysmetabolism has now been validated 
in vivo in experimentally induced type-2 diabetic rats (Bharti et al., 2013). 
 
Figure 2.3: Terpenes identified as active principles from plants used in diabetes management. 
 
2.3.1.3.3 Phenolic compounds 
A wide range of phenolic compounds have been identified as active principle(s) in some of 
the plants. Anthraquinone glycosides from Morinda citrifolia L, namely damnacanthol-3-O-
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levels in STZ-induced diabetic mice at 100 mg/kg (Kamiya et al., 2008). Incidentally, this 
plant is not native to Nigeria and isn’t known to grow in Nigeria. However, the use of a 
registered herbal product of the juice extract, Tahitian noni juice
®
 (TNJ) is quite popular in 
Nigeria for various ailments including diabetes. Administration of 1ml/150mg body weight 
of the rats twice daily for four weeks prior to and after the induction of diabetes with alloxan 
resulted in significant decrease in blood sugar levels, indicating a prophylactic effect of the 
extract against alloxan-induced diabetes (Horsfal et al., 2008). The presence of these 
phenolic compounds in the marketed product has however not been confirmed. 
Kolaviron (17) is a mixture of flavanones (GB1, GB2 and kolaflavanone) isolated from the 
acetone extract of the edible nuts of Garcinia kola Heckel (bitter kola), which is valued in 
most parts of West Africa. It decreased blood sugar levels in normal and alloxan induced 
diabetic mice at a dose of 100mg/kg; as well as inhibited rat lens aldose reductase (RLAR) 
activity (Iwu et al., 1990).  
Other phenolic compounds have been identified as bioactive constituents but not from plant 
samples collected in Nigeria. A diacylated anthocyanin peonidin 3-O-[2-O-(6-O-E-feruloyl-
β-D-glucopyranosyl)-6-O-E-caffeoyl-β-D-glucopyranoside]-5-O-β-d-glucopyranoside 
isolated from the root of Ipomoea batatas (L.) Poir. showed potent maltase inhibitory effects 
in vivo (Matsui et al., 2002); while ellagic acid (26) and 3,5-dicaffeoylquinic acid (27) 
isolated from the hot water extract of the leaves showed potent aldose reductase inhibitory 
effects (Terashima et al., 1991).  
Lawsone (20) (a naphtoquinone) and gallic acid (21) isolated from the ethanol extract of the 
aerial parts of Lawsonia inermis L. inhibited the formation of advanced glycated end 
products in vitro (Sultana et al., 2009).  
Some methoxy phenyl derivatives (22-25) isolated from the rhizomes of Zingiber officinale 
Roscoe have been identified as aldose reductase inhibitors both in vitro and in vivo; 
suppressing sorbitol accumulation in human erythrocytes as well as lens galactitol 
accumulation in 30% galactose-fed rats (Kato et al., 2006). 
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Several isolated flavonoids have also been identified as bioactive constituents. 
Isoscutellarein (8-hydroxy apigenin)  (28) is a flavonoid isolated from the hot water extract 
of the leaves of Bixa orellana L., which was identified as an aldose reductase inhibitor 
(Terashima et al., 1991).  
Rutin (29) and quercetin (30) were isolated from the leaves of Bauhinia monandra Kurz as 
the anti-hyperglycaemic constituents in alloxan-induced diabetic rats (Alade et al., 2011) 
(Alade et al., 2012).  A bioassay guided fractionation of the stem bark of Cassia fistula L. 
led to the identification of catechin (33) as the bioactive agent. It decreased plasma glucose 
levels in STZ-induced diabetic rats, with direct effects on glucose metabolizing enzymes and 
expression of the glucose transporter GLUT4 (Daisy et al., 2010). 
Fractionation of the methanol extract of the leaves of Senna alata (L.) Roxb. (syn- Cassia 
alata), which showed potent α-glucosidase inhibitory effects, identified kaempferol 
gentiobioside (31) and kaempferol (32) as the bioactive compounds (Varghese et al., 2013).  
Increased translocation of GLUT4 receptors to the plasma membrane of L6 myotubes was 
also observed with a flavonoid-rich fraction of Scoparia dulcis L. (Beh et al., 2010), 
although the bioactive constituent(s) was not identified. 
The presence of aromatic hydroxyl groups in the benzo-ɣ-pyran structure of flavonoids is 
associated with its antioxidant properties, particularly its free radical scavenging effects. 
These properties have been shown to protect pancreatic islet cells from oxidative stress as 
well as help in the regeneration of β-cells as shown with epicatechin found in green tea 
(Sabu et al., 2002) and quercetin (Coskun et al., 2005). More importantly, they can prevent 
the formation of advanced glycated end products (AGEs) and other diabetic complications 
associated with high oxidative stress conditions such as artherosclerosis, nephropathy, 
neuropathy, retinopathy and erectile dysfunction (Rahimi et al., 2005). Thus, the presence of 
quercetin and epicatechin as well as other potent antioxidant flavonoids in a wide range of 
plants such as Irvingia gabonensis, Khaya senegalensis, Mangifera indica, Securidaca 
longipedunculata and Ocimum gratissimum, will contribute to -and in some cases may be 
the basis for- their use in the holistic management of diabetes which includes the prevention 
of diabetic complications.  
Other flavonoids have also been shown to directly affect specific therapeutic targets in 
diabetes. For instance, supplementation of mice diet with naringin or hesperidin modulated 
the activity of glucose metabolizing enzymes, with an increase in hepatic glucokinase 
activity and decrease in hepatic glucose-6-phosphatase activity in diabetic db/db mice (Jung 
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et al., 2004) and GK type-2 diabetic rats (Akiyama et al., 2009). These two flavonoids are 
constituents of all citrus fruits and have also been identified in Senna alata (Hennebelle et 
al., 2009) and Rauvolfia vomitoria (Campbell-Tofte et al., 2011) and as such may account 
for some of their effects. Myricetin is another flavonoid that has shown direct beneficial 
effects in diabetes through enhanced glycogen metabolism (Ong and Khoo, 2000) and 
improved insulin sensitivity (Liu et al., 2007). It has been identified in some of the plants 
either in its aglycone form or as a glycoside and may thus contribute to their anti-diabetic 
effects. These are the Allium species, Aloe vera, Azadirachta indica, Citrus species, Carica 
papaya, Bryophyllum pinnatum, Cassia sieberiana, Chrysophyllum albidum, Ipomoea 
batatas and Bridelia ferruginea.  
2.3.1.3.4 Hydroxylated compounds including sugars 
Some other non- phenolic hydroxylated cyclic compounds have been isolated and identified 
as bioactive agents. These include 6- (34), 8- (35) and 10-gingerols (36) from Zingiber 
officinale, which were shown to enhance glucose uptake into muscles as a result of a direct 
increase in the expression of the GLUT4 receptor (Li et al., 2012).  
An inositol derivative, D-3-O-methyl chiroinositol (37) isolated from the methanol extract of 
the stem bark of Bauhinia thonningii Schum. produced a dose-dependent decrease in blood 
glucose levels in alloxan-induced diabetic rats (Asuzu & Nwaehujor 2013).  
 
Figure 2.5: Other hydroxylated compounds identified as active principles from plants used in 
diabetes management. 
 
Finally, a number of benzyl derivatives including carbamates and thiocarbamates have been 
isolated from fractions of the methanol extract of the fruits of Moringa oleifera Lam. These 
compounds have been shown to possess insulin secretory effects in pancreatic INS-1 cells at 
the very low dose of 100ppm. Some of these compounds were identified as 1-O-phenyl α-L-
rhamnopyranoside (38), methyl N-(4-α-L-rhamnopyranosyl)benzylcarbamate (39); and 
methyl N-4-(4’-O-acetyl-α-L-rhamnopyranosyl)benzylcarbamate (40).  
(37) (34);  [R= (CH2)4CH3] 
(35) ; [R= (CH2)6CH3]
(36); [R= (CH2)8CH3] (38); (R=H, R1=H)
(39); (R=H, R1=CH2-H-CO-Ome)
(40); (R=CO-Me, R1=CH2-NH-CO-Ome)
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2.3.2 Assessment of the Clinical Evidence 
The validation of biologically active plants in randomized, placebo-controlled clinical trials 
involving human subjects is a necessary step towards the possible integration of traditional 
herbal products into health systems. For these purposes, isolation of the active constituent 
may not be necessary. The European Directive of Traditional Herbal Medicinal Products is 
an example of how reports of traditional use and a sound safety profile are enough to 
regulate herbal medicines (Cox and Roche, 2004). However, knowing the identity of the 
active principle would be ideal in order to ensure a better quality control and perhaps a more 
defined dosage. 
Fourteen plants have been clinically evaluated in human subjects, either singly or in 
combination. These are Bridelia ferruginea, Citrus aurantium, Gongronema latifolium, 
Ocimum gratissimum, Rauvolfia vomitoria, Vernonia amygdalina, Carica papaya, Curcuma 
longa, Ipomoea batatas, Irvingia gabonensis, Gymnema sylvestre, Phyllanthus amarus and 
Solanum aethiopicum (Table 1; Appendix 1), of which the first six involved plant samples 
collected from Nigeria. Only Phyllanthus amarus did not produce the desired clinical effect 
(Moshi et al., 2001).   
Most of the clinical studies were not randomized, controlled trials but preliminary studies 
evaluating the therapeutic effect of the plant in human subjects. Exceptions to these were 
those carried out on Rauvolfia vomitoria and Citrus aurantium (Campbell-Tofte et al., 
2011), Irvingia gabonensis (Ngondi et al., 2009) and Ipomoea batatas (Ludvik et al., 2004). 
A meta-analysis by Leung and his colleagues of all clinical studies carried out on 
Momordica charantia identified flaws in most of the study design, despite the extract 
consistently producing a hypoglycaemic effect (Leung et al., 2009). These imitations in 
study design hinder their clinical utilization as herbal medicines as appropriate conclusions 
that will act as guidelines for their use cannot be drawn.  
A good knowledge of the traditional use of plants based on ethnobotanical studies is very 
important in the design of a good clinical study. This is especially important for plants which 
are used as mixtures, as the individual components may be working synergistically to 
produce the overall desired effect. An example is the synergistic effect produced by a 
decoction mix of the leaves of Gongronema latifolium, Ocimum gratissimum and Vernonia 
amygdalina in modulating baseline blood glucose levels, which was not observed with the 
individual plants (Ejike et al., 2013). Given that many of these herbal remedies are currently 
being taken by diabetic patients alongside their prescription medicines, a concerted effort 
between clinicians and researchers would be an ideal way to recruit patients to such studies.  
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To ensure the reliability of conclusions drawn from any clinical study, they should always 
involve proper planning with appropriate controls and ought to be conducted within a 
reasonable time frame; in line with the guidelines of the ‘Declaration of Helsinki’. In 
addition, the recommendations for reporting randomized clinical trials, as defined in the 
‘Consolidated Standards of Reporting Randomized Clinical Trials (CONSORT) statement’ 
(Schulz et al., 2010) should also be followed. Nonetheless, this relatively high ‘success’ rate 
amongst the various studies conducted highlights the potential of harnessing ethnobotanical 
information in enhancing patient therapy. 
2.3.3 Assessment of the Toxicological Evidence 
The administration of whole plant extracts or fractions consisting of a myriad of compounds, 
can elicit different biological effects in the body, some of which may be harmful. 
Sometimes, these toxic effects are only associated with certain parts of the plant. For 
example, the leaves of Senna occidentalis have hepatoprotective effects and are used 
traditionally for the treatment of liver disorders (Jafri et al., 1999). However, ingestion of 
toxins found in the seeds (beans) is thought to be the probable cause of acute hepato-
myoencephalopathy (HMP) in children (Vashishtha et al., 2009). This risk of toxicity 
associated with the use of herbal products is one of the main reasons for the hesitance 
amongst healthcare practitioners towards promoting their integration into healthcare 
systems.  
Adequate knowledge about the traditional use of such plants is very necessary as this often 
helps to forestall the ingestion of such toxic plants or plant parts. Sometimes the toxic 
component may have been identified such as abrin, a toxic protein found in the seeds of 
Abrus pecatorius, with an estimated human fatal dose of 0.1-1µg/kg (Kirsten et al., 2003). In 
rare cases, the hypoglycaemic agent in the plant could also be the toxic agent, such as with 
hypoglycin from Blighia sapida (Sherratt, 1986).  Thus, the therapeutic use of such plants as 
whole extracts is therefore not recommended.  
Various plants have been associated with specific organ toxicity. Examples include the 
nephrotoxic effects of Alstonia congensis, Aristolochia spp, Cassia sieberiana, Ficus 
exasperata, Securidaca longipedunculata and the hepatotoxic effects of Cassia sieberiana, 
Ficus exasperata, Morinda citrifolia, Ocimum gratissimum, Picralima nitida, Senna 
occidentalis and Sphenocentrum jollyanum. The cardiotoxic and neurotoxic effects of some 
other extracts have also been identified. Sometimes, these toxic effects are only seen at high 
doses, which would therefore not preclude their continued use as medicinal plants so long as 
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there is appropriate information about the safe dose ranges. The use of other more toxic 
plants would however need to be completely discontinued.  
A thorough analysis of the plant extracts as well as identified phytochemical constituents 
with respect to their safety/toxicity profile particularly in humans can ensure a critical 
assessment of its therapeutic potential. Previously, coumarins which are a component of a 
wide range of plants were identified as hepatotoxic based on various studies carried out in 
rodents. However, further studies have showed that certain animal species are resistant to 
coumarin-induced toxicity. The 7-hydroxylation metabolic pathway is the most favoured in 
humans leading to the formation of non-toxic metabolites, whereas in rats the most favoured 
pathway is a 3,4-epoxidation leading to the formation of toxic metabolites. Knowledge of 
this and a quantitative health risk assessment has now confirmed its safety in humans (Lake, 
1999; Felter et al., 2006). 
2.3.4 Assessment of the Potential Herb-Drug Interactions 
Evaluation of medicinal plants for potential herb-drug interactions is equally as important as 
its evaluation for efficacy and safety. Out of the one hundred and fifteen plants, thirty of 
them have shown in vitro and/or in vivo modulation of the activity of one or more of these 
ADME parameters (Figure 7). Some of these interactions were on absorption, either by 
modulating the effect of P-glycoprotein (P-gp), or by direct effects on the intestinal tight 
junctions. Other pharmacokinetic interactions were on metabolism, by interacting with one 
or more cytochrome P450 enzymes responsible for phase 1 metabolism or either of the 
phase 2 metabolic enzymes (Table 1; Appendix 1). 
For drugs that are P-gp substrates such as glibenclamide, this effect of the efflux transporter 
is one of the determinant factors in the recommended dose of the drug to ensure that an 
adequate therapeutic concentration is achieved in the blood stream. Co-administration of the 
drug with a herb with inhibitory effects on P-gp such as Acacia nilotica, Annona 
senegalensis, Bauhinia thonningii, Bridelia ferruginea, Carica papaya and Morinda lucida 
might result in increased plasma concentration of the drug.  
The activity of CYP enzymes can be modified either by induction or inhibition as seen with 
the extracts of Bixa orellana and Jatropha curcas respectively. The biological activity of the 
xenobiotics metabolized by these enzymes can be greatly altered as a result (Rendic and 
Carlo, 1997). St John’s wort (Hypericum perforatum) is a very good example of a herbal 
product that has produced clinically significant effects as a result of its interactions with P-
gp and CYP enzymes (Henderson et al., 2002). 





Figure 2.6: Identified in vitro pharmacokinetic herb-drug interactions. 
In vitro interactions have also been identified with the phase 2 metabolizing enzymes, 
particularly with the glutathione transferases (GSTs). As with P-gp & CYPs, such 
interactions can alter the plasma concentration and resulting therapeutic effect of the co-
administered substrate drug. In addition, GSTs directly control the levels of glutathione 
(GSH) within the cell. GSH also acts as an antioxidant within cells, and is particularly 
important in diabetic conditions characterized by oxidative stress.  Unfortunately, plants 
such as Securidaca longipedunculata which decrease GSH levels might be counter-
productive in diabetic patients. 
For many of the plants shown in Figure 2.6, the phytochemical constituents responsible for 
the pharmacokinetic interaction are still unknown. Polyphenols present in plants especially 
flavonoids have been the most implicated in herb-drug interactions, with direct effects seen 
with specific flavonoids on P-gp and drug metabolizing enzymes (Morris and Zhang, 2006) 
(Galati and O'Brien, 2004) (Hodek et al., 2002). It should however be taken into account that 
many of the in vitro pharmacokinetic interactions or alarming case studies published in 
primary literature fail to translate into significant clinical risks for the patients, as seen with 
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need for effective pharmacovigilance of herbal medicines to ensure their safe and effective 
use in therapeutic management (Shaw et al., 2012). 
2.4 CONCLUSIONS 
This assessment, which is based on data mining of already existing published data for the 
selected plant species, shows that there is very good preclinical evidence for the efficacy of 
most of the plants traditionally used in Nigeria for the management of diabetes, either as 
hypoglycaemic agents or as useful agents in the management of diabetic complications. The 
original contribution of this work is in the mapping of (1) their identified pharmacological 
mechanism/s of action and (2) potential interactions with key parameters of the ADME 
process that can arise from the use of these plants. This can serve to promote the more 
rational use of these plants as herbal medicines based on the expected therapeutic outcome 
and their tabulated toxicological effects.  
Given that only twenty three plants have been further explored to identify the active 
constituents responsible for their biological activity, the pharmacological evidence available 
for most of the plants can incentivise phytochemists to evaluate those plants with a potential 
for drug development. Particular emphasis can be given to those with no known 
toxicological effects but with identified molecular mechanisms of action. These include 
Anacardium occidentale, Ananas comosus, Carica papaya, Citrus aurantium, Irvingia 
gabonensis, Sarcocephalus latifolius, Solanum aethiopicum, Sorghum bicolour, Tamarindus 
indica, Telfaria occidentalis and Vernonia amygdalina. 
Finally, these data can provide evidential support for the clinical development of a number 
of medicinal plants as adjuvant therapy. The criteria for selection should be based on social 
acceptance/frequency of use (with particular focus on those commonly encountered as food 
and vegetables), efficacy and toxicity profile, and availability/sustainability of the supply 
chain, possibly tailored to each region. A set of quality parameters for the standardisation of 
these plants as herbal preparations (such as Pharmacopoeial monographs) would be required 
to ensure the reproducibility of their therapeutic effects. As a means of giving credence to 
the pre-clinical experimental evidence, intervention or clinical studies with the standardised 
materials should be carried out in order to validate their usefulness in diabetes management. 
With this assessment, the therapeutic potential of these medicinal plants may be harnessed 
towards a possible integration into the healthcare system. 
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3 ASSESSMENT OF PHARMACOKINETIC HERB-DRUG 
INTERACTIONS AMONGST DIABETIC PATIENTS- FIELD 
WORK IN NIGERIA  
  




The use of herbal medicines as one of the aspects of traditional medicine practice is 
increasingly being promoted in developing countries as a means of meeting the unmet 
healthcare needs of the population.  As a result, a number of diabetic patients utilize herbal 
medicines as supplementation to their conventional medicines for their disease management.  
The chronic nature of the treatment for diabetes however increases the risk of potential herb-
drug interactions. The implications of clinically relevant herb-drug interactions can have far-
reaching effects for the Nigerian population. Thus, by anticipating potential toxicities or 
possible herb–drug interactions, clinically relevant HDIs with significant risks which would 
otherwise present a further burden on the patient and on the country’s healthcare system can 
be avoided. 
A fieldwork study to identify the herbal medicines used by diabetic patients in Nigeria in 
their disease management was carried out. The objective of the study was to assess the 
potential for pharmacokinetic herb-drug interactions amongst this ‘at risk’ group based on 
available information about herbal medicines and the pharmacokinetic profile of the 
prescribed drugs used by the patients. 
3.2 RESEARCH DESIGN AND METHODS 
3.2.1 Management of Diabetes in Nigeria by Traditional Medicine 
Practitioners 
In order to obtain information about herbs traditionally used in the management of diabetes 
in Nigeria, visits were done to five of the six geopolitical zones in Nigeria (Kaduna-North 
west, Abuja-North central, Imo-South east, Benin- South south and Lagos & Ibadan- South 
west) between February and April 2011 (Figure 3-1). The North east could not be visited 
due to political unrest and militant activities in the area.  
Based on recommendations by members of the communities visited or visits to local herbal 
markets (Bode market in Ibadan Oyo state, Mushin market in Lagos and Zaria market in 
Kaduna and herbal trade fairs in Lagos and Kaduna), a total of thirty persons involved in 
traditional herbal medicine practice were approached to be interviewed about their 
traditional management of diabetic patients. 
Semi structured interviews based on a sample questionnaire were conducted on those 
persons who consented. Data obtained from those contacted include- background 
information about age, sex and occupation, duration of practise as a traditional medicine 
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practitioner, understanding of diabetes and method(s) employed for treatment including the 
names of any herbal medicines used. 
Information provided about medicinal plants used in diabetes management was verified by 
consulting different literature to determine the botanical names of plants from their given 
local names. Identification of collected plant samples was done by Mr. Ibrahim Muazzam, 
an ethnobotanist and staff of the department of medicinal plant research & traditional 
medicine, National Institute for Pharmaceutical Research & Development (NIPRD) for plant 
samples collected in the north; and by staff of the Forestry Research Institute of Nigeria 
(FRIN) in Ibadan for samples collected in the south. 
 
  Figure 3-1: Map of Nigeria with stars indicating places visited as part of field work. 
                                  





Figure 3-2: Aerial photograph of Bode market in Ibadan 
 
   
Figure 3-3: (a) Close-up photos of some medicinal plant leaves and (b) Fruits of 
Pseudocolocynth or ‘Tagiri’ (Lagenaria breviflora (Benth.) Roberty) sold in the herbal market. 
(Pictures taken during fieldwork visit).  
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3.2.2 Assessing the Risk of Herb-Drug Interactions amongst Diabetic Patients 
A follow-up study to obtain information about the use of herbal medicines alongside 
prescription drugs by diabetic patients in Nigeria was conducted in August and September 
2012 in the Pharmacy departments of two secondary health care facilities- General hospital 
Lagos Island and Central hospital Benin City- two urban cities in the southern part of 
Nigeria. The study -including the proposed questionnaire to be administered- was approved 
by the ethics committee of UCL (Appendix 2- Ethics Application 4124/001); and prior 
consent was also obtained from the hospitals (Appendix 3).  
Diabetic patients visiting the Pharmacy departments of the hospitals were selected based on 
the presence of an anti-diabetic drug on their prescription sheet. All patients meeting the 
above criteria were approached to be interviewed. However, only those who gave their 
consent were asked questions assessing their herb use based on a semi-structured 
questionnaire (Appendix 4). These questions were asked while drugs were being dispensed 
and medication counselling was given to the patients afterwards.  
Information obtained from the questionnaire are  demographic background of respondents 
including age and sex, information on the identity of the herbs (where available) and 
prescription drugs used either for diabetes or other co-morbidities as well as the monthly 
cost of prescription. Herbal medicines as used in this study consisted of the following: 
supplements containing extracts of medicinal plants, un-standardised herbal preparations 
from herbalists, herbal preparations made by the patients themselves using plant parts 
purchased in herbal markets or collected from their own gardens. 
The descriptive and inferential statistics to determine measures of frequency and relationship 
between variables were carried out using IBM SPSS statistical package (version 22, IBM 
U.S.A.). Chi square test was used to test the association of herb use with patients’ 
background characteristics such as gender, age groups, presence of co-morbidities and cost 
of monthly prescription. Significant relationship between variables was identified if p < 
0.05. 
3.3 RESULTS AND DISCUSSION 
3.3.1 Management of Diabetes by Traditional Medicine Practitioners  
Only twenty of the thirty persons contacted agreed to be interviewed about their use of the 
herbs in diabetes management. A summary of their socio-demographic characteristics are 
given in Table 3-1. Most of the respondents were male (85%). Half of them were aged 
between 45 & 60 years. Their years’ of experience ranged from 5 to 50, but did not always 
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correlate with the age of the practitioner. Those who obtained their knowledge from family 
members often started practising at an early age; and so might have more years of 
experience than older respondents.  
Eighteen respondents were traditional medicine practitioners (TMPs), one of whom was also 
a trained ethnobotanist; while two were herbal sellers in local markets. For the former, the 
conducted interviews were aimed at obtaining information about their management of 
diabetic patients. The results are shown in Table 3-2. While for the latter, only information 
about plants used and/or sold for the management of diabetes was obtained. A summary of 
the plants mentioned by all the respondents is given in Table 3-3. 
Table 3-1: Socio-demographic characteristics of TMPs & Herbal sellers 



























Type of herbal education/training (TMPs) 
Family inheritance only 
Informal education/Apprenticeship only 
Formal education 
Family inheritance & Formal education
§
 
Family inheritance & Apprenticeship 












§Formal education undertaken by these respondents was for formulation and packaging of herbal 
medicines. 
 
A general consensus amongst all the TMPs was that diabetes is a disease characterised by an 
excessive amount of ‘sugar’ in the body, often as a result of improper diet habits. This 
understanding of diabetes, may be due to the local names for diabetes in Nigeria; known as 
‘ciwan sugar’ in Hausa, ‘oria sugar’ in Igbo and ‘ito-sugar’ in Yoruba. When literally 
translated to English, these all mean ‘sugar disease’. Other local names for diabetes include 
‘atogbe’ in Yoruba, ‘yar maiko’ in Hausa and ‘oboro mammiri’ in Igbo, which in translation 
represent one of the other mentioned symptoms of diabetes.  
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Table 3-2: Knowledge of diabetes and its management by herbalists and herbal sellers 
TMP’s knowledge of diabetes & its management  Respondents (n=18) 













Delayed wound healing 
Coughing 
Memory loss             
Yellowing of the eyes 





















Method of diagnosis: 
Symptoms only 
Symptoms & diagnostic test 









Mode of treatment: 
Herbs only 
Herbs & diet 
Herbs & non-plant parts  
Herbs & nutritional supplements 
Herbs & divinations 








Duration of treatment: 
≤ 2 weeks 
2 weeks – 3 months 







*Respondents’ made a diagnosis based on one or more of the symptoms indicated, with or without a 
laboratory test. 
#The patient is asked to urinate on a particular local leaf called ‘awede’ (Heterotis rotundifolia 
commonly known as ‘chickweed’); and then a confirmatory diagnosis is given if the leaf changes 
colour from green to black. 
 
Some of the symptoms used by the TMPs for their diagnosis such as ‘yellowing of the eyes’, 
‘memory loss’ and ‘coughing’ are not known clinical symptoms of diabetes. However, these 
were each mentioned by only one of the herbalists. In addition, most of the respondents 
mentioned the use of at least one known clinical symptom of diabetes in their diagnosis.  
One of the TMP’s description of the disease was unrelated to the clinical understanding of 
diabetes, while another suggested it to have an underlying spiritual basis. 
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“The definition of diabetes in the context of sugar isn’t correct because diabetes 
existed long before sugar was known. It is an air-borne disease that is carried by the 
wind, which affects the liver when inhaled”. (MC) 
“Diabetes is a spirit-related disease linked to sugar, which is why it is called ‘yar 
maiko’ in Hausa. Although it is associated with starchy diet and sweet foods, these 
are only contributory factors and not the causative agent”. (MM) 
The first response might indicate a false diagnosis and pose a risk of the patient not being 
properly managed for diabetes. Interestingly though, the TMP mentioned the use of only one 
plant Anogeissus leiocarpus (DC.) Guill. and Perr. in his management of diabetic patients, 
whose hypoglycaemic effects in vivo in alloxan-induced diabetic rats has previously been 
evaluated based on an ethnobotanical study (Etuk and Mohammed, 2009).  
The traditional management of diabetes by the herbalists is usually aimed at reducing the 
high blood sugar levels. Several herbalists posit that ‘bitter-tasting’ plants are effective 
treatments for diabetes. The perception of most TMPs is that the use of herbal medicines 
brings about a complete cure of diabetes, which orthodox medicines fail to do. This is 
probably because most practitioners consider blood glucose control as the end goal for 
diabetes treatment. Only five of the respondents associated the disease with an impairment 
of the function of insulin from the pancreatic beta cells. As such, they were all aware that a 
reduction in blood glucose levels is not an indication for ‘cured diabetes’. For this latter 
group, their focus in diabetes management is twofold: first for blood glucose control and the 
second for pancreas regeneration.  
When asked about the side effects and possible interactions of herbal medicines, most TMPs 
considered these medicinal plants to be relatively ‘safe’ compared to conventional drugs; 
although one respondent identified possible side effects like dizziness, body weakness and 
night sweats. Two respondents mentioned that the unwanted effects produced by certain 
plants are not seen with the leaves but by the stem bark and roots.  
“Although plants can produce certain unwanted effects in people, these interactions 
are more common with the other parts of the plant like the root and the bark, but not 
the leaves”. (EO) 
It however seems that most respondents consider these ‘more toxic’ plant parts as having 
greater efficacy as reflected in table 2-3, given that the barks and the roots are the more 
frequently used plant parts. Most TMPs said that they discourage their patients from using 
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orthodox medications when undergoing treatment, not necessarily to prevent herb-drug 
interactions since they weren’t aware of that but to prove the efficacy of their treatment.  
The full cost of diabetes ‘treatment’ by the TMPs varied greatly, ranging from 15000 naira 
(≈ £60) to 250000 naira (≈ £1000). This was often dependent on the severity of the patients’ 
symptoms (based on the blood glucose level at diagnosis) which would in turn determine 
what plant parts would be used as well as the duration of treatment. For less readily available 
plants which need to be collected from the forests, incurred transportation costs would 
contribute towards the treatment costs. A few respondents said that the patients’ financial 
status sometimes determines how much he/she is asked to pay for treatment.  
The advantage of herbal medicine use to low income earners is the option of flexible 
payment to TMPs or self-sourcing of the plant themselves if the identity is known. An 
alternative is that patients visit herbal markets (Figure 3-2) and the herbal sellers recommend 
different medicinal plants for the particular ailment of interest, which can either be single or 
multi-component. The patients then purchase the plant parts and prepare it for themselves at 
home, either by infusion or decoction.  
A total number of fifty eight identified medicinal plants used for the traditional management 
of diabetes were obtained from the respondents (Table 3-3). Some plants which could not be 
identified by their local names are not included in the table due to the absence of plant 
samples/voucher specimens. Forty of the identified medicinal plants were mentioned by only 
one of the respondents. This may not necessarily be due to the unpopularity of these plants 
but might be a result of the few number of respondents interviewed. In fact, only two of the 
identified medicinal plants- Phaseolus lunatus L. and Stachytarpheta indica (L.) Vahl  are 
herein identified for the first time as being used in diabetes management in Nigeria, although 
ethnobotanical studies has identified their use in other parts of the world. 
Two of the plants- Picralima nitida (Stapf) T. Durand & H. Durand (PN) and Vernonia 
amygdalina Delile (VA) were the most frequently used based on informant consensus. They 
were both mentioned by nine out of the twenty respondents interviewed, with the use of the 
former by at least one TMP in all of the geopolitical zones visited. Pharmacological 
evidence of their hypoglycaemic effects has been confirmed, including a study carried out 
with VA in human subjects (Ejike et al., 2013). The alkaloid akuammicine has also been 
isolated from the seeds of PN and identified as one of the constituents responsible for its 
biological activity (Shittu et al., 2010). 
Chapter Three – Assessment of Pharmacokinetic Herb-Drug Interactions in Diabetic Patients 
71 
 





Local name(s) Places where 
plant is used 
No of times 
mentioned (%) 
Part(s) used Mode of use in diabetes management 
Ageratum conyzoides 
 (L.) L. 
Compositae Goat weed Imi esu (Ibo) 
Arusansan (Yoruba) 
Abuja (NC) 1 (5%) Whole plant The fresh plant sample is macerated and the liquid extract 
taken twice daily. 
Juice extract from the fresh plant is applied to diabetic foot 
ulcers to promote wound healing.  




Kaduna (NW)  
Lagos(SW) 
4 (20%) Bulb The fresh bulb is added to liquid herbal preparations 
containing other medicinal plants. 
Aloe vera (L.) Burm.f. Asparagaceae Aloe vera  Imo (SE) 1 (5%) Whole plant Juice extract is drunk or used as a component of a mixed 
anti-diabetic herbal preparation for diabetes. 
 

















3 (15%) Bark 
 Leaves  
Gum 
A decoction of the leaves (or bark) is taken twice daily. 
The gum bark can also be chewed. 
Annona senegalensis 
 Pers. 
Annonaceae Wild custard 
apple  
Uburu ocha (Ibo) 
Ogoganto (Esan),  




Edo (SS) 1 (5%) Stem-bark A decoction of the stem bark is drunk as a mixture of barks 
used in the management of diabetes. 
Anogeissus leiocarpus 
 (DC.) Guill. & Perr. 
  




Abuja (NC) 1 (5%) Stem-bark A decoction of the stem bark (boiled for several hours) is 
taken twice daily. 
Anthocleista 
djalonensis A. Chev.  
Gentianaceae Cabbage tree Uvuru (Igbo) 






2 (10%) Stem-bark 
Root 
A decoction of the stem bark is drunk, either singly or as a 





Ako-igun (Yoruba) Lagos (SW) 
Edo (SS) 
Kaduna (NW) 
5 (25%) Root One teaspoon of the powdered root (mixed with Khaya spp, 
Mondia whitei) is dissolved in warm water & taken twice 
daily. 
Powdered root (with Picralima nitida seeds) are mixed in 
lime juice and taken twice daily. Substitute lime juice with 
coconut water in patients with ulcer. 
 
Beta vulgaris L. Amaranthaceae Beetroot  Imo (SE) 1 (5%) Root 
vegetable 
Juice extract is drunk or used as a component of herbal 
preparation for diabetes. 
 
Bridelia ferruginea  
(Benth.) Mull.Arg 
 






1 (5%) Stem-bark 
Root 
A decoction of the stem bark is drunk, either singly or as a 
mixture with other barks used in the management of 
diabetes. 
 







Local name(s) Places where 
plant is used 
No of times 
mentioned (%) 
Part(s) used Mode of use in diabetes management 
Bryophyllum pinnatum 
 (Lam.) Oken 






Lagos (SW) 1 (5%) Leaves The powdered leaf (mixed with Picralima nitida seeds and 
the bark of unripe plantain) is given as maintenance 
medication when the glucose level is controlled. 
 




Kaduna (NC) 1 (5%) Seeds Dried powdered seeds are mixed with other plants (see 
above). 










2 (10%) Root A pinch of the powdered root (mixed with Picralima nitida 
seeds and Diterium senegalensis stem bark) is taken 2ce 
daily after food. 
A glass full of a decoction of the root is taken twice daily. 
Cassytha filiformis L. Lauraceae Love vine Rumfargada 
(Hausa) 
 




Sapotaceae Star apple Agbalumo (Yoruba) 
Udala (Igbo) 
Imo (SE) 1 (5%) Stem-bark 
Seeds 
Fruit 
A decoction of the stem bark is drunk, either singly or as a 
mixture with other barks used in the management of 
diabetes. 
Citrullus lanatus 
 (Thunb.) Matsum. & 
Nakai 
Cucurbitaceae Water melon Bara (Yoruba) 
Egusi (Igbo) 
Kaduna (NC) 1 (5%) Seeds 
Fruits 
The powdered seeds are used as a condiment in local soups. 
Citrus aurantiifolia 
(Christm.) Swingle 








3 (15%) Fruit The juice from the fruit is often used as the vehicle for 
herbal preparations. 
Cochlospermum 
planchonii Hook. F. ex 
Planch. 
Bixaceae False cotton Awo owu (Yoruba) 
Zunzunaa (Hausa) 
Abuja (NC) 1 (5%) Roots 
Stem-bark 
 
A decoction of the powdered roots is taken twice daily. 










An infusion of the leaves is drunk or the powder is sprinkled 
on food. 
Cucumis sativus L. Cucurbitaceae Cucumber  Imo (SE) 1 (5%) Fruit The fruit is eaten or the juice extract drunk.  
The juice an ingredient in a multi-component herbal 
preparation. 
Daniellia ogea (Harms) 
Holland 






Edo (SS) 1 (5%) Stem bark A decoction of the stem bark is drunk as a mixture of barks 
used in the management of diabetes. 
Daucus carota L. Apiaceae Carrot  Imo (SE) 1 (5%) Root 
vegetable 
The root vegetable is eaten fresh or the extract is drunk 
regularly by diabetic patients. 
Detarium senegalense 
J.F.Gmel. 




Abuja (NC) 1 (5%) Stem bark A pinch of the powdered stem bark (mixed with Picralima 
nitida seeds and Cassia sieberiana root) is taken twice daily 
after food. 







Local name(s) Places where 
plant is used 
No of times 
mentioned (%) 





Botanical synonym:  
Marsdenia latifolia 
(Benth.) 






4 (20%) Leaves Powdered dried leaves are taken as a tea infusion. 
Fresh leaves are blended (mixed with Vernonia amygdalina) 
and the liquid extract is drunk. 





Apocynaceae  Erin (Yoruba) Ibadan (SW) 1 (5%) Stem bark A decoction of the stem/root is drunk, either singly or as a 
mixture of barks used in the management of diabetes. 
 
Isoberlinia doka  Craib 
& Stapf 
Leguminosae Doka Doka (Hausa) Kaduna (NW) 1 (5%) Stem 
Root 
A decoction of the stem/root is drunk, either singly or as a 
mixture of barks used in the management of diabetes. 
 










2 (10%) Stem bark A decoction of the stem bark is drunk, either singly or as a 
mixture of other barks used in the management of diabetes. 
A teaspoonful of the powdered stem bark in a mix with other 
plants is dissolved in warm water and drunk twice daily. 
Khaya senegalensis 











2 (10%) Stem bark A decoction of the stem bark is drunk, either singly or as a 
mixture of other barks used in the management of diabetes. 
Mangifera indica L. 
  
Anacardiaceae Mango Mangoro Edo (SS) 1 (5%) Stem bark A decoction of the stem bark is drunk as a mixture of barks 
used in the management of diabetes. 
Mondia whiteii (Hook. 
F.) Skeels  
Apocynaceae White ginger Isirigun (Yoruba) 
 
Lagos (SW) 1 (5%) Root The powdered root (with Aristolochia repens root and 
Khaya spp bark) is mixed in warm water and the liquid is 
taken. 
Moringa oleifera Lam. Moringaceae  Zogale (Hausa) 
Ewe igbale 
(Yoruba) 
Okwe oyibo (Igbo) 
Imo (SE) 
Kaduna (NC) 
1 (5%) Leaves A warm infusion of the powdered leaves (mixed with 
Vernonia amygdalina, Picralima nitida and pawpaw seeds) 
is taken twice daily. 
Powdered leaves are sprinkled on meals. 
 
Musa spp  Musaceae Plantain 
Banana 
 Imo (SE) 
Kaduna (NW) 
Lagos (SW) 




The plant parts are crushed with a mortar and pestle and the 
juice extract is taken (half a shot 3ce daily with/without 
honey). 
The unripe plantain fruit is cut into small pieces and then 
macerated in water for a few days. The liquid is taken as a 
drink several times a day. 
 
Nauclea pobeguinii 
 (Pobeg. Ex Pellegr.) 
Merr. Ex E.M.A. Petit 
 
Rubiaceae  Ubulu-ilu (Igbo) Imo (SE) 1 (5%) Bark A decoction of the stem bark is drunk, either singly or as a 
mixture with other barks used in the management of diabetes 
Ocimum gratissimum 
L. 








2 (10%) Leaves Powdered leaves are drunk as a tea infusion. 







Local name(s) Places where 
plant is used 
No of times 
mentioned (%) 
Part(s) used Mode of use in diabetes management 
Persea americana Mill. Lauraceae Avocado 
pear 
 Kaduna (NW) 
Edo (SS) 
2 (10%) Seed 
Stem-bark 
A decoction of the stem bark/seed is drunk, either singly or 
as a mixture of other barks used in the management of 
diabetes. 
 
Phaseolus lunatus L. Leguminosae Lima beans Akidi (Igbo) Imo (SE) 1 (5%) Seeds The seeds are cooked and eaten as a meal. 
A decoction of the seeds is taken mixed with other plants 
used for diabetes. 
Picralima nitida (Stapf) 









Apocynaceae  Osu-igwe (Igbo) 







9 (45%) Seeds Powdered seeds are sprinkled on food (alone or mixed with 
Cassia sieberiana root and Diterium senegalensis stem bark) 
before eating. 
An infusion of the powdered seeds is made with warm water 
and drunk before meals. 
Powdered seeds are macerated overnight in water or in lime 
juice (mixed with mistletoe leaves) and one or two shots of 
the mix taken thrice daily. 
The powdered seeds are macerated (in a mixture with 
Bryophyllum pinnatum and the bark of unripe plantain) and 
the liquid is taken thrice daily. 
Powdered seeds (with Aristolochia repens) are mixed in 
lime juice and taken twice daily. Substitute lime juice with 







Leguminosae Camel’s foot Kalgo (Hausa) Abuja (NC) 1 (5%) Roots A decoction of the roots is taken thrice daily. 
Piper nigrum L. Piperaceae Black 
pepper 









Lagos (SW) 1 (5%) Stem A decoction of the stem/root is drunk, either singly or as a 
mixture of barks used in the management of diabetes. 
Sarcocephalus 
latifolius (Sm.) E. A. 
Bruce 
Botanical Synonym: 





Abuja (NC) 1 (5%) Stem bark A decoction of the stem bark is drunk, either singly or as a 
mixture with other plant materials used in diabetes 
management. Alcohol can also be used as the vehicle. 
Scoparia dulcis L. Plantaginaceae  Roma fada (Hausa) 
Mesenmesen/gogor
o (Yoruba) 
Abuja (NC) 1 (5%) Whole plant A decoction of the whole plant is drunk. 









Lagos (SW) 2 (10%) Root  
Leaves 
Powdered parts (singly or together) are macerated in warm 
water and the liquid taken twice daily. 
Sphenocentrum 
jollyanum Pierre 
Menispermaceae  Akerejupon 
(Yoruba) 
Lagos (SW) 1 (5%) Root The roots are macerated in water for three days. Half a glass 
of the filtrate is drunk every day. 







Local name(s) Places where 
plant is used 
No of times 
mentioned (%) 
Part(s) used Mode of use in diabetes management 
Stachytarpheta indica 
(L.) Vahl 
Verbenaceae   Abuja (NC) 1 (5%) Whole plant The fresh plant sample is macerated and the liquid extract 










3 (15%) Stem A decoction of the stem bark is drunk, either singly or as a 




Myrtaceae  Malmoo (Hausa) 
Adere (Yoruba) 
Ori (Igbo) 
Kaduna (NW) 1 (5%) Stem 
Root 
A decoction of the stem/root is drunk, either singly or as a 
mixture of barks used in the management of diabetes. 
Tamarindus indica L. Leguminosae  Tsamiya (Hausa) 
Icheku oyibo (Igbo) 
Ajagbon (Yoruba) 
Kaduna (NW) 1 (5%) Stem 
Root 
A decoction of the stem/root is drunk, either singly or as a 
mixture of barks used in the management of diabetes. 
Tapinanthus 
bangwensis (Engl. & 
K. Krause) Danser 
Botanical Synonym: 
Loranthus bangwensis 




 Imo (SE) 
Lagos (SW) 
Abuja (NC) 
5 (25%) Leaves Powdered leaves are soaked overnight in water and the 
mixture is heated up the next day and drunk. 
Powdered leaves are soaked overnight in lime juice (mixed 
with Picralima nitida) and a shot is taken thrice daily. 
Powdered dried leaves are drunk as a tea infusion. 
A tablespoonful of the powdered leaves (mixed with equal 
amount of Securidaca longepedunculata) are taken at night. 




Ugwu (Igbo) Imo (SE) 1 (5%) Seeds The seeds are dried for several days and the powdered form 
is either sprinkled on food or taken as an infusion. 
 
Terminalia 
avicennioides Guill. & 
Perr. 
Combretaceae  Baushee (Hausa) Kaduna (NW) 1 (5%) Stem 
Root 
A decoction of the stem/root is drunk, either singly or as a 
mixture of barks used in the management of diabetes. 
Tetrapleura tetraptera 
(Schum. & Thonn.) 
Taub. 

















9 (45%) Leaves Fresh leaves are squeezed & the juice drank (could be mixed 
with garlic and ginger). 
Powdered dried leaves are drunk as a tea infusion.  
Powdered dried leaves (teaspoonful) are sprinkled on food. 
 
Ximenia americana L. Olacaceae  Tsaada (Hausa) Kaduna (NW) 1 (5%) Stem 
Root 
A decoction of the stem/root is drunk, either singly or as a 
mixture of barks used in the management of diabetes. 
 
Xylopia aethiopica 










Zingiberaceae Ginger Atale (Yoruba) Lagos (SW) 
Imo(SE) 
Kaduna (NW) 
3 (15%) Rhizome The fresh rhizome is added to liquid herbal preparations 
containing other medicinal plants (such as Alstonia boonei 
and Vernonia amygdalina) 
 
* This column indicates the ‘accepted’ botanical names of the identified plants according to the website http://www.theplantlist.org.  
† This botanical name by which the plant is known in Nigeria is not an ‘accepted’ name on http://www.theplantlist.org but is a synonym for the name indicated under botanical synonym. 
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3.3.2 Assessing the Risk of Herb-Drug Interactions amongst Diabetic Patients 
3.3.2.1 Patients’ background characteristics and health status 
A total number of one hundred and twelve (112) Type-2 diabetic patients, thirty seven (37) 
from Central hospital Benin-city and seventy five (75) from General hospital Lagos gave 
their consent and were interviewed for the study. A summary of the background 
characteristics of the interviewed patients is given in Table 3-4. Five age categories were 
created: < 30 years, 31-45 years, 46-60 years, 61-75 years and > 75 years. Most of the 
patients were aged between 61-75 years (50.9%), followed by those between 46-60 years 
(34.8%). More than 70% of the patients had one or more chronic co-morbidity alongside 
their diabetes, the most common of which was hypertension. The other identified co-
morbidities were arthritis, arteriosclerosis, hypercholesterolemia and neuropathy (Table 3-4).  
Exactly 50% of the patients took herbal medicines alongside their prescription drugs either 
for diabetes, for one of the co-morbidities or for the management of diabetes-related side 
effects such as erectile dysfunction. Reasons given by the patients for the use of these herbal 
preparations alongside their prescription drugs were: (a) General perception that herbs are 
very good especially when taken as part of the patient’s diet; (b) To decrease the costs of 
disease management since herbs are relatively inexpensive. In this case, the herbs are 
alternated with the drugs thereby resulting in non-adherence to pharmacotherapy; (c) Better 
feeling of ‘wellness’ when herbs are taken alongside the orthodox medications.  
Fourteen patients had recently discontinued their use of herbal medicines. Reasons given 
were- ‘based on advice by their doctor’, ‘due to perceived side effects’ and ‘disappointment 
at its lack of efficacy’. 
In general, for both males and females, approximately 50% used herbal medicines alongside 
their prescription drugs; and older patients (61-75 years) seemed more likely to use herbs 
than younger patients (Table 3-4). There was no statistically significant association between 
gender and herb use (x
2 
= 0.188, df = 1, p = 0.665); or between age and herb use (x
2 
= 1.555, 
df=4, p = 0.817).  
Given that the inherent characteristics of the individuals were not a predictor of herb use, it 
was hypothesised that the presence of one or more chronic co-morbidity as well as a high 
monthly prescription cost would incentivize more patients to use herbal medicines. These 
relationships were however not statistically significant (x
2 
= 3.041, df = 3, p = 0.385) for 
presence of co-mobidity and (x
2 
= 4.643, df=3, p = 0.2) for monthly cost of prescription.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               
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Age groups (years) 
 
≤ 30 
31 – 45 
46 – 60 


















Presence of co-morbidities Hypertension + Arteriosclerosis + Arthritis  
Hypertension + High cholesterol + Arthritis 
Hypertension + High cholesterol + Arteriosclerosis 
Hypertension + High cholesterol 
Hypertension + Arteriosclerosis  
Hypertension + Arthritis 




































                                                                                                                                                                                                        
Monthly prescription cost (Naira)* < 5000 



















* Data on cost of prescription was not obtained from all the interviewed patients (£1 ≈ 265 Naira, $1≈ 170 naira www.xe.com; Accessed 13th Nov 2014) 
+ Information about herb use in two patients was not obtained.  
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Based on this study, although there were more herb users within the group of patients with 
two or more chronic co-morbid conditions than the group with only one or none at all, 
patients in the former group were not more likely to use herbs than those without. In 
addition, contrary to expectation, a higher number of the patients who had to spend less 
money for their drugs (< 10,000 naira) used herbs than those who had to pay more. Finally, 
none of the individual co-morbidities was identified as a predictor for herb use among 
diabetic patients (Statistical data not shown).  
In trying to understand the opposing relationship between number of co-morbidities or 
monthly cost of prescription and herb use, it was observed that the prescription cost was not 
necessarily dependent on the number of co-morbidities the patient was being treated for, but 
on the choice of medication on the patient’s prescription. For instance, a patient might have 
only diabetes but may have been prescribed gliclazide by his/her doctor, which is more 
expensive than other types of sulphonylureas. Another patient on the other hand, having 
diabetes alongside other co-morbidities might be prescribed a cheaper sulphonylurea such as 
glibenclamide as well as other non-expensive medications for the co-morbidities resulting in 
lower prescription costs. Thus, patients with the need to purchase more drugs have the 
option and may request for less expensive alternative brands so as to minimize their drug 
expenses.  
3.3.2.2 Pharmacological management of diabetes 
A summary of the drugs used in the pharmacological management of diabetes in the 
interviewed patients is given in Table 3-5. The biguanide metformin was the most 
commonly prescribed anti-diabetic medication with over 90% of the interviewed patients on 
it. Most patients were however on more than one prescription drug, with 75% on metformin 
taken in combination with another anti-diabetic medication, most commonly a 
sulphonylurea. This is in addition to the drugs prescribed for other existing co-morbidities. 
Only three patients were on a single prescription drug for their diabetes management with no 
co-morbidity.  
Insulin was prescribed to less than 10% of the interviewed patients. The high costs of the 
injection as well as the need for it to be stored in the fridge makes it an unfavourable choice 
for patients since most of the Nigerian population do not have access to constant electricity. 
The preference for metformin as the first choice of treatment for diabetic patients in Nigeria 
is most likely due to its cheap costs (generic brands of metformin can be purchased for as 
little as 20 Naira – or 0.07 GBP- per tablet). Glibenclamide is another cheaply available oral 
anti-diabetic agent in Nigeria hence its popularity.  
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Table 3-5: Tabular summary of the pharmacological management of the patients’ based on 
their prescribed hypoglycaemic agents.  
Anti-diabetic Drug(s) No of Patients  Presence of co-morbidities* 
Glibenclamide only 1  1  
Insulin only 4  2 
Insulin + Gliclazide 1 0 
Metformin + Acarbose + Glibenclamide 2 1 
Metformin + Acarbose + Gliclazide + Insulin 1 1 
Metformin + Glibenclamide 42 25 
Metformin + Gliclazide 10 8 
Metformin + Gliclazide + Pioglitazone 3 3 
Metformin + Glimepiride 19 16 
Metformin + Glimepiride + Pioglitazone 2 2 
Metformin + Insulin 3 2 
Metformin + Insulin + Glibenclamide 2 1 
Metformin + Pioglitazone 1 1 
Metformin + Vidagliptin 1 1 
Metformin only 18 17 
* The presence of co-morbidities indicates that there are other non-hypoglycaemic agents on the patients’ 
prescription. 
 
Several studies show that the risk of harmful drug interactions increases with the number of 
drugs given to a patient (Fakeye et al., 2008). Similarly, the risk of herb-drug interactions is 
greatly increased for those patients taking herbal medicines who are on more than one 
prescription drug (Patsalos et al., 2002). Based on the results of this study, it can be stated 
that diabetic patients are high risk candidates for herb-drug interactions since they are likely 
to be on a multiple drug regimen of orally administered drugs.  
Table 3-6 gives a summary of the pharmacokinetic effects of the different drugs prescribed 
to the patients, including those for other co-morbidities. In particular, the table highlights the 




Chapter Three– Assessment of Pharmacokinetic Herb-Drug Interactions in Diabetic Patients 
80 
 
Table 3-6: Tabular summary of the interaction profile of the prescription drugs used by the surveyed diabetic patients on pharmacokinetic parameters 
commonly implicated in drug interaction studies 
Pharmacokinetic Interaction Prescription Drug  
P-glycoprotein Glibenclamide is a known substrate/inhibitor of P-gp (Lilja et al., 2007) (Golstein et al., 1999) 
Metformin inhibits P-gp expression (Kim et al., 2011) 
Vildagliptin & sitagliptin are known substrates for P-gp (He et al., 2007) (Krishna et al., 2007) 
Atorvastatin has been identified as a P-gp substrate in vitro & possibly an inhibitor due to interaction 
with digoxin (Lennernäs, 2003) 
Amlodipine stimulates P-gp efflux activity at low concentrations & inhibits it at higher concentration 
(Katoh et al., 2000b) 





























Competitive inhibition of CYP 1A2 activity by Nifedipine (Katoh et al., 2000a) 
 
Carriers of a reduced function allele of CYP2B6 tend to have about 15% relative reduction in the 
active metabolite of Clopidogrel (Mega et al., 2009) 
CYP2B6 catalyzes the metabolism of Tramadol to one of its metabolites M2 (Subrahmanyam et al., 
2001) 
 
About 56% of Pioglitazone is metabolised to its primary metabolite M-IV by CYP2C8 (Jaakkola et 
al., 2006) 
 
Glibenclamide & other sulphonylureas are primarily metabolized by CYP2C9. Some alleles of the 
enzyme metabolise the drug slower resulting in higher blood concentration & either greater therapeutic 
effect or increased risk of hypoglycaemia (Surendiran et al., 2011, Holstein et al., 2005, Yin et al., 
2005). 
Losartan is metabolized by CYP2C9 to its more pharmacologically active metabolite E3174 (Stearns 
et al., 1995). 
 
Clopidogrel is metabolized by CYP2C19 & genetic polymorphism in this isoenzyme affects its 
pharmacokinetics & pharmacodynamics. Carriers of a reduced-function allele had about 30% lower 
levels of the active metabolite of clopidogrel, diminished platelet inhibition, and a higher rate of major 
adverse cardiovascular events (Mega et al., 2009). 
 
 
The opioid effect of Tramadol is mediated by its M1 metabolite, which is catalysed by CYP2D6. The 
analgesic effect of tramadol has been found to be diminished when co-administered with inhibitors of 
the enzyme (Laugesen et al., 2005). 
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Competitive inhibition of CYP2E1 activity by Nifedipine (Katoh et al., 2000a) 
 
CYP3A4 has been identified as the other main enzyme responsible for the metabolism of 
Glibenclamide (Zhou et al., 2010a) 
CYP3A4 is responsible for the formation of two active metabolites from the acid and the lactone 
forms of Atorvastatin (Lennernäs, 2003) 
CYP3A4 is also responsible for the metabolism of Tramadol to its M2 metabolite (Subrahmanyam et 
al., 2001) 
Nifedipine is a known substrate for metabolism by CYP3A4 & prone to drug interactions with 
inhibitors of the enzyme (Patki et al., 2003) 
Indapamide is excreted after extensive metabolism by CYP3A4 (Sun et al., 2009) 
Losartan is also metabolized by CYP3A4 to its pharmacologically active metabolite E3174 & is also 
prone to clinically important drug interactions as seen when co-administered with grape fruit juice, a 
known CYP3A4 inhibitor (Zaidenstein et al., 2001) 
CYP3A4 is responsible for the metabolism of 37% of Pioglitazone (Jaakkola et al., 2006) 
Clopidogrel is also metabolized by CYP3A4 and inter individual variability in enzyme activity can 
significantly affect its efficacy (Lau et al., 2004)  
 
Increased risk of hepatotoxicity/hepatic impairment  Atorvastatin can induce asymptomatic mild elevation of serum transaminases, with the risk of 
hepatobilliary disease due to significant liver dysfunction in certain cases (Clarke and Mills, 2006)  
Risk of hepatotoxicity with Pioglitazone, thus caution is advised for patients with elevated ALT levels 
(Marcy et al., 2004).  
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3.3.2.3 Assessment of potential herb-drug interactions in the surveyed patients 
Less than 40% of the herb users were aware of the identity of the herbs used which they 
either grow or purchase themselves from herbal markets. The remaining 60% of the herb 
users (over 30% of all the diabetic patients) were unaware of the identity of the herbs used 
(Table 3-7). This is primarily because these were unlabelled herbal preparations (often 
multi-component) whose constituents were not divulged by the herbalists. In some instances, 
the patients said they were not very interested in finding out the identity as long as the 
preparation was effective. Thus, the risk of herb-drug interactions is even greater amongst 
this cohort of diabetic patients as they wouldn’t be able to give any information to their 
physicians/healthcare practitioners that can enable them provide appropriate advice with 
regards to its efficacy and/or safety. 
A total number of twelve medicinal plants were identified amongst the patients who knew 
the composition of the herbal remedies they used for their disease management. The most 
commonly used medicinal plant were the leaves of Vernonia amygdalina (Bitter leaf). It was 
also one of the most commonly used medicinal plants by the TMP’s in their diabetes 
management (Table 3-3). It is also a commonly used food vegetable particularly in the 
southern part of Nigeria, which may contribute to its popularity. As such, many diabetic 
patients easily include it as part of their diet.  
The other identified plants used by the diabetic patients are given in Table 3-7. Only four out 
of the twelve identified plants- Abelmoschus esculentus, Azadirachta indica, Terminalia 
catappa and Camellia sinensis weren’t previously mentioned by any of the herbalists 
contacted (Table 2-3). They are however known for their use in diabetes management based 
on other ethnobotanical surveys (Ezuruike and Prieto, 2014) (Oboh et al., 2014).  
Seven of these twelve plants have previously been identified as having the potential to cause 
pharmacokinetic herb-drug interactions based on interactions with prescription medicines or 
known pharmacokinetic parameters. In addition, three of the twelve plants Azadirachta 
indica, Picralima nitida and Terminalia catappa have also been shown to cause specific 
organ toxicities in large doses (Table 3-7). 
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Table 3-7: Tabular summary of the medicinal plants used by the diabetic patients and their known pharmacokinetic profile 




Effect on intestinal P-gp or other absorption 
mechanisms 
Effect on cytochromes or other hepatic 
enzymes (GSTs, ALT, AST) 
Other toxic effects 
Vernonia amygdalina Delile 
(Bitter leaf) 
13 (11.6) Inhibits P-gp efflux activity (Oga et al., 2012)  _ _ 
Ocimum gratissimum L. (Scent 
leaf) 
5 (4.5)   Dose dependent increase in AST & ALT 




3 (2.7) Polyvalent cations in the plant form non-
absorbable complexes with certain drugs (Nwafor 
et al., 2003) 
 _ _ 
Mangifera indica L. (Mango) 3 (2.7) Inhibits the P-gp efflux activity (Chieli et al., 
2009) 
 Inhibits CYP 1A1/2 & 3A4 activities in rat 
liver microsomes (Rodeiro et al., 2009) 
_ 
Persea americana Mill. (Avocado 
pear) 
2 (1.8) _  Inhibits CYP 3A4/5/7 enzymes to different 
extents (Agbonon et al., 2010) 
_ 
Gongronema latifolium Benth.  1 (0.9) _  _ _ 
Abelmoschus esculentus (L.) 
Moench (Okro) 
1 (0.9) Water soluble fractions inhibits metformin 
absorption in vivo (Khatun et al., 2011) 
 _ _ 
Anarcadium occidentale L. 
(Cashew) 
1 (0.9) _  _ _ 
Azadirachta indica A. Juss. 
(Neem) 
1 (0.9) _  _ Pharmacotoxic effects of neem 
oil in lungs & CNS (Gandhi et 
al., 1988) 
Camellia sinensis (L.) Kuntze 
(Tea) 
1 (0.9) _  _ _ 
Picralima nitida (Stapf) T.Durand 
& H.Durand (Akuamma plant) 
1 (0.9) _  Elevated AST, ALT & GSH levels 
(Kouitcheu Mabeku et al., 2008) 
Hepatotoxic effects (Fakeye et 
al., 2004) 
Terminalia catappa L. (Tropical 
almond) 
1 (0.9) _  _ Hepatotoxic at high doses due 
to punicalagin (Lin et al., 2001) 
Unknown 36 (31.9) NA  NA NA 
Discontinued 14 (12.4) NA  NA NA 
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One of the interviewed respondents ‘X’ was a 41 year old lady who took the squeezed 
extract of Vernonia amygdalina (VA) regularly as well as an overnight decoction of 
Mangifera indica (MI) and had the following drugs on her prescription- Metformin 1g twice 
daily, Glimepiride 4mg daily, Lisinopril 2.5mg daily, Atorvastatin 20mg daily and Aspirin 
75mg daily.  
Atorvastatin is a known P-gp substrate and is also metabolized by CYP3A4 enzymes to 
active metabolites (Lennernäs, 2003) . A combination of the inhibitory effects of VA and MI 
on P-gp efflux activity as well as the ability of metformin to decrease P-gp expression could 
bring about an increase in the plasma concentration of atorvastatin beyond the expected 
level. If the activity of CYP3A4 is however significantly inhibited by MI, then the effects of 
atorvastatin may not be seen despite its high plasma concentration given that the metabolite 
is the pharmacologically active entity.  
The afore-mentioned scenario is an identified ‘potential’ herb-drug interaction that may or 
may not translate to a clinical effect. It is however very useful preliminary information that 
would enable clinicians undertake better clinical monitoring of a patient’s disease 
management; and hence be more likely to identify clinically relevant herb-drug interactions 
if encountered.  
Table 3-8 represents a schematic map of the different potential pharmacokinetic interactions 
that can arise between the prescribed drugs and the identified herbs used by the surveyed 
diabetic patients and for which some form of monitoring should be done. The table shows 
that all the prescribed drugs could interact with one or more of 7 out of the 12 identified 
herbs (Table 3-8). Concurrent use of A. esculentus (okro) with metformin is a case to 
highlight, because of the extensive use of the drug and the in vivo experimental evidence for 
a herb-drug interaction. The use of avocado leaves, bitter leaf and mango leaves interfere 
with efflux pumps or cytochromes 1A2 and 3A4, with the latter potentially interacting with 
almost all drugs in the table. Finally, consumption of scent leaf, akuamma plant, and/or 
tropical almond could enhance the adverse hepatic effects of pioglitazone and atorvastatin.  
In addition to the possibility of an enhanced therapeutic effect for herbal medicines taken for 
the same pharmacodynamic effect as the prescription drug (i.e. increased hypoglycaemia); it 
is important for healthcare practitioners to be aware and on the lookout for any associated 
pharmacokinetic interactions of co-administered herbal medicines. Such pharmacovigilance 
monitoring would however only be possible when patients divulge their use of herbal 
medicines as well as the identity.   
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Table 3-8: Map of the potential pharmacokinetic interaction of prescribed drugs and herbs used by surveyed diabetic patients 
Prescription drug Pharmacokinetic effects  
Intestinal 
Absorption 
Efflux Cytochromes Liver Toxicity 
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Key: For the prescription drugs (a) is an identified substrate of the enzyme/protein; (b) inhibits enzyme/protein activity; (c) enhances enzyme/protein activity; (d) increases plasma 
levels of transaminases. The two letter codes denotes a herb which also affects the same PK target of the prescription drug: (MI) Mangifera indica (Mango); (VA) Vernonia 
amygdalina (Bitter leaf); (OG) Ocimum gratissimum L. (Scent leaf); (PN) Picralima nitida (Akuamma plant); (AE) Abelmoschus esculentus (Okro); (PA) Persea americana 
(Avocado pear); (TC) Terminalia catappa (Tropical almond). In bold, preclinical in vivo evidence is available for this potential herb-drug interaction.




The interviews conducted with TMPs, herbal sellers and diabetic patients in Nigeria have 
shown that a wide range of plants are still being used in the traditional management of 
diabetes in Nigeria. Most of these plants have previously been reported for their use in 
diabetes management with available experimental evidence of their pharmacological activity 
for all but six of the plants- Aristolochia repens, Cassia sieberiana, Citrus aurantifolia, 
Croton lobatus, Curculigo pilosa and Khaya ivorensis (Table 1, Appendix 1). 
Surprisingly, Aristolochia repens was the third most commonly identified medicinal plant, 
mentioned by five out of the twenty respondents contacted despite having no experimental 
evidence for its use. In addition, various species of the Aristolochia genus are known to 
cause nephrotoxic effects suggesting that this may pose a potential health risk; with its use 
banned in a number of countries (Heinrich et al., 2009).  
Although the TMPs purport that using herbal medicines can ‘cure’ diabetes, with some 
suggestions that some plants are able to regenerate the pancreas, this is yet to be proven. As 
such, contrary to the desire of TMPs to have their diabetic patients exclusively treated with 
herbal medicines, this is unlikely to be the case from the patient’s perspective. At the 
moment, diabetes is not known to have any ‘cure’, even with prescription drugs. Thus, for 
most diabetic patients who use herbal medicines, there might be a preference to co-
administer these ‘safer’ alternatives with their prescription drugs to bring about better blood 
glucose control. This rationale on the other hand can promote the risks of herb-drug 
interactions amongst these patients. 
One of the key findings of our study was that 50% of diabetic patients visiting hospitals in 
Nigeria use herbal medicines alongside conventional drugs for their disease management 
(Table 3.4). This result is similar to that obtained from a previous study carried out amongst 
diabetic patients visiting two different hospitals in Lagos which gave a prevalence of 46% 
(Ogbera et al., 2010).  
Neither the sex of the individual or his/her age was identified as a predictor of herb use 
within the sample population of diabetic patients interviewed during the fieldwork, even 
though herb use was more common amongst older patients than younger ones (Table 3-4). In 
addition, the choice of herbal medicine use was independent of the presence of co-
morbidities or the monthly cost of prescriptions. This lack of clinical predictors points 
towards cultural factors influencing the use of herbal medicines by Nigerian adult diabetic 
patients. A patient is therefore more likely to use herbal medicine if such practice is common 
in his/her family and he/she is convinced of the health benefits of the herbal medicine.  
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As a response to the changing attitudes of patients of Western medicine to the use of herbal 
medicines, this study is the first one to be carried out in Nigeria with the aim of specifically 
assessing the risks of herb-drug interactions amongst diabetic patients in Nigeria. The 
importance of this is highlighted not only by the high percentage of persons using herbal 
medicines alongside their conventional drugs but also by the high percentage of patients 
(>30%) who do not know the identity of the herbal medicines being taken, which equates to 
>60% of herb users (Table 3-7). This poses a huge problem since the toxicity and efficacy of 
the medicinal plant cannot be assessed, which also constitutes a serious limitation to the 
identification of herb-drug interactions.  
Unfortunately, the issue of ‘non-identification’ of herbs used by patients in Nigeria is 
unlikely to be immediately tackled. This is because TMPs who prepare the herbal 
preparations themselves insist that it is a ‘family secret’ of which a disclosure will rob them 
of their business (Ogbera et al., 2010). This is not an exaggerated claim if we take into 
account the history of “bio-piracy” by companies seeking to patent and profit from their 
knowledge without sharing benefits (Willcox and Bodeker, 2010). In any case, patients 
should be advised on the importance of knowing the identity of their herbal medicines 
especially as this would enable a proper identification of those with true therapeutic benefits. 
More importantly, this study highlights the need for an increased emphasis on the evaluation 
of herbal medicines used in Nigeria for potential pharmacokinetic and pharmacodynamic 
interactions. Not only because of the paucity of information available but also because of the 
overlap of a number of pharmacokinetic interactions between some of the herbal medicines 
and prescription drugs co-administered by diabetic patients as well as the lack of awareness 
by patients of the potential risks associated with herbal medicine use.  
Herbal preparations particularly for diseases like diabetes are often multi-component 
preparations whereby the management entails not just plants with hypoglycaemic effects, 
but also medicinal plants that might address the underlying symptom as well as resultant 
complications of the disease. Thus an increased risk of clinically relevant herb-drug 
interactions may be seen with these multi-component mixtures which with only one of the 
constituent plants may have produced an insignificant interaction effect.  
There is therefore always a need to follow up pre-clinical in vitro evaluations with a clinical 
assessment in humans utilizing the herbal formulations as they are used in practice. In the 
presence of sufficient appropriate information, other predictions of herb-drug interactions 
can be made by healthcare practitioners thereby necessitating appropriate clinical advice to 
forestall unwanted effects. 
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4 PHYTOCHEMICAL, BIOCHEMICAL AND BIOLOGICAL 
ANALYSIS OF PLANTS USED IN DIABETES 
MANAGEMENT IN NIGERIA 
  






Identification of pharmacokinetic herb-drug interactions would ideally require in vivo 
experimentation, preferably with human subjects if meaningful results are to be obtained. 
The ethical issues and high costs associated with this approach are often justified by the 
existence of case reports, pharmacovigilance data and/or preliminary in vitro studies on key 
targets of the different ADME process. 
The experimental evaluation of the pharmacokinetic effects of medicinal plants collected 
during the field work carried out in this chapter focuses on intestinal absorption and phase 2 
metabolism. To this end, a set of in vitro assays have been selected including cytotoxicity, 
modulation of P-gp activity, transport across cell monolayers and modulation of intracellular 
glutathione levels. The last target also provides information on the potential protective effect 
against oxidative damage, which is a well known complication in diabetes. To further assess 
this, the radical scavenging activity of the plant extracts towards nitric oxide will be 
evaluated. 
This chapter also describes the phytochemical analysis of the plant materials. When the 
identity of individual active compound(s) is not known, a “chemical fingerprint” is the 
recommended technique to ensure quality standards for plant species used as herbal 
medicines (Bauer and Tittel, 1996). Although no single high performance liquid 
chromatography with diode array detection (HPLC-DAD) analysis can provide a full 
account of all chemicals present in the sample, it is considered as a code of practice for the 
quality control of herbal extracts. Its sensitivity and low cost has been suggested as an 
affordable way to complement/corroborate the botanical analysis of African plants 
(Springfield et al., 2005). 
4.2 MATERIALS AND METHODS  
4.2.1 Preparation of Plant Materials  
4.2.1.1 Selection Criteria and Botanical Identification 
The plant samples to be analysed were obtained either from the traditional medicine 
practitioners or purchased from the herbal markets visited during the field work study. 
Verification of plant samples was carried out as described in chapter 2. Voucher specimens 
for samples collected in their natural habitat (Agbede forest) have been deposited at the 
herbarium of the School of Pharmacy, University College London. 





4.2.1.2 Processing of Plant Materials 
All plant samples were air-dried for about two weeks (average temperature 30°C) to remove 
as much moisture as possible to prevent deterioration. Samples were then packed in freezer 
bags and couriered to the School of Pharmacy, University College London. Upon arrival, 
they were further dried in a Samas Vickers
®
 laboratory drying chamber electrically heated to 
30°C with continuous ventilation. Samples were powdered using a laboratory scale mill (MF 
10 Basic IKA WERKE blender) or an industrial size mill (FRITSCH miller), depending on 
the part of the plant collected and the quantity of plant material. 
A) Plant samples are air dried at 30°C for 2 weeks
B) Dried plant samples are powdered using a 
laboratory/industrial miller
C) Extraction of plant samples based on 
preparation method used by respondent
D) Filtered liquid extracts are frozen at -20°C for 
a few days
E) Frozen liquid extracts are freeze-dried to 
obtain dried plant extracts
Infusion- 300ml of boiled
water is added to 10g of
plant sample with stirring
for 15 minutes
Decoction- 400ml of boiled
water is added to 20g of
plant sample and heated
continuously under reflux
for 1 hour
F) Dried plant extracts 
are stored in sample 
bottles at 20°C until 
needed
 
Figure 4.1: Schematic summary of method(s) used to process plant samples 
  
The procedure for extraction of the plant samples (infusion or decoction) was based on the 
traditional use of the plants as described by the respondents (Table 2-3). For infusion, 300ml 
of boiled distilled water was added to 10g of plant material with continuous stirring for 
15minutes on a laboratory hot plate magnetic stirrer (IKA WERKE labortechnik electric 
stirrer). For decoction, 20g of plant material was heated continuously under reflux in a round 
bottom flask containing 400ml of distilled water for one hour using an Electrothermal® 3-
in-1 laboratory heating mantle.  
All extracted plant samples were allowed to stand until cold before filtering with a Buchner 
flask. All the filtered extracts were frozen in round bottom flasks and then freeze dried 
(Edwards Pirani 501 Savant super modulo freeze drier) to obtain the dried extract. All dried 





plant extracts were stored in 10ml sample bottles at -20°C until needed. A schematic 
summary of the steps used in sample preparation is shown in Figure 4.1. 
4.2.2 Phytochemical Analysis 
Phytochemical analysis of samples of the freeze dried plant extracts was carried out using a 
high performance liquid chromatography (HPLC) system- Agilent 1200 series equipped 
with an ultraviolent/visible (UV-Vis) diode array detector to obtain a ‘fingerprint’ of the 
samples. The conditions used for the analysis have previously been used for the detection of 
phenolic compounds in plant samples (Giner et al., 1993). 
The stationary phase was a Phenomenex® synergi Polar-RP80A column (250mm x 4.6mm, 
I.D = 4µm) column maintained at 40°C and protected with a Nova-Pak® C18 guard column. 
The mobile phase was a binary system consisting of (A) water-glacial acetic acid (99.8:0.2, 
v/v) and (B) methanol-glacial acetic acid (99.8:0.2, v/v). The gradient elution program for 
the mobile phase was 10-20% B (0-5mins), 20-50% B (5-65mins), 50-80% B (65-75mins) 
and 80-100% B (75-80mins) at a flow rate of 1ml/min. The injected volume of sample was 
10µl and the UV-Vis spectra were recorded in the range 190 to 400nm, while 
chromatographic peaks were monitored at 254 and 360nm.  
The plant extracts were prepared as 25mg/ml solutions in either micro-filtered double 
distilled water or HPLC-grade methanol (All solvents were purchased from Fisher Scientific 
UK). Fifteen plant phenolic compounds: Gallic acid, 2,4-dihydroxybenzoic acid, caffeic 
acid, epicatechin, epigallocatechin, catechin, vitexin rhamnoside, vitexin, rutin, ellagic acid, 
quercitrin, hesperidin, quercetin, luteolin and kaempferol were used as standards at 
concentrations between 0.5 and 1mg/ml in methanol, depending on the intensity of the peak. 
All standard phenolic compounds were purchased from Sigma Aldrich UK. Samples were 
filtered through a 0.45µm syringe filter (Millipore Millex® PTFE) before the analysis. 
4.2.3 Determination of the Antioxidant Effects of Plant Samples 
Aqueous extraction of plant samples results in the preferential extraction of mainly polar 
compounds such as flavonoid glycosides and tannins (generally known as phenolic 
compounds) (Seidel, 2006). These phenolic compounds are usually endowed with free-
radical scavenging effects due to their labile ‘H’ atom, and hence are responsible for most of 
the plant’s antioxidant effects. This is because the phenolic groups can accept an electron to 
form relatively stable phenoxyl radicals, thereby disrupting chain oxidation reactions in 
cellular components. As a result, plant extracts with potent antioxidant effects are also 
thought to be beneficial in mitigating hyperglycaemia-induced oxidative stress common in 
diabetes (Pandey and Rizvi, 2009).  





Given that the plant samples were all selected on the basis of their use in the management of 
diabetes, we wanted to determine if they had good antioxidant activity, which contributes to 
their benefits in diabetes. Several methods for determining the free radical scavenging 
effects of compounds have been developed. Two of these, the DPPH (2, 2-diphenyl-1-
picrylhydrazyl) radical scavenging assay and the nitric oxide scavenging assay were used to 
evaluate the antioxidant effect of the different extracts. 
4.2.3.1 DPPH Radical Scavenging Assay 
DPPH is a stable radical compound whose odd valence electron readily becomes paired with 
either hydrogen or another reducing molecule from a free radical scavenger. This forms the 
reduced DPPH-H or the corresponding hydrazine as shown in the equation below (Figure 
4.2), resulting in a change in the purple colour of the DPPH to the yellow colour of its 
reduced form. The purple-coloured DPPH gives a maximum absorption at 517nm, thus its 
signal intensity is inversely proportional to the concentration of the antioxidant present in the 
system. 
 
Figure 4.2: Reaction between the free stable radical DPPH and a free radical scavenger (R*) to 
give reduced DPPH 
  
The method used for this assay was modified for microplate readings from that described by 
Sharma et al. (Sharma and Bhat, 2009). 200µM stock solution of DPPH (Sigma Aldrich UK) 
was prepared in HPLC-grade methanol buffered with 1mM ammonium acetate (Fisher 
Scientific UK). The absorbance of DPPH is pH sensitive. The buffered methanol keeps it 
within a pH range of 5.0-6.0. A stock solution was prepared fresh each week and stored at 
4°C wrapped in foil paper to protect from light. 500µM stock solution of caffeic acid (Sigma 
Aldrich UK) in phosphate buffered saline (Gibco® Invitrogen UK) was also prepared as 
positive control. A maximum concentration of 5mg/ml dissolved in double distilled water 
was prepared for all plant extracts. All solutions were filtered through a 0.45µm syringe 
filter and stored at -20°C until needed. 
The assay was carried out in transparent, flat bottom Nunclon® 96 well plates (Thermo 
Scientific UK). 200µl of the maximum concentration of each of the plant extracts 
(250µg/ml) and the caffeic acid (100µM) were added in triplicates to the first row of the 





plate. Serial dilutions of each sample solution (or the control) was then prepared down the 
row using the appropriate solvent to a final volume of 100µl in each well. To each of these 
wells was added 100µl of the DPPH solution (to give a final concentration of 100µM).  
A negative control (100µl DPPH solution + 100µl buffered                                                                                                                                                                                                                                                                                                                                    
methanol or any other solvent used to dissolve extract) and a blank determination (100µl 
buffered methanol + 100µl solvent) were also carried out. The covered microtitre plate was 
wrapped with aluminium foil and incubated for 30mins at room temperature away from any 
light source. After incubation, the absorbance of each well was measured with a plate reader 
(Tecan® Infinite M-200) at a wavelength of 517nm. 
The percentage of DPPH remaining in each well was calculated with the following equation:  
%DPPH = 100 X [(AS - ASB)/C]; where AS is the absorbance of the test solution, ASB is the 
absorbance of the blank and C is absorbance of the negative control. The percentage 
inhibition is given as I (%) = 100 - %DPPH. The IC50 values for each of the samples were 
interpolated from a graph plot of the different concentrations of the samples against the 
percentage inhibition. 
4.2.3.2 Nitric oxide Scavenging Assay 
Nitric oxide is an important physiological messenger and effector molecule in many 
biological systems including immunological, neuronal and cardiovascular tissues. Under 
conditions of oxidative stress (such as in hyperglycaemic states), elevated levels of 
superoxide (O2
-
) and nitric oxide (NO) free radicals are formed. These react to form 
peroxynitrite (ONOO
-
), a toxic metabolite which contributes to islet β-cell destruction 
(Suarez-Pinzon et al., 2001); as well as promotes vascular injury resulting in damage to the 
cardiovascular system (Förstermann, 2010). An antioxidant that can scavenge NO will 
therefore be beneficial in hyperglycaemic conditions. 
One means of investigating nitric oxide levels in any biological system is to measure nitrite 
using the Griess reagent. Nitrite (NO2
–
) is one of two primary, stable and non-volatile 
breakdown products of nitric oxide. When working without cells, a source for nitrite has to 
be introduced. Sodium nitroprusside (SNP) is a molecule that is highly unstable when 
introduced into a solution at physiological pH or in the presence of known biological 
reducing agents, such that it spontaneously decomposes. The decomposition first generates 
nitric oxide, which then produces nitrite ions through interaction with oxygen. Scavengers of 
nitric oxide compete with oxygen thereby leading to decreased production of nitrite. 





A typical commercial Griess reagent contains 0.2% naphthylenediamine dihydrochloride 
(NED) and 2% sulphanilamide in 5% phosphoric acid. The nitrite ions enter into an 
equimolar reaction with sulphanilamide forming a diazonium cation, which then reacts with 
the NED to produce the azo compound (as shown in Figure 4.3 below). This azo compound 
is easily quantifiable by measuring the absorbance at 546 nm with a spectrophotometer. By 
incubating the reaction medium with free-radical scavenging agents, this assay can be used 
to determine the antioxidant effects of various compounds including plant extracts. 
 
Figure 4.3: Sulphanilamide reacts with the nitrite ions (NO2
–
) to form a diazonium cation which 
reacts with NED to form the coloured azo compound 
 
Different concentrations of sodium nitrite (NaNO2) (Sigma Aldrich UK) in PBS were 
prepared in triplicates in different wells of a 96-well microplate up to a maximum 
concentration of 500µM. 50µl of Griess reagent (Sigma Aldrich UK) was added to each of 
these wells containing 100 µl of the different NaNO2 concentrations and incubated for 
15mins to allow the azo dye to develop. The absorbance of the different wells was then 
measured using a plate reader (Tecan Infinite M-200 Plate reader) at 546nm and the 
calibration curve of the different nitrite concentrations against absorbance of the 
corresponding azo compound was determined using the Magellan® analyzing software. 
Serial dilutions of each sample solution and the control were prepared down the row of the 
96-well plate (in the DPPH assay) to a final volume of 50µl in each well. 50µl of a 5mM 
freshly prepared stock solution of SNP in phosphate buffered saline (PBS) was immediately 
transferred to each of the wells containing either the positive control or the test samples and 
then placed in the incubator. 90mins after addition of the SNP, 50µl of the Griess reagent 
was added to each of the wells and incubated for a further 15mins to allow the azo dye to 
develop. The absorbance of each well was then measured at 546nm in the plate reader.  
The concentration of nitrite (NO2
– 
sample) remaining in each well was estimated from the 
NaNO2 calibration curve by comparing each measured absorbance value. Wells containing 
SNP and vehicle only were taken as the wells with the maximum concentration of nitrite 
generated (NO2
– 
max). The percentage of nitrite scavenged in each well was then estimated 




max))*100. The IC50 values for each 





of the samples were interpolated from a graph plot of the different concentrations of the 
samples against the concentration of nitrite scavenged in each well. 
4.2.4 Mammalian Cell Culture Techniques 
Two adherent mammalian cell lines, the human hepatocellular carcinoma cell (HepG2) and 
the human epithelial colorectal adenocarcinoma cell (Caco-2) were used for the biological 
assays carried out in this thesis. They were both purchased from Sigma Aldrich UK at 
passages 100 and 43 respectively. A vincristine resistant subline of Caco-2 cells (Caco-2 
VCR) was also obtained. This was kindly provided by Dr Elisabeta Chieli of the department 
of Experimental Biology, University of Pisa, Italy.  
Figure 4.4: Microscopic image of (a) Caco-2 cells and (b) HepG2 cells. Courtesy: American type 
culture collection (ATCC) 
 
The routine use and maintenance of mammalian cell culture as well as all biological assays 
involving the different cell lines undertaken in this thesis were carried out under sterile 
conditions in a laminar flow cabinet (Walker Class 2 laminar air-flow cabinet) unless 
otherwise stated. Personal protective equipment (gloves, lab coats, masks and hair covers) 
were worn at all times to reduce the risks of contamination. Gloves were sprayed with 70% 
ethanol and allowed to air-dry before and after use. 
4.2.4.1 Resuscitation of frozen cell stocks 
Cell lines are usually stored in frozen form (in liquid nitrogen) when not in use. This is also 
the form of the cells when purchased. To resuscitate them, the cells were thawed rapidly at 
37°C by placing the vial of cells in a pre-heated water bath. The thawed cells were then 
diluted slowly into a centrifuge tube containing the appropriate warm growth media (see 
below) to eliminate DMSO, which is toxic to cells. DMSO is used as a cryoprotectant to 
prevent crystallization, which will otherwise cause cells to lyse during cryopreservation. The 
tubes were then centrifuged (Biofuge primo R Heraeus centrifuge) for 5 minutes at 1000rpm 
(a) Caco-2 cells (b) HepG2 cells





to separate the cell pellet from the culture media. Inside the laminar flow cabinet, the media 
was removed from the centrifuge tube and the cells were properly re-suspended in 15ml of 
pre-warmed complete media. This was then transferred to a culture flask pre-labelled with 
the name of the cell line, passage number and date. An inverted microscope (Nikon TMS 
10/0.25 lens) was used to check the morphology of the cells before placing in an incubator. 
4.2.4.2 Subculture/Maintenance 
All cell culture reagents were obtained from Gibco® Invitrogenn UK unless otherwise 
stated. HepG2 cells were routinely grown in Minimum Essential Medium Alpha + 
Glutamax. The medium was supplemented with 10% heat inactivated foetal bovine serum 
(FBS)-EU and 1% penicillin-streptomycin antibiotic (10000units/ml penicillin & 10000 
µg/ml streptomycin). Caco-2 cells were maintained in Dulbecco’s minimum essential 
medium with high glucose (4.5g/l) and L-glutamine. The medium was supplemented with 
10% FBS, 1% penicillin-streptomycin and 1% non essential amino acids 100X. The Caco-2 
VCR cells were maintained in the same media as the wild type Caco-2 cells, but also 
containing 50nM vincristine (Vincristine 2mg/ml, Hospira UK Limited). 
Cells were routinely grown as a monolayer in TPP 75cm
2
 tissue culture flasks (T75) 
containing 15ml of complete media  in an incubator at 37°C, 5% CO2/95% O2 (Nuaire DH 
Auto-flow CO2 air jacketed Incubator). The culture media was changed every 2-3 days until 
they were approximately 80% confluent. To sub-culture cells, old media was removed and 
the flask gently rinsed with 5ml of PBS. The monolayer of cells was then detached by 
adding 1ml of 0.25% Trypsin/EDTA to the flask and placed in the incubator for not more 
than 5 minutes. Thereafter, 5ml of complete media was added to the flask to dilute and 
inactivate the trypsin and the cell suspension collected and centrifuged. The media was 
aspirated off and the cells re-suspended in fresh complete media and then counted. Cells 
were split into new T75 flasks at an appropriate ratio depending on the cell growth rate and 
then placed back in the incubator. 
In order to maintain an available stock of each cell line, cells were re-suspended in freshly 
prepared freezing medium (culture media for the cells containing 20% FBS & 10% DMSO) 
(≈ 106 cells/ml). The cell suspension was aliquoted into sterile cryogenic vials, and 
transferred to a Nalgene® Cryo Styrofoam freezing container containing 250ml isopropranol 
(to achieve a -1°C/min cooling rate) and stored overnight at -80°C. The next day, the 
cryovials were transferred to a liquid nitrogen dewar and stored until needed. All cells were 
only used for a maximum of fifteen passages before they were discarded and a new 
cryogenic vial of cells defrosted/resuscitated.                     





4.2.4.3 Cell Counting 
To determine the growth rate of the cells or the exact dilution of cell suspension needed for 
an assay, a trypan blue dye exclusion method was used to count the number of viable cells. 
An aliquot of cell suspension (20µl) was taken and diluted with 180µl of 0.4% trypan blue 
stain in an eppendorf tube. The Neubauer haemocytometer was then carefully loaded with 
10µl of the mixed sample on either side. The number of unstained cells was counted with an 
inverted microscope and the total number of viable cells estimated. 
4.2.5 Neutral Red Uptake Assay for Determination of Cell 
Viability/Cytotoxicity 
Prior to the use of the afore-mentioned cell lines in the different biological assays, the 
toxicity profile of all the extracts were assessed in an in vitro cytotoxicity assay. The assay is 
based on the uptake of neutral red (3-amino-m-dimethylamino-2-methylphenazine 
hydrochloride), a supra-vital dye, and its accumulation in the lysosomes of viable uninjured 
cells. The uptake of the dye depends on the cell’s capacity to maintain pH gradients, through 
the production of ATP. The dye is weakly cationic and at physiological pH, presents a net 
charge close to zero, enabling it to penetrate the cell membranes by non-ionic passive 
diffusion and concentrates in the lysosomes. Inside the lysosome, there is a proton gradient 
to maintain a pH lower than that of the cytoplasm. Thus the dye becomes charged and is 
retained, where it binds to anionic and/or phosphate groups of the lysosomal matrix (Repetto 
et al., 2008).  
Extraction of the dye from the viable cells is done using an acidified ethanol solution, and 
the absorbance of the solubilised dye is quantified spectrophotometrically at 540nm. 
Quantification of the dye extracted from the cells has been shown to be linear with cell 
numbers, both by direct cell counts and by protein determinations of cell populations 
(Weyermann et al., 2005). Given that the toxicity of the extracts is inversely proportional to 
the viability of the cells, more toxic extracts will result in fewer cells being available for 
neutral red uptake.  The neutral red assay has been identified as a reliable in vitro assay that 
can be used to estimate in vivo starting doses for acute toxicity based on its low coefficient 
of variation from several inter- and intra- laboratory experiments (Interagency Coordinating 
Committee on the Validation of Alternative Methods (ICCVAM), 2001), hence its selection 
for this study.  






Figure 4.5: Chemical structure of Neutral red 
The method used for this assay is as described in Repetto et al. (2008) with slight 
modifications. Cells to be used for the assay should be ≤ 80% confluent to ensure that they 
are in their exponential growth phase. After trypsinization, 200 µl of the appropriate cell 
suspension was plated out in each of the inner wells of a sterile, flat bottom 96-well plate at 
a density of 1 x 10
5
 cells per ml in complete media. The plate was then incubated overnight 
at 37°C, 5% CO2/95% O2. The next day, serial dilutions of the plant extracts to be tested, 
including the positive control, hydrogen peroxide (BDH laboratory supplies) were made in 
complete media from the appropriate stock solutions. 
On day two, the growth media was carefully aspirated from each well of the microplate and 
replaced with 200µl of the test solution in replicates. Complete media without drug was 
added to some of the wells with cells as well as the outer wells without cells to act as 
positive control and blank respectively. The microplate was then incubated for 24hours. 
40µg/ml of neutral red (Sigma Aldrich) in complete media was prepared in a centrifuge tube 
from a stock solution of 4mg/ml in PBS and incubated overnight, wrapped in foil paper at 
the same temperature as the cells. 
On the third day, the neutral red solution was centrifuged for 10mins at ≈ 1800 rpm to 
remove precipitated dye crystals.  The microplate was then removed from the incubator and 
briefly examined under the microscope to physically identify the highest tolerated dose 
(HTD) for each of the extracts. The media in each of the wells was gently aspirated off and 
replaced with 100µl of the neutral red solution in each well of the plate and then incubated 
for another 2 hours. After 2 hours, each well of the plate was gently rinsed with 150µl of 
PBS and the washing solution removed by decanting or gently tapping the plate.  
150µl of neutral red de-stain solution (96% ethanol, deionised water, glacial acetic acid; 
50%:49%:1%) was added to each well of the plate after the washing step. The plate was 
immediately shaken on a microplate shaker (IKA MS3 basic shaker) for at least 10 minutes 
until the neutral red had been completely extracted from the cells and formed a homogenous 
solution. The optical density (O.D)/absorbance of the neutral red extract was read out in the 
plate reader at 540nm. The percentage viability for each of the concentrations of the 





drug/extract was estimated as follows: % viability = (O.DS-O.DB/O.DM-O.DB) x 100; 
where O.DS is the optical density of the sample (either drug or plant extract), O.DB is the 
optical density of the blank wells without cells, O.DM is the optical density of the wells of 
the positive control containing only complete media. The IC50 values for each of the samples 
were interpolated from a graph plot of the different concentrations of the samples against the 
percentage viability. 
4.2.6 Estimation of Intracellular Glutathione Levels in HepG2 Cells 
Glutathione (GSH) is a ubiquitous tri-peptide thiol (L-γ-glutamyl-L-cysteinylglycine) or α-
amino acid present in various mammalian cells in millimolar range (0.5-10mM). It is known 
to function directly or indirectly in many important biological phenomena, including the 
synthesis of proteins and DNA, transport, enzyme activity, metabolism and protection of 
cells (Meister and Anderson, 1983). Of all the functions of GSH, two of these are relevant in 
the process of cell detoxification- (1) its role as an antioxidant, and (2) its role in the phase 2 
metabolism of xenobiotics. In general, both of these are as a result of the general function of 
GSH to protect cells against oxygen toxicity (Fahey and Sundquist, 2006).  
 
Figure 4.6: Chemical structures of the oxidized (GSH) and reduced (GSSG) forms of 
glutathione. 
 





GSH exists in two different forms within cells: the reduced sulfhydryl form (GSH) and the 
glutathione disulfide (GSSG) (Figure 4.6). In healthy cells, GSSG is less than 0.2% of the 
total GSH concentration. Oxidative stress has a profound effect on the cellular thiol balance 





, H2O2 & R-OOH) as well as xenobiotics are neutralized by GSH through a 
cascade of detoxification mechanisms involving the enzymes glutathione peroxidases (GPx), 
glutathione-S-transferases (GST) and glutathione reductase (GR) (Rahman et al., 2007). 
Thus, disease conditions or xenobiotics that induce oxidative stress would in turn affect 
intracellular GSH concentrations. By measuring the intracellular GSH levels in the presence 
of the plant extracts, we can determine if the extracts would enhance or diminish the 
detoxification effects of GSH. 
The method used in the intracellular determination of GSH levels was adapted from that 
described by Rahman et al., (2007) and Allen et al., (Allen et al., 2000) with slight 
modifications. The assay is based on the reaction of GSH with DTNB (5, 5’-dithio-bis (2-
nitrobenzoic acid)), also known as Ellman’s reagent to produce TNB (5-thio-2-nitrobenzoic 
acid), a yellow coloured chromophore which can be measured spectrophotometrically at 
405nm, and an oxidized glutathione-TNB adduct (GS-TNB). The GS-TNB adduct is 
reduced by GR in the presence of NADPH to form GSH and TNB, with the former being 
recycled back into the system to produce more TNB (Rahman et al., 2007) (Figure 4.7).  
 
Figure 4.7: Enzymatic recycling of glutathione (GSH) from glutathione disulfide (GSSG) by 
glutathione reductase (GR) in the presence of NADPH. GSH reacts with DTNB to GS-TNB and 
TNB, with subsequent reduction of the former to GSH. TNB can be measured at 405 nm. 
(Adapted from Rahman et al., 2007). 
 
 





The GSSG present in the sample is also reduced by GR to form two molecules of GSH. 
Thus, the amount of glutathione measured represents the sum of reduced and oxidized GSH 
in the sample. The rate of change in absorbance of TNB at 405nm is linearly proportional to 
the total concentration of GSH in the sample. The concentration of an unknown sample can 
therefore be determined by calculating from the linear equation or the regression curve 
generated from several standard concentrations of GSH. 
All chemicals and reagents used in this assay were purchased from Sigma Aldrich UK, 
unless otherwise stated. HepG2 cells were seeded out in sterile, flat bottom 96-well plates at 
a density of 1 x 10
5
 cells per ml (2 x 10
4 
cells per well). Only the wells of the inner last three 
columns of the plate (columns 9-11) of the plate were used as shown in the coloured wells of 
figure 3.6 below, and the plate was incubated overnight to allow for cell attachment. The 
next day, the cells were treated with the plant extracts to be tested in triplicates, at their 
maximum non toxic concentration as determined by the neutral red assay. Three wells were 
not treated with any drug and served as media control, while three other wells were treated 
with 10µM buthionine sulphoximine (BSO) as the positive control. All drug/extract 
incubations were done for 24 hours. 
Prior to commencing the GSH assay, the following solutions ought to be prepared- 
phosphate buffer solution containing 168ml of a 286mM solution of sodium phosphate 
dibasic in distilled water, 32ml of a 286mM solution of sodium phosphate monobasic and 
6.3mM EDTA; 5% sulfosalicylic acid in double distilled water (SSA); 0.1% Triton X-100; 
1mM stock solution of reduced glutathione in 5% SSA solution and 10mM DTNB in 
phosphate buffer solution (this solution can be stored in aliquots at -20°C, protected from 
light for up to two months). Apart from the DTNB, all the other solutions can be stored in 
the fridge at 2-4 °C for up to a week. 2.39mM or 2mg/ml β-NADPH in phosphate buffer 
solution was freshly prepared on the day of the assay. 
24 hours after incubation with the extract/drug, the cells were washed with PBS (200µl per 
well) and the PBS aspirated off. 60µl of 0.1% Triton X-100 was added to each well of the 
plate containing cells and then shaken on a microplate shaker for 2 minutes to lyse the cells. 
25µl of the cell lysate from each well was transferred to another microplate with cover, 
wrapped in foil to prevent evaporation and set aside for protein assay determination. The UV 
light of the laminar flow hood was turned off for the rest of the assay to minimize GSH 
oxidation.  






Figure 4.8: Schematic representation of layout of 96-well plate for GSH assay 
 
To the remaining cell lysate, 25 µl of 5% sulfosalicylic acid solution (Sigma Aldrich UK) 
was added and the plate shaken for another 2 minutes. After shaking, 25 µl of the lysed cell 
solution was transferred to the wells of the next three inner columns of the plate (columns 6 -
8). 25 µl of the 5% SSA solution was added to each well of the first column of the plate as 
blank. A double dilution of a standard solution of reduced glutathione in 5% SSA, starting 
from 100µM GSH as the highest concentration was then prepared (often in the last column 
of the plate-column 12). 25µl of each concentration of the standard was then transferred in 
triplicates to the wells of Columns 2-5 (Figure 4.8).  
The glutathione reaction buffer needed for the assay was prepared by adding 1ml of the 
freshly prepared β-NADPH and 3µl of glutathione reductase (equivalent to 2 units of GR) to 
7.5ml of the phosphate buffer solution for each 96-well plate. This is vortexed for 5 seconds 
and then 1 ml of DTNB solution is immediately thawed and added to the reaction buffer and 
then vortexed for another 5 minutes. All solutions to be used were kept on ice until needed. 
125µl of the reaction buffer was added to each well of the 96-well plate containing either 
25µl of the blank SSA solution, 25µl of the GSH standards or 25µl of the cell lysate 
solution. The microplate was immediately covered and then wrapped in foil paper and then 
shaken in the microplate for 15 seconds. Immediately after, the absorbance of the wells of 
the microplate was read in a kinetic cycle in the TECAN plate reader every 30 seconds for 5 
minutes at 405nm (11 readings).  





The slope of the curve obtained from the 11 readings of each of the GSH standard 
concentrations (otherwise known as the I-slope), which represents the rate of change of GSH 
levels at that concentration is plotted against the GSH concentration to give a regression 
curve (otherwise known as the F-slope curve). The concentration of GSH in the samples 
from the cell lysate solutions is then estimated by substituting the average I-slope values for 
each of the extract/drug into the equation of the F-slope curve. 
Cell protein estimation was carried out using the DC® protein assay kit (Bio-Rad, -500-
0116). The kit consists of an alkaline copper tartrate solution (reagent A), dilute Folin 
reagent (reagent B) and a solution of sodium dodecyl sulphate (reagent S). A serial dilution 
of bovine serum albumin in 0.1% triton X-100 was prepared from a 1mg/ml stock solution. 
25µl of each of the standards was transferred in replicates to different wells of the microplate 
containing the cell lysate that was set aside for protein estimation. 25µl of reagent A’ 
(reagent A containing 2% reagent S) was added to each well followed by 200µl of reagent B. 
The contents of the microplate were mixed in the plate reader for 5 seconds and the 
absorbance read after 15minutes at 750nm. 
Statistical analysis was carried out using GraphPad Prism Version 6.0 (GraphPad software 
Inc., San Diego, CA). A paired student’s t-test between the intracellular GSH concentration 
obtained for the control cells and that obtained with the cells treated with either extracts or 
BSO was carried out. A change in intracellular GSH levels was considered statistically 
significant when p < 0.05.  
4.2.7 Modulation of P-glycoprotein Dependent Rhodamine-123 Efflux in 
Caco-2 Cells 
Rhodamine-123 (Rh-123) is a cationic hydrophilic fluorescent P-gp substrate, which has 
been used as a probe to assess the functional activity of P-gp in a variety of cell lines and 
assays (Lee et al., 1994). In the intestine, the absorptive transport of Rh-123 occurs primarily 
by a passive diffusion process via the paracellular pathway. However after absorption, Rh-
123 is secreted back into the lumen, first of all via a transcellular uptake process through the 
basolateral membrane followed by P-gp mediated efflux through the apical membrane 
(Troutman and Thakker, 2003).  
Caco-2 cells and Caco-2 VCR cells were used for this drug accumulation/efflux assay where 
the amount of the Rh-123 retained by the cells after an incubation period (in the presence or 
absence of inhibitors) is measured spectrofluorometrically (Chieli and Romiti, 2008). 
Compounds that interact with the P-gp transporter either as substrates or inhibitors as 





depicted in Figure 4.9 below will modulate the P-gp mediated efflux of Rh-123 and can 
therefore be identified.  
 
Figure 4.9: Schematic representation of the inhibition of Rhodamine-123 efflux by modulators 
of the P-glycoprotein transporter 
 
The protocol used for this assay is as described in Chieli et al., (Chieli et al., 2009) with 
slight modifications. Both Caco-2 cells to be used are routinely grown in the appropriate 
complete growth media in 75cm2 tissue culture flasks as described in section 3.4.2. The 
culture media of the cells were usually changed a day before plating out to ensure that the 
cells were in their exponential stage of growth. The media of Caco-2 VCR cells was 
replaced with complete media without vincristine at this point.  
80 to 90% confluent culture flask of cells were trypsinized and then plated out in the inner 
wells of a sterile 96-well plate at a density of 7.5 x 10
4
 cells/ml (1.5 x 10
4
 cells per well) in 
full culture media (without vincristine). The cells were then placed in the incubator 
overnight to allow for attachment. The next day, the growth media of the cells was changed 
to serum free media (without 10% FBS). This was to ensure a more uniform condition for 
the majority of the cell population as well as to prevent adsorption of drugs to the serum 
proteins. The microplates were then replaced back in the incubator for 24 hours.  
On the day of the assay 5µg/ml Rhodamine-123 (Sigma Aldrich UK) solution in serum free 
media sufficient for the assay was prepared from a 5mg/ml stock solution in DMSO 
(solution A). 100µg/ml of all the extracts to be tested were then prepared in solution A 
(solution B), while 20µM verapamil (Securon® I.V. 2.5mg/ml, Abbot Laboratories Limited) 
was also prepared in solution A as positive control (solution C). The media in each of the 
wells of the microplate was then aspirated off and then replaced with either solution A, B or 
C in replicates. The microplates were placed back in the incubator for 2hours to allow for 
Known P-gp inhibitor 
or herbal extract
Rhodamine-123





intracellular rhodamine accumulation within the cells. At the same time, 20µM verapamil in 
PBS (solution D) was also prepared and stored in the fridge at 4°C. 
After the two hours of incubation, the media in the wells are all aspirated off and each well 
was washed three times, gently but quickly with 200µl each of the ice cold solution D to 
stop the P-gp efflux activity. 100µl of 0.1% Triton X-100 in PBS was then added to each 
well and then placed in the incubator for fifteen minutes to lyse the cells and completely 
solubilise the intracellular rhodamine. 80µl of each of the cell lysates in each well was 
transferred to a 96-well black plate and the fluorescence intensity of each well was measured 
in a Tecan® plate reader (Exc-485nm, Em-525nm). The cellular accumulation of Rh-123 for 
each of the extracts was expressed as the percentage of the accumulation measured for 
rhodamine only (solution A), that is under control conditions. 
4.2.8 Effects of the P-gp Modulatory Extracts on Glibenclamide Transport in 
Caco-2 Monolayers 
Caco-2 cells grown in monolayers on permeable filters are used for the in vitro prediction of 
intestinal drug permeability and transport. Many of the brush border enzyme and transport 
proteins that mediate the active uptake or efflux of drugs in the intestine are functional in 
Caco-2 cells (Hubatsch et al., 2007); and maintenance of the cells on permeable filter inserts 
has been shown to facilitate cell differentiation and polarity. As a result, over the years, 
Caco-2 cells have become the best established model of the intestinal absorptive epithelium 
and have been extensively utilised to study the transport and toxicity of nutrients (Ranaldi et 
al., 2003). 
Sulphonylurea receptor 1 (SUR1), the binding site of action for glibenclamide is a member 
of the ABC (ATP binding cassette) family of transporters, which also includes P-gp and 
cystic fibrosis transmembrane conductance regulator protein (CFTR). Glibenclamide has 
been shown to also interact with these latter members of the ABC transporters. The 
interaction of glibenclamide with P-gp was confirmed by its ability to enhance cellular 
accumulation of [
3
H]colchicine, a known substrate of P-gp in cells which express significant 
amounts of P-gp as well as an enhanced [
3
H]glibenclamide accumulation in the presence of 
other known P-gp substrates/inhibitors (Golstein et al., 1999). The aim of this experiment 
was therefore to elucidate the effects of the plant extracts previously identified as P-gp 
modulators on the intestinal transport of glibenclamide in Caco-2 cells.  






Figure 4.10: Schematic representation of the transport of glibenclamide across a monolayer of 
Caco-2 cells grown on a permeable filter in the presence of an identified P-gp modulator. 
The protocol used for this assay is as described in Hubatsch et al., (Hubatsch et al., 2007) 
with slight modifications. 24-well cell culture polyethylene terephthalate (PET) inserts with 
0.4µM pore size and 0.33cm2 surface area (Millipore UK, -PIHT12R48) pre-loaded in sterile 
24-well plates were used for the transport studies. Caco-2 cells from maximally confluent 
flasks (80-90%) were trypsinized and then seeded out in the apical layer of the permeable 
filters at a density of 5 x 10
5
 cells/ml in 200µl of complete media (1 x 105 cells/insert). The 
filters were pre-wet with 30µl of complete media prior to seeding. The basolateral chamber 
of the inserts were each filled with 1ml of complete media and the plates with the filter 
support were then placed in the incubator overnight (for a maximum of 16hours to allow for 
cell attachment). After the incubation period, the medium in the apical layer was replaced 
with 0.2ml of fresh medium so as to remove non-adherent cells as well as prevent the 
formation of a multilayer.  
Cells were maintained every other day for at least 21days by carefully aspirating off the 
media in both the apical and basolateral layers and replacing with appropriate volume of 
fresh medium. The transepithelial electrical resistance (TEER) of the monolayer was 
measured at least once each week with a Millicell ERS-1 voltohmmeter (Millipore UK) to 
monitor the integrity of the monolayer. Cells were only used for transport experiments if 
TEER values were > 300Ωcm2 (calculated by subtracting the resistance reading from that of 
a blank filter without cells and multiplying by the surface area of the monolayer). Culture 
media of the cells must be changed at most 24 hours prior to the transport experiment itself 
to prevent an exhaustion of the media nutrients. 
Glibenclamide
P-gp modulator (Extract)





On the day of the experiment, the physiological transport solution- Hank’s balanced salt 
solution (HBSS) was prepared by dissolving one packet of the powder sufficient for making 
one litre (Sigma Aldrich) in double distilled water and buffered with 25mM HEPES and 
0.35g/l NaHCO3 and the pH adjusted to 7.4. The donor solution was prepared by adding 
10µM glibenclamide (Sigma Aldrich) to the transport solution alone or with the plant 
extracts identified as modulators (at a concentration of 50 or 100µg/ml depending on the 
estimated NR cytotoxicity). 20µM verapamil added to the transport solution containing 
glibenclamide was used as positive control. The receiver solution was either the HBSS 
transport solution alone for glibenclamide transport alone, or the transport solution with 
either the extracts or verapamil. All donor solutions contained 1mg/ml Fluorescein 
isothiocyanate-dextran (FD4) (Sigma Aldrich) for monitoring the integrity of the monolayer 
during the course of the experiment. All solutions were sterile filtered with 0.22µm 
Millipore filters and then pre-warmed at 37°C before use. 
The filter supports with the cell monolayers to be used for the transport experiment were 
pre-washed to remove residual medium by gently replacing the media with the HBSS 
transport solution. The washing was done under gentle shaking at 60 r.p.m. for 15-20 
minutes on a PS-3D laboratory orbital shaker (Grant-bio Instruments, Cambridge UK) 
within a humidified incubator without CO2 set at 37°C (Memmert D-91126, Schwabach 
FRG Germany). After washing, the TEER of the monolayers was measured prior to 
commencing the transport studies. 
Transport studies were carried out in the apical to basolateral (AP-BL) and basolateral to 
apical (BL-AP) directions. For AP-BL transport studies, the washing solutions were gently 
removed from the inserts and the 24-well plate and replaced with 1ml of the appropriate 
receiver solution in the BL layer and 0.2ml of the appropriate donor solution in the AP layer. 
For BL-AP transport studies, the washing solution was replaced with 0.2ml of the 
appropriate receiver solution in the AP layer and 1ml of the appropriate donor solution in the 
BL layer. An excess of 200µl was added to all donor solutions when adding them to inserts, 
which was immediately removed at t=0mins and used to estimate C0.  
Sample withdrawals were carried out from the chamber containing the receiver solution at 
regular time intervals (15mins, 30mins, 1hr, 1hr 30mins and 2hours) by removing 0.5ml for 
AP-BL transport and 0.19ml for BL-AP transport at each time point. Immediate replacement 
of the exact volume withdrawn by the appropriate receiver solution was done. The 
withdrawn samples were placed into eppendorf tubes and immediately covered and placed 
on ice to prevent sample evaporation. Care must be taken during sample withdrawals not to 





disrupt the monolayer of cells. The culture plate with inserts was placed back on the orbital 
shaker in the incubator in between sample withdrawals to maintain sink conditions.  
Sample analysis- Two sets of sample analysis were done for the withdrawn samples. An 
aliquot (50µl) from each time interval was used for spectrophotometric analysis (Ex-490nm, 
Em-520nm) of the transported FD4. A calibration curve of FD4 was included in each plate 
and used to estimate the amount of FD4 transported at each time point. The remaining 
withdrawn samples were analysed using a Perkin Elmer HPLC equipped with an 
ultraviolent/visible (UV-Vis) diode array detector to measure the amount of glibenclamide 
transported at each time point. The HPLC conditions used for glibenclamide analysis were 
as follows: stationary phase was a Phenomenex® synergi Polar-RP80A column (150mm x 
4.6mm, I.D = 4µm) column maintained at 30°C. The mobile phase was an isocratic system 
consisting of 40% (A) 25mM potassium phosphate buffer (pH 4.5) and 60% (B) 
Acetonitrile. The injected volume of sample was 20µl and the UV-Vis spectrum was 
monitored at 230nm with glibenclamide eluting at 2minutes.  
The apparent permeability (Papp) of drugs across the monolayers was estimated as follows: 
Papp = dQ/dt (1/AC0); where dQ/dt is change in the amount of drug (in nanomoles) 
transported per time, A is the surface area of the insert and C0 is the initial concentration of 
the drug in the donor chamber. 
  





4.3 RESULTS AND DISCUSSION 
4.3.1 Preparation of Plant Materials 
A total number of thirty plant samples comprising twenty seven species from seventeen 
families were collected from either the herbalists or bought from the herbal markets during 
the field work for in vitro analysis of their risks of herb-drug interactions. Their 
identification was carried out as described in chapter 2. Six species were from the 
Apocynaceae family while four were from the Leguminosae family. Meliaceae and 
Combretaceae families had two species each, while the other families had only one each.  
Eight samples were extracted by infusing with hot water, while the remaining twenty two 
were extracted by decoction. The yields of the different plant samples varied greatly from as 
low as 3% w/w to as high as over 75% w/w. The yield of the samples were independent of 
the plant part used or the method of extraction since the highest and lowest observed yields 
were from the stem-bark of two different samples (Bridelia ferruginea and Anthocleista 
djalonensis), which were extracted by the same decoction method (Table 4.1). 
 
 
Figure 4.11: Pictures of some of the plant samples collected during field work.  
(a) (b) (c)
Anogeissus leiocarpus (a) tree, (b) stem in close view and (c) stem-bark sample (AL1) obtained 
from herbalist





Table 4.1: Tabular summary of plant samples- Collection & Extraction 
Plant name  Family Plant Part Sample ID Place of collection/purchase Extraction method Yield (%w/w) 
Alstonia boonei De Wild.  Apocynaceae Stem-bark AB1 Mushin herbal market Decoction 5.03 
Annona senegalensis Pers.  Annonaceae Stem-bark AS1 Agbede forest Decoction ND 
Anogeissus leiocarpa (DC.) Guill. & Perr. Combretaceae Stem-bark AL1 Herbalist in Abuja Decoction ND 










Aristolochia repens Mill.  Aristolochiaceae Stem AR1 Mushin herbal market Infusion 18.11 
Bridelia ferruginea Benth.  Phyllanthaceae Stem-bark BS1 Ibadan herbal market Decoction 75.86 










Cassytha filiformis L.  Lauraceae Whole plant CF1 Ethnobotanist in Abuja Decoction 12.66 
Daniellia ogea (Harms) Holland  Leguminosae Stem-bark DO1 Agbede forest Decoction 6 
Gongronema latifolium Benth.  Apocynaceae Leaves GL1 Mushin herbal market Infusion 8.37 
Isoberlinia doka Craib & Stapf  Leguminosae Stem ID1 Zaria herbal market Decoction 4.69 




Mushin herbal market 





Khaya senegalensis (Desv.) A.Juss.  Meliaceae Stem-bark KS2 Agbede forest Decoction 5.02 
Mondia whitei (Hook.f.) Skeels  Apocynaceae Stem MW1 Mushin herbal market Infusion 20.24 
Moringa oleifera Lam.  Moringaceae Leaves MO1 Home garden in Imo Infusion 35.54 
Ocimum gratissimum L.  Lamiaceae Leaves OG1 Mushin herbal market Infusion 17.04 
Picralima nitida (Stapf) T.Durand & H.Durand  Apocynaceae Seeds PN1 Ibadan herbal market Infusion 23.71 
Rauvolfia vomitoria Afzel.  Apocynaceae Stem-bark RV1 Ibadan herbal market Decoction 3.9 
Scoparia dulcis L.  Plantaginaceae Whole plant SD1 Ethnobotanist in Abuja Decoction 16.35 
Securidaca longipedunculata  Fresen.  Polygalaceae Root SL1 Mushin herbal market Decoction 7.49 
Strophanthus hispidus DC.  Apocynaceae Stem SH1 Ibadan herbal market Decoction 12.2 
Syzygium guineense (Willd.) DC.  Myrtaceae Stem SG1 Zaria herbal market Decoction 8.01 
Tamarindus indica L.  Leguminosae Stem TI1 Zaria herbal market Decoction 6.05 
Tapinanthus bangwensis (Engl. & K.Krause) Danser  Loranthaceae Leaves ML1 Herbalist in Imo Infusion 32.2 
Terminalia avicennioides Guill. & Perr.  Combretaceae Stem TA1 Zaria herbal market Decoction 13.25 
Vernonia amygdalina Delile  Compositae Leaves VA1 Home garden in Lagos Infusion 15.54 
Ximenia Americana L.  Olacaceae Stem XA1 Zaria herbal market Decoction 11.5 





4.3.2 Phytochemical Analysis 
The elution conditions previously described in section 4.2.2 allowed for a good separation of 
all the fifteen phytochemical standards, which were detectable at 254nm and/or 360nm. The 
chromatogram obtained is shown below (Figure 4.12). A HPLC-DAD fingerprint for each of 
the plant extracts was also obtained under the same chromatographic conditions (Appendix 
5). Based on this fingerprint, some of the phytochemical standards were identified in the 
plant samples by comparing the retention time (Rt) and UV absorption spectra of each 
identified peak with those of the known standards.  
 
Figure 4.12: HPLC-UV chromatogram of phytochemical standards at 254 nm (up) and 360 nm 
(down).  
(1) Gallic acid, (2) 2,4-dihydroxybenzoic acid, (3) Caffeic acid, (4) Epicatechin, (5) 
Epigallocatechin, (6) Catechin, (7) Vitexin rhamnoside, (8) Vitexin, (9) Rutin, (10) Ellagic acid, 
(11) Quercitrin, (12) Hesperidin, (13) Quercetin, (14) Luteolin and (15) Kaempferol. Each 
standard was present in the cocktail at a final concentration between 0.5 & 1mg/ml. 





Table 4-2: Tabular summary of phenolic compounds present in plant samples 
 
Plant name (Sample ID) Phenolic standards detected 
in sample based on HPLC-
DAD analysis* 
Phenolic standards undetected in the 
sample but known to be present in specie 
(Ref: Ezuruike and Prieto, 2014) 
Other phenolic compounds known to be present in specie 
(Ref: Ezuruike and Prieto, 2014) 
A. boonei (AB1) Quercitrin None None 
A. senegalensis (AS1) Epigallocatechin,  Gallic 
acid 
Catechin, Epicatechin, Quercetin, Rutin Quercitin-3-O-glucoside (Isoquercetin) 
 
A. leiocarpa (AL1) Epigallocatechin, Ellagic 
acid, Gallic acid 
None Castalagin, Chlorogenic acid, Flavogallonic acid, p-Coumaric 
acid, Protocatechuic acid (3,4-dihydroxybenzoic acid),  
A. djalonensis (AD1/AD2) None None None 
A. repens (AR1) None None None 
B. ferruginea (BS1) Epicatechin, Gallic acid Kaempferol, Quercitrin, Vitexin,  Apigenin, Ferrugin (Tri-O-methylmyricetin), Gallocatechin-
(4’-O-7)-epigallocatechin, Isoquercetin, Myricetin, Myricetin-
3-rhamnoside, Quercetin-3-neohesperidoside, Tetra-O-
methylmyricetin, Rutisin (Tetra-O-methylquercetin), 3-O-
methylquercetin 
C. sieberiana (CS1/CS2) Epicatechin (CS1), None 
(CS2) 
Quercitrin (Quercetin-3-O-rhamnoside) Epiafzelechin 
C. filiformis (CF1) Gallic acid,  
Vitexin rhamnoside 
Rutin (Quercetin-3-O-rutinoside) Isorhamnetin, Isorhamnetin-3-O-β-glucoside, Isorhamnetin-3-
O-rutinoside, Isorhamnetin-3-O-robinobioside, Quercetin-3-
O-robinobioside, Isovanillin, Kaempferol-3-O-robinobioside, 
Vanillin 
D. ogea (DO1) Epicatechin, Gallic acid None None 
G. latifolium(GL1) Caffeic acid, Vitexin 
rhamnoside 
None None 
I. doka (ID1) None None None 
K. ivorensis (KS1/KS3) None None None 
K. senegalensis (KS2) None Catechin, Quercitrin, Rutin Procyanidin 
M. whitei (MW1) None None Isovanillin (2-hydroxy-4-methoxybenzaldehyde), Vanillin (3-
methoxy-4-hydroxybenzaldehyde), 6-methoxy-7- hydroxy 
coumarin, 6-methoxy-7,8-dihydroxy coumarin 
M. oleifera (MO1) None None Chlorogenic acid, Isoquercetin, Kaempferol glycoside, 
Rhamnetin, Vanillin 





Plant name (Sample ID) Phenolic standards detected 
in sample based on HPLC 
analysis* 
Phenolic standards undetected in the 
sample but known to be present in specie 
(Ref: Ezuruike and Prieto, 2014) 
Other phenolic compounds known to be present in specie 
(Ref: Ezuruike and Prieto, 2014) 
O. gratissimum (OG1) Caffeic acid Rutin, Vitexin Apigenin-7-O-glucosdie, Caffeoyl derivatives, Cichoric acid, 
Circiliol, Cirsimaritin, Isoquercetin, Isothymusin, Isovitexin, 
Kaempferol-3-O-rutinoside, Luteolin-5-O-glucoside, 
Luteolin-7-O-glucoside, Nevadensin, Rosmarinic acid, 
Vicenin-2 
P. nitida (PN1) None None None 
R. vomitoria (RV1) Gallic acid None Apigenin rhamnoside, Naringenin 
S. dulcis (SD1) Vitexin Luteolin, Quercetin Apigenin, Hispidulin, p-Coumaric acid 
S. longipedunculata (SL1) None Gallic acid, Caffeic acid, Epicatechin, 
Quercetin, Rutin 
Apigenin, Cinnamic acid, Chlorogenic acid, p-Coumaric acid, 
Sinapic acid, 3,4,5-tri-O-caffeoylquinic acid, 4,5-di-O-caffeic 
acid 
S. hispidus (SH1) None None None 
S. guineense (SG1) Gallic acid None None 
T. indica (TI1) None Luteolin, Vitexin Apigenin, Naringenin, Procyanidin B2, Vanillin 
T. bangwensis (ML1) Gallic acid Catechin, Epicatechin, Rutin Catechin-3-O-rhamnoside, Catechin-7-O-rhamnoside, 
Epicatechin gallate, Peltatoside, Quercetin-3-O-β-D-
glucopyranoside, 4-methoxy-catechin-7-O-rhamnoside 
§
T. avicennioides (TA1) None Ellagic acid Ellagic acid rhamnoside, Flavo-gallonic acid, Punicalagin 
(Shuaibu et al., 2008); Trimethyl gallic acid (Ekong and 
Idemudia, 1967) 
V. amygdalina (VA1) None Luteolin, Rutin Apigenin glucuronide, Caffeoylquinic acid, Chlorogenic acid, 
Luteolin-7-O-glucosdie, Luteolin-7-O-glucuronide, Luteolin-
7-O-rutinoside, Luteolin-4-O-rutinoside 
X. americana (XA1) Gallic acid Quercetin, Quercitrin Kaempferol-3-O-(6”-gallyolyl)-β-glucopyranoside, Quercetin-
3-O-(6”-gallyolyl)-β-glucopyranoside, Quercetin-3-O-β-
xylopyranoside 
The compounds highlighted in bold have not previously been reported in the plant species. 
§ TA1 isn’t reviewed in {Ezuruike and Prieto, 2014) so the references for its identified phenolic compounds are included in the table. 





A preliminary identification of phenolic compounds present in each plant sample was 
carried out by comparison of the Rt and UV spectra (Table 4.2). They were however a 
number of unidentified peaks present in most plant samples due to the absence of the 
appropriate phenolic standard (Appendix 5). Many of the phenolic standards detected in our 
plant samples are being reported in those species for the first time to the best of our 
knowledge (as indicated in bold in Table 4.2). At the same time, some phenolic standards 
which have previously been shown to be present in some of the plants were not detected in 
our samples. For example, HPLC analysis identified the presence of catechin and 
epicatechin in the leaves of A. senegalensis collected from Burkina Faso; and isoquercetin 
and rutin in samples collected from Togo (Potchoo et al., 2008). These four phenolic 
compounds were however not present in our stem-bark extract. 
It is very well known that the chemical composition of a plant including those of phenolic 
compounds vary greatly from one plant sample to another as well as between one plant part 
and another of the same sample. This is primarily because of the influence of a combination 
of genetic, environmental and edaphic factors such as condition of the soil, weather, season 
or time of day of harvesting, place and method of storage; as well as the extraction 
procedure employed (Peschel et al., 2013, Pandey and Rizvi, 2009). The absence of some of 
the previously identified standards could therefore be due to any of these reasons. In 
particular, the extraction method chosen for our samples was based on its traditional use and 
would not necessarily ensure the optimum extraction of polyphenols from the plant. 
The most common phenolic compound(s) detected in the plant samples was gallic acid 
and/or derivatives of gallic acid. One plausible reason for this might be that the detected 
compound could either be that of gallic acid itself as found in the plant species or a 
hydrolysis product of gallocatechins present in the plant. For example, from our analysis, 
some plant samples in which epigallocatechin was detected- Annona senegalensis and 
Anogeissus leiocarpus were also found to contain gallic acid. In addition, although previous 
reports have confirmed the presence of an epigallocatechin gallate in samples of Bridelia 
ferruginea, the phytochemical analysis of our sample identified only its hydrolysis products- 
gallic acid and epicatechin.  
Some plant samples – such as Anthocleista djalonensis, Aristolochia repens and Picralima 
nitida- have so far not been reported to contain any phenolic compounds. Our studies shown 
that indeed, their chromatograms present very few peaks consistent with phenolic 
compounds. This however does not imply that these species do not contain any phenolic 
compounds, but that these may be in very low amounts and yet to be identified. 
  





4.3.3 Antioxidant Effects of Plant Samples 
The maximum concentration tested for each of the plant extracts was 500µg/ml. At this 
concentration, only five plant extracts- AD1, AR1, CF1, MW1 and VA1 did not show any 
antioxidant effect in the two assays (Table 4.3). Most of the extracts (sixteen of them) 
produced some antioxidant activity in the DPPH assay but not in the nitric oxide scavenging 
assay; while the remaining eight extracts- AS1, BS1, DO1, KS1, KS3, KS2, ML1 and SG1 
produced good antioxidant activity in both the DPPH assay and the NO assay.  
All the eight extracts with activity in the NO assay produced greater antioxidant effect in the 
DPPH assay with lower IC50 values (< 20µg/ml), except for KS2 whose IC50 was 47.3 µg/ml. 
These results are not surprising given that the NO scavenging assay is a more selective assay 
compared to the DPPH assay. Whereas the presence of compounds with free labile hydrogen 
atoms is sufficient to produce good antioxidant effects in the DPPH assay, NO scavenging 
requires the presence of compounds that can out-compete its reaction with oxygen to form 
nitrite ions.   
It could therefore be proposed based on our results, that plant extracts with good NO 
scavenging effects such as the aforementioned eight extracts (and/or superoxide scavenging 
effects) are likely to be more beneficial antioxidants in hyperglycaemic states than those 
without. The relevance of NO in diabetes will be further discussed in Chapter 5. 
Four of the five extracts which did not produce any antioxidant effects in the DPPH or the 
NO assay- AD1, AR1, MW1 and VA1 were also samples in which no phenolic compounds 
were detected based on our phytochemical analysis (Table 4.2). As mentioned previously, 
this might be because the extraction method utilized did not ensure extraction of its 
antioxidant components. For instance, although our sample did not produce any antioxidant 
activity, in vitro antioxidant effects of polyphenol rich fractions of Vernonia amygdalina in 
free radical scavenging assays have previously been shown (Fasakin et al., 2011, Igile et al., 
1994).  
To further buttress this effect of extraction method on biological activity, the methanol 
extract of the leaves of Ocimum gratissimum has previously been shown to possess nitric 
oxide scavenging effects at < 250µg/ml as well as a higher DPPH radical scavenging activity  
with an IC50 of 12.3µg/ml (Awah and Verla, 2010). The aqueous extract of our sample on 
the other hand did not show any NO scavenging effect at > 500µg/ml and had a higher 
DPPH scavenging IC50 of 59µg/ml.  
  





Table 4.3: Tabular summary of IC50 of plant samples in Antioxidant assays 
Sample Name 
 
Sample ID  IC50 [µg/ml] in DPPH 
Mean ± SD (n = 3) 
IC50 [µg/ml] in NO 
Mean ± SD (n = 3) 
Alstonia boonei  AB 1 83.06 ± 2.63 > 500 
Annona senegalensis  AS 1 17.15 ± 4.76 39.50 ± 4.45 
Anogeissus leiocarpa  AL 1 80.19 ± 27.93 > 500 
Anthocleista djalonensis bark AD 1 > 500 > 500 
Anthocleista djalonensis root AD 2 214.44 ± 40.45 > 500 
Aristolochia repens  AR 1 > 500 > 500 
Bridelia ferruginea  BS 1 13.29 ± 6.29 43.34 ± 9.23 
Cassia sieberiana  CS 1 51.79 ± 2.00 > 500 
Cassytha filiformis  CF 1 > 500 > 500 
Daniellia ogea  DO 1 8.57 ± 1.11  168.49 ± 8.16 
Gongronema latifolium  GL 1 143.34 ± 10.84 > 500 
Isoberlinia doka  ID 1  40.14 ± 5.11 > 500 
Khaya ivorensis  KS1 10.87 ± 1.05 66.68 ± 3.94 
Khaya ivorensis  KS 3 10.35 ± 2.42 41.88 ± 8.41 
Khaya senegalensis  KS 2 47.30 ± 13.09 118.49 ± 20.41 
Tapinanthus bangwensis ML1 15.40 ± 4.21 91.93 ± 13.07 
Mondia whitei  MW 1 > 500 > 500 
Moringa oleifera MO 1 71.35 ± 6.53 > 500 
Ocimum gratissimum OG 1 59.02 ± 3.30 > 500 
Picralima nitida  PN 1 138.85 ± 15.95 > 500 
Rauvolfia vomitoria  RV 1 122.94 ± 26.69 > 500 
Scoparia dulcis  SD 1  80.00 ± 2.86 > 500 
Securidaca longipedunculata SL 1 291.50 ± 14.74 > 500 
Strophanthus hispidus  SH 1 117.45 ± 21.06 > 500 
Syzygium guineense  SG 1 15.10 ± 6.23 34.44 ± 3.95 
Tamarindus indica TI 1 70.01 ± 7.64 > 500 
Terminalia avicennioides  TA 1 33.18 ± 1.86 > 500 
Vernonia amygdalina                                                                                                                                                                                                                                                                                                                VA 1 > 500 > 500
Ximenia americana  XA 1 82.21 ± 2.59 > 500 
Caffeic Acid CA 0.41 ± 0.09  10.67 ± 2.30 
Gallic Acid GA 0.85 ± 0.14 20.875 ± 1.27 
 





Surprisingly, although we identified the presence of vitexin rhamnoside and gallic acid in 
Cassytha filiformis (CF1); in addition to other phenolic compounds that have been detected 
in the species, the plant sample did not produce any antioxidant effect at 500µg/ml. A 
comparison of the results of the phytochemical analysis and the antioxidant assays carried 
out on the plant samples therefore indicate that there is no correlation between the number of 
phenolic compounds detected in the sample and the observed antioxidant effects. One reason 
for this might be that the phenolic compounds though present, may be in such low amounts 
that no antioxidant effects may be seen. No quantification of the phenolic compounds was 
however carried out in this study to confirm this.  
It is however worthwhile to note that a higher amount of phenolic compounds in a plant 
sample may not necessarily translate to higher antioxidant activity. Another study in which a 
quantification of the phenolic compounds detected in different samples was carried out did 
not see a proportional relationship between the quantity of phenolic compounds detected and 
the antioxidant potential of the plant sample (Proestos et al., 2005).  
KS1 was the most active of all the samples in both antioxidant assays, but yet none of the 
phenolic standards was detected in our sample. There have also not been any previous 
reports of the identification of any phenolic compounds in that specie, although a 
phytochemical screening confirmed the presence of phenols in the leaves but not in the bark; 
and the absence of flavonoids in both the stem-bark and the leaves (Ibrahim et al., 2006). On 
the other hand, Khaya spp are known to contain a large number of limonoids, a class of 
triterpenoids (Roy and Saraf, 2006, Adesida et al., 1971). The antioxidant effects of 
limonoids found in Citrus spp. have been reported (Poulose et al., 2005, Yu et al., 2005). 
Thus, the presence of limonoids may account for the good antioxidant effects observed for 
Khaya ivorensis (KS1 and KS3) as well as Khaya senegalensis (KS2).  
These considerations further highlight the absence of a clear relationship between 
polyphenolic compounds and antioxidant effects.  
  





4.3.4 Neutral Red Uptake Assay for Determination of Cell 
Viability/Cytotoxicity 
The viability of the cells was determined after 24 hours incubation with either the plant 
extracts or drugs to be used in the different assays. 24 hours was selected as the maximum 
time of incubation since subsequent cellular assays to be conducted with the extracts were ≤ 
24 hours.  
Prior to evaluation of the extracts, the viability of the cells in the presence of different 
concentrations of hydrogen peroxide (H2O2) and/or dimethyl sulfoxide (DMSO) were 
determined (Figure 4.13). Polyphenols under certain cell culture conditions are known to 
bring about a generation of hydrogen peroxide (H2O2) in the culture media (Bellion et al., 
2009, Halliwell, 2003), which in themselves can be toxic to cells. DMSO on the other hand 
is commonly used a vehicle for drugs to be used in biological assays. It is however known to 
be toxic to cells above a given concentration.  
 
Figure 4.13: Viability of HepG2 & Caco-2 cells in the presence of different 
concentrations of H2O2 and/or DMSO. (Results show mean ± SEM, N ≥ 3) 
 





The cytotoxicity of the two compounds was therefore carried out in order to estimate the 
non-toxic concentration range. Either of these chemicals was subsequently included as 
positive controls during the cytotoxicity estimation of the extracts as validation for the assay. 
From the inhibitory dose response curve obtained for hydrogen peroxide in Caco-2 cells, if 
the extracts generate H2O2 levels above 100µM during the course of their incubation in cell 
culture, this might induce cytotoxic effects in the cells. However, Bellion et al. (2009) 
showed that 100µg/ml of the polyphenolic extracts of fruits generated ≤ 50 µM of H2O2 after 
24hours incubation in culture. One could therefore safely infer that the H2O2 generated by 
the incubation of ≤ 100µg/ml of any of the extracts would not be sufficient as to induce a 
cytotoxic effect on the Caco-2 cells. This is in addition to the presence of antioxidants in the 
samples that could also contribute to the breakdown of H2O2 further decreasing its toxicity. 
Similarly, the use of DMSO concentrations ≤ 1% would also not induce cytotoxic effects in 
the cells (Figure 4.13). 
The IC50 and MNTC values were determined for all the plant samples in the two different 
cell lines- HepG2 and Caco-2. This was to provide an indication of the cytotoxic nature of 
the collected plant samples. Given that the extracts are complex mixtures containing a 
myriad of phytoconstituents, the use of an inhibitory dose response curve to estimate both 
the IC50 and MNTC values would result in an over-estimation, in which the complex mixture 
is being subjected to a model intended for single pure compounds. Thus, the results obtained 
for the samples are expressed as range values as shown in Table 4.4, from which an 
approximate MNTC concentration was determined.  
A number of studies have identified the neutral red (NR) cytotoxicity assay as a sensitive in 
vitro assay for detecting early toxicity in cells (Fotakis and Timbrell, 2006, Weyermann et 
al., 2005). In addition, IC50 values obtained from in vitro NR assays gave a good correlation 
with in vivo LD50 values for some identified chemicals, with suggestions that the former can 
be a good predictor for in vivo acute toxicity (Konsoula and Barile, 2005). Thus, at IC50 
values of ≥ 100µg/ml and estimating a plasma volume of about 16L in an adult, most of the 
extracts would need to be taken in amounts greater than 1g in order to produce a toxic effect 
in vivo (Houghton et al., 2007). 
Most of the plant extracts were non-cytotoxic in HepG2 cells with approximate IC50 values ≥ 
200µg/ml except DO1, KS1, KS3, SH1 and TA1 which had IC50 values > 50µg/ml. Possible 
hepatotoxic effects of these five extracts have not been previously evaluated. However 
punicalagin which is a known component of TA1 has been shown to be hepatotoxic at high 
doses, bringing about elevation of serum AST and ALT levels (Lin et al., 2001).  





Table 4-4: Tabular summary of cytotoxicity of plant extracts in HepG2 and Caco-2 cells 
Plant name(s)
 
Sample ID Cytotoxicity HepG2 (µg/ml) Cytotoxicity Caco-2 (µg/ml) 
IC50 MNTC IC50 MNTC 
A. boonei AB1 > 500 > 500 31.25 < IC50 < 62.5 < 10 
A.senegalensis AS1 ≈ 500 ≥ 3.5 15.625 < IC50 < 62.5 < 10 
A.leiocarpa AL1 200< IC50 <500 15 < MNTC < 30 > 125 10 < MNTC < 31.25 
A.djalonensis AD1 > 500 1 < MNTC < 10 > 500 < 250 
 AD2 > 500 1 < MNTC < 10 > 500 < 1 
A. repens AR1  > 500 31.25 < MNTC < 62.5 > 500 ≥ 500 
B. ferruginea BS1 250 ≤ IC50 ≤ 500 ≥ 3.5 250 < IC50 < 500 ≤ 5 
C. sieberiana CS1 > 500 31.25 < MNTC < 62.5 ≥ 250 ≤ 1 
C. filiformis CF1 > 500 7.5 < MNTC < 15 > 500 ≤ 30 
D. ogea DO1 31.25 < IC50 < 62.5 < 2 > 500 < 0.1 
G. latifolium GL1 > 500 62.5 < MNTC < 125 ≤ 10 < 0.1 
I.doka ID1 > 500 < 1 > 500 > 500 
K.  ivorensis KS1 
KS3 
125 < IC50 ≤ 250 
62.5 < IC50 < 125 
62.5 < MNTC < 125 
31.25< MNTC < 62.5 
> 500 
IC50 > 500 
≥ 100 
> 500 
K. senegalensis KS2 >500 ≤ 5 100 < IC50 < 500 ≤ 50 
M. whitei MW1 >500 < 2 IC50  ≥ 500 ≤ 100 
M. oleifera MO1 >500 < 2 250 < IC50 < 500 < 5 
O. gratissimum OG1 >500 < 2 125 < IC50 < 500 < 0.5 
P. nitida PN1 
PN2 
250 < IC50 < 500 
250 < IC50 < 500 
125 < MNTC < 250 
62.5< MNTC<125 
250 < IC50 < 500 
IC50 ≥ 500 
125 < MNTC < 250 
≤ 1 
 







Sample ID Cytotoxicity HepG2 (µg/ml) Cytotoxicity Caco-2 (µg/ml) 
  IC50 MNTC IC50 MNTC 
R.vomitoria RV1 125< IC50 < 250 < 2 250 < IC50 < 500 ≤ 50 
S. dulcis SD1 >500 > 500 ≥ 500 ≤ 100 
S. hispidus SH1 31.25<IC50<125 < 2  ≤ 50 ≤ 1 
S. guineense SG1 >500 1 < MNTC < 10 250 < IC50 < 500 125 < MNTC < 250 
T. indica  TI1 >500 1 < MNTC < 30 IC50 ≥ 500 ≤ 100 
T. bangwensis ML1 >500 < 2  ≥ 500 ≤ 50 
T. avicennioides TA1 125 < IC50 < 250 1 < MNTC < 10 250 < IC50 < 500 ≤ 125 
V.amygdalina VA1 >500 62.5 < MNTC < 125 > 500 ≤ 0.5 
X. americana XA1 250< IC50<500 125 < MNTC < 250 > 500 ≤ 50 





On the other hand, although samples of Cassia sieberiana (CS1), Ocimum gratissimum 
(OG1) and Picralima nitida (PN1) did not show cytotoxic effects in the HepG2 cells, the 
stem bark and pods of CS1 (Obidah et al., 2009, Toma et al., 2009); the leaves of OG1 
(Ajibade et al., 2012, Onaolapo and Onaolapo, 2012); and stem-bark and fruit rind of PN1 
(Kouitcheu Mabeku et al., 2008, Fakeye et al., 2004) have been shown to produce 
hepatotoxic effects in vivo either at high doses or after chronic administration. 
Most of the extracts seemed to be more toxic to the Caco-2 cells, producing lower IC50 
values than that obtained in HepG2 cells. The only exceptions to this were Khaya ivorensis 
(KS1 & KS3) and Terminalia avicennioides (TA1) whose IC50 values were lower in Caco-2 
cells compared to HepG2 cells. However their IC50 values were not low enough as to suggest 
specific toxicity for hepatic cells compared to intestinal cells. Nonetheless, only four 
extracts- AB1, AS1, GL1 and SH1 produced IC50 values ≤ 100µg/ml in Caco-2 cells 
indicating a relative non-toxic profile for more than twenty of the collected plant samples.  
Although IC50 values are often the parameter used to estimate toxicity, one cannot overlook 
the obtained maximum non-toxic concentration (MNTC) values, particularly for extracts 
with values ≤ 1µg/ml, which is equivalent to approximately 10mg in vivo. It therefore 
requires that such plant extracts would need to be ingested in amounts less than 10mg so as 
not to produce any toxic effect. It is important to note here that several limitations (as 
mentioned in Chapter 1) can affect the estimation of the in vivo toxic profile of these extracts 
based on in vitro results. In addition, the cell lines used in this study are rapidly proliferating 
cancer cell lines and similar results may not be obtained when an evaluation of the toxicity 
profile is done in normal cells. 
In addition to being used to evaluate the toxic profile of the plant samples, the NR 
cytotoxicity assay was also used to estimate the concentration of the plant extracts to be used 
in subsequent assays. For extracts which gave MNTC concentrations ≥ 100µg/ml, this was 
used as the test concentration for the GSH assay in HepG2 cells, while the nearest lower 
approximate value was used for those with MNTC < 100µg/ml (Table 4.5).  
For cellular assays involving Caco-2 cells, all extracts were tested at 100µg/ml for the Rh-
123 efflux assay. Extracts which produced MNTC concentrations < 100µg/ml after a 24 
hour incubation were re-tested in a 4 hour incubation assay since the Rh-123 efflux assay 
and the transport assay require a two hour incubation of the extracts. At the end of the four 
hour incubation period, most extracts produced > 90% cell viability except AS1, AL1, BS1 
and DO1 which produced approximately 50% viability (Data not shown). 
  





4.3.5 Estimation of Intracellular Glutathione Levels in HepG2 Cells 
 The rate of change in the kinetic absorbance of TNB for the different GSH standard 
concentrations is linearly proportional to the amount of GSH in each sample. Thus, a graph 
plot of the slopes of each GSH standard concentration (I-slopes) against the GSH 
concentration, otherwise known as the F-slope curve can be used to estimate the amount of 
GSH in the treated wells given their individual I-slopes (Figure 4.14).  
 
 
Figure 4.14: Graph plot of the rate of change in TNB absorbance at the different GSH standard 
concentrations (a), which is used to estimate the amount of GSH in each sample from the 
obtained f-slope curve (b)  
 
 





The glutathione concentration obtained for the control cells was 26.66 ± 3.74 µM. Three of 
the extracts- the stem-bark of Khaya ivorensis obtained from Lagos and Ibadan (KS1 & 
KS3) as well as the stem-bark of Ximenia americana (XA1) decreased the intracellular GSH 
concentration beyond levels seen with the control cells to 21.23 ± 6.45 µM, 18.98 ± 7.66 µM 
and 17.84 ± 6.03 µM respectively. This decrease was found to be statistically significant 
(P<0.05). However, none of the decreases produced by the extracts were as much as that 
produced by the positive control BSO, which decreased intracellular GSH levels to 12.76 ± 
2.08 µM (P<0.0001) (Figure 4.15 and Table 4.5). 
 
Figure 4.15: Effect of 24-hour incubation of extracts at MNTC values on the intracellular GSH 
concentration in HepG2 cells. Only three extracts KS1, KS3 and XA1 produced a statistically 
significant (P<0.05) decrease in GSH concentrations based on a paired student’s t-test. (Results 
show Mean ± SEM, n ≥ 3) 
  





Table 4-5: Tabular summary of intracellular GSH concentrations in HepG2 cells in the 
presence and/or absence of extracts. (Results show mean ± SEM, n ≥ 3) 
Plant/Drug name (Sample ID) Conc (µg/ml) GSH (µM /10
5
 cells) 
Control  (Water) - 26.66 ± 3.74 
Alstonia boonei (AB1) 100 31.66 ± 6.86 
Annona senegalensis (AS1) 5 40.21 ± 7.29 
Anogeissus leiocarpa (AL1) 20 35.49 ± 4.83 
Anthocleista djalonensis (AD1) 
                                       (AD2) 
5 
5 
43.78 ± 5.28 
45.2 ± 7.1 
Aristolochia repens (AR1) 50 38.12 ± 8.3 
Bridelia ferruginea (BS1) 5 38.96 ± 4.98 
Cassia sieberiana (CS1) 50 37.45 ± 6.91 
Cassytha filiformis (CF1) 10 43.23 ± 5.45 
Daniellia ogea (DO1) 1 40.43 ± 5.58 
Gongronema latifolium (GL1) 100 30.74 ± 7.38 
Khaya ivorensis (KS1) 
                          (KS3) 
100 
50 
21.23 ± 6.45 
18.98 ± 7.66 
Khaya senegalensis (KS2) 1 45.2 ± 7.19 
Mondia whitei (MW1) 1 48.53 ± 8.94 
Moringa oleifera (MO1) 1 45.2 ± 12.22 
Ocimum gratissimum (OG1) 1 33.72 ± 9.71 
Picralima nitida (PN1) 
                          (PN2) 
100 
100 
37.78 ± 8.22 
38.93 ± 10.9 
Rauvolfia vomitoria (RV1) 1 45.2 ± 12.22 
Scoparia dulcis (SD1) 100 36.06 ± 6.4 
Securidaca longipedunculata (SL1) 10 34.06 ± 4.61 
Strophanthus hispidus (SH1) 1 25.66 ± 6.41 
Syzygium guineense (SG1) 5 29.64 ± 6.1 
Tamarindus indica (TI1) 20 39.83 ± 2.25 
Tapinanthus bangwensis (ML1) 1 37 ± 5.81 
Terminalia avicennioides (TA1) 5 29.71 ± 9.43 
Vernonia amygdalina (VA1) 100 37.13 ± 5.8 
Ximenia americana (XA1) 100 17.84 ± 6.03 
Buthionine sulfoximine (BSO)  10µM 12.76 ± 2.08 
 





Reduced glutathione plays a very important role in decreasing xenobiotics-induced toxicity 
in cells. Thus depletion of intracellular GSH levels can result in an exacerbation of toxicity 
in the cells. Buthionine sulfoximine (BSO) which was used as the positive control in the 
assay brings about a depletion of intracellular GSH levels by inhibiting γ-glutamylcysteine 
synthetase (γ-GCS), one of the enzymes needed for intracellular GSH synthesis (Drew and 
Miners, 1984). As expected, BSO (10µM) depleted the intracellular GSH levels in the 
HepG2 cells by over 50% compared to control (Table 4.5).  
Although the mechanism by which KS1, KS3 and XA1 depleted the intracellular GSH levels 
is not known, their presence in cells have the potential to enhance xenobiotics-induced 
toxicity, especially when co-administered with drugs requiring glutathione-S-transferases 
(GSTs) for their detoxification. In addition, they also pose an additional risk of worsening 
hyperglycaemia-induced oxidative stress conditions in diabetic patients. This would 
however depend on the overall effect of the extracts on other intracellular antioxidant 
enzymes.  
The intracellular GSH-depletion effect of KS1 & KS3 was quite surprising given that they 
have previously been shown to be potent nitric oxide (NO) scavengers (Table 4.3). It has 
previously been shown that depletion of intracellular GSH levels significantly increases NO-
mediated cytotoxicity (Walker et al., 1995). In this regard, one would have expected an 
increase in GSH levels to be partly responsible for its NO-scavenging effects but this was 
not the case. Thus the expected theoretical protection of KS1 and KS3 against this radical is 
offset by the depletion of intracellular GSH levels. This highlights the risk of minimalistic 
marketing approaches focusing on the idea that “antioxidant plants” are healthy without a 
better understanding of the other biological effects of the plant.  
Apart from KS1, KS3 and XA1, the other extracts increased the intracellular GSH 
concentration above the levels seen with the control cells after 24 hours incubation, although 
these increases were not statistically significant. It has previously been mentioned that 
incubation of extracts containing polyphenols brings about an increase in extracellular H2O2 
levels in cell culture but not in vivo, which could in turn result in an induction of 
intracellular antioxidant enzymes (Bellion et al., 2009). It is therefore possible that the 
observed increased GSH levels may be partly due to this and should not necessarily be 
extrapolated to in vivo conditions without further investigation.  





4.3.6 Modulation of P-Glycoprotein Dependent Rhodamine-123 Efflux in 
Caco-2 Cells 
By culturing wild type Caco-2 cells in increasing concentrations of vincristine over a period 
of time, P-gp expression can be induced in cells with previously low levels of P-gp (Eneroth 
et al., 2001). The intracellular accumulation of P-gp substrates is inversely proportional to 
the activity of the transporter in these P-gp expressing cells. Cells with higher P-gp 
expression have a higher efflux activity for P-gp substrates resulting in lower intracellular 
concentration. Similarly, the addition of a P-gp inhibitor will limit its efflux activity with a 
resultant increase in intracellular concentration of the P-gp substrate. 
 
Figure 4.16: Effect of increased P-gp expression and presence of a P-gp inhibitor on the 
intracellular concentration of a P-gp substrate in Caco-2 WT and Caco-2 VCR cells. (Results 
show mean ± S.D, N ≥ 2). Statistical significance based on a paired T-test. 
 
To confirm this, we measured the intracellular rhodamine (Rh-123) fluorescence in both 
Caco-2 WT and Caco-2 VCR cells incubated for two hours with 5µg/ml Rh-123 in the 
presence or absence of 20µM verapamil as described in section 4.2.7. As shown in Figure 
4.16, the intracellular Rh-123 fluorescence measured in relative fluorescence units (RFU) 
was lower in the Caco-2 VCR cells compared to Caco-2 WT cells. Addition of verapamil 
brought about an increase in intracellular Rh-123 fluorescence in both the Caco-2 VCR and 
the Caco-2 WT cells. 





Table 4-6: Effect of plant extracts on intracellular Rh-123 accumulation in Caco-2 VCR and 
Caco-2 WT cells. 
Plant/Drug name (Sample ID) Intracellular  Rh-123 Fluorescence ( % of control) 
 Caco-2 VCR (N ≥ 3) Caco-2 WT (N ≥ 2) 
VERAPAMIL 176 ± 47 163 ± 32 
Alstonia boonei (AB1) 95 ± 5 87 ± 3 
Anthocliesta djalonensis (AD1) 88 ± 11 106 ± 44 
Anogeissus leiocarpus (AL1) 108 ± 15 80 ± 20 
Aristolochia repens (AR1) 125 ± 22 118  ± 10 
Annona senegalensis AS1) 278 ± 136 185  ± 91 
Bridelia ferruginea (BS1) 564 ± 124 397  ± 81 
Cassytha filiformis (CF1) 180 ± 10 150  ± 40 
Cassia sieberiana (CS1) 159 ± 23 138  ± 35 
Daniellia ogea (DO1) 299 ± 39 274  ± 95 
Gongronema latifolium (GL1) 99 ± 4 79  ± 2 
Isoberlinia doka (ID1) 165 ± 42 89  ± 47 
Khaya ivorensis (KS1) 285 ± 54 208  ± 89 
Khaya ivorensis (KS3) 288 ± 53 228  ± 72 
Khaya senegalensis (KS2) 126 ± 10 89  ± 13 
Moringa oleifera (MO1) 122 ± 12 88  ± 88 
Mondia whitei (MW1) 109 ± 7 113  ± 32 
Ocimum gratissimum (OG1) 110 ± 9 99 * 
Picralima nitida (PN1) 121 ± 7 115  ± 34 
Picralima nitida (PN2) 122 ± 4 91  ± 1 
Rauvolfia vomitoria (RV1) 106 ± 8                                      101 ± 23 
Scoparia dulcis (SD1) 113 ± 30 92  ± 0 
Syzygium guineense (SG1) 224 ± 52 251  ± 49 
Strophanthus hispidus (SH1) 120 ± 46 98  ± 26 
Securidaca longipedunculata (SL1) 112 ± 27 105* 
Tamarindus indica (TI1) 116 ± 27 90  ± 13 
Tapinanthus bangwensis (ML1) 116 ± 5 121* 
Terminalia avicennioides (TA1) 224 ± 49 142  ± 27 
Vernonia amygdalina (VA1) 107 ± 17 112  ± 15 
Ximenia americana (XA1) 447 ± 97 412  ± 54 
* Results for these extracts are based on data from only one experiment. 
 





To identify extracts that modulate P-gp efflux activity, Rh-123 was co-incubated with 
100µg/ml of each extract for two hours in both Caco-2 WT and Caco-2 VCR cells, and the 
intracellular Rh-123 fluorescence determined after cell lysis. Cells were also incubated with 
20µM verapamil as positive control while cells with only Rh-123 served as negative control.  
The percentage change in Rh-123 fluorescence relative to the fluorescence in the control 
cells after co-incubation with most of the extracts was greater in Caco-2 VCR cells 
compared to Caco-2 WT cells (Table 4.6). This indicates increased                                                                                                                                                                                                                                                                                                                   
P-gp efflux activity in the vincristine resistant cells, such that modulation of the efflux 
transporter resulted in a greater change in intracellular Rh-123 accumulation.   
 
 
Figure 4.17: Increased intracellular Rh-123 concentration in Caco-2 cells (WT and VCR) in the 
presence of either extracts or 20µM verapamil. (Resuts show mean ± SD, N ≥ 3. One-way 
ANOVA  followed by Bonferroni’s post test was carried out to determine significance of 





































































Nine extracts- Annona senegalensis (AS1), Bridelia ferruginea (BS1), Cassytha filiformis 
(CF1), Daniellia ogea (DO1), Khaya ivorensis (KS1 & KS3), Syzygium guineense (SG1), 
Terminalia avicennioides (TA1) and Ximenia americana (XA1) produced a change in 
intracellular accumulation of Rh-123 which was significantly different from control in the 
Caco-2 VCR cells but not necessarily in the Caco-2 WT cells. Similar to the effect of the 
positive control verapamil, these extracts increased the percentage Rh-123 fluorescence 
(Figure 4.17) which suggests that all the extracts are acting as P-gp inhibitors. 
In Caco-2 VCR cells, the highest observed inhibitory effect was produced by BS1 with more 
than 500% increase in Rh-123 accumulation compared to control cells followed by XA1 
with more than 400% increase. These inhibitory effects of BS1 and XA1 were 3-fold and 2-
fold that produced by the positive control verapamil. Such high changes in intracellular Rh-
123 accumulation by plant extracts are not uncommon. A similar study carried out with the 
stem bark extract of Mangifera indica produced a 1000% increase in intracellular Rh-123 
accumulation (Chieli et al., 2009). 
Not all of the nine extracts however produced a significant change in Rh-123 accumulation 
in Caco-2 WT cells. AS1, CF1 and TA1 produced a P-gp inhibitory effect in the VCR 
resistant cells but not in the WT cells. These results are not surprising as various studies 
have only been able to identify modulators of the P-gp efflux transporter when using 
modified cell lines with increased P-gp activity but not with the wild type cells (Taub et al., 
2005, Lee et al., 1994). The modulatory effect of SG1 was however quite surprising given 
that it produced a greater change in intracellular rhodamine accumulation in the WT cells 
than in the VCR cells, both of which were significant. The reason for this is still unclear 
although it is quite possible that the increased intracellular Rh-123 accumulation due to SG1 
(and possibly for some of the extracts) may not be as a result of a direct inhibition of P-gp as 
other tests are necessary to confirm this. 
Finally, different concentrations (100µg, 50 µg, 10 µg and 5 µg) of the active extracts were 
co-incubated with Rh-123 to determine if the proposed interaction with P-gp was dose-
dependent. As shown in Figure 4.18, most of the extracts except CF1 and SG1 produced a 
dose-dependent inhibition of P-gp activity, although the intracellular Rh-123 fluorescence at 
5µg/ml and 10µg/ml for all the extracts were not significantly different from those of the 
control cells at 100% (statistical error bars not shown). 
 






Figure 4.18: Effect of different concentrations of extracts on the intracellular Rh-123 


















































4.3.7 Effects of the P-Gp Modulatory Extracts on Glibenclamide Transport in 
Caco-2 Monolayers 
A number of studies have identified glibenclamide as a substrate and inhibitor of P-gp in P-
gp over expressing cell lines (Gedeon et al., 2006, Golstein et al., 1999). In line with this, 
clarithromycin (a known P-gp inhibitor) altered the pharmacokinetics of glibenclamide in 
healthy subjects by increasing its peak plasma concentration (Cmax) and area under the 
plasma concentration-time curve (AUC) by 1.25 and 1.35 fold respectively (Lilja et al., 
2007); indicating a potential risk of P-gp induced DDI. This transport study was therefore 
carried out to assess the potential for HDIs between the extracts previously identified as P-
gp modulators in the Rh-123 accumulation assay and glibenclamide when both are co-
administered by diabetic patients. 
To evaluate the effects of the co-incubated extracts on the permeability and transport of 
glibenclamide, three parameters were measured- the TEER value before and after the 
transport experiment and the apparent permeability of the paracellular marker FD4 across 
the Caco-2 monolayers; as well as the apparent permeability of glibenclamide across the 
monolayer. The first two measurements were carried out to monitor the effect of the extracts 
on the integrity of the monolayer, which could in turn affect glibenclamide transport; while 
the last measurement was for direct estimation of its effect on glibenclamide transport. 
The maturation of tight junctions during differentiation of Caco-2 cells grown in vitro is a 
crucial factor for its use as a model for intestinal drug permeability and transport. Various 
studies recommend the use of cells that have been grown in a monolayer for at least 21 days 
for transport experiments based on evidence of morphological changes related to cellular 
differentiation (Hilgers et al., 1990). A decrease in the permeability of the cell monolayer is 
an indicator for tight junction maturation and can be monitored by measuring the TEER 
values of the monolayer over several days (Ranaldi et al., 2003).  
To confirm tight junction formation and maturation as well as readiness of the monolayer for 
transport experiments, TEER values were monitored at least once a week up to Day 26. As 
shown in Figure 4.19, a steady increase in TEER values was observed for the Caco-2 cells 
grown on monolayers with values of over 400Ωcm2 eighteen days post–seeding. Only 
monolayers whose TEER values were ≥ 300Ωcm2 after growing for a minimum of 21 days 
were subsequently used for the assay. 





               
Figure 4.19: TEER values of Caco-2 cells during differentiation when grown in monolayers. 
(Each point represents the mean ± SD, N ≥ 10 for cells plated out on two different days). 
 
In bi-directional transport experiments, P-gp substrates are confirmed by comparing 
apparent permeability in the apical to basolateral (AP-BL) direction with that in the 
basolateral to apical (BL-AP) direction. Compounds with efflux ratio (Papp (BL-AP)/Papp 
(AP-BL) greater than 2 to 3 are typically identified as P-gp substrates (Balimane et al., 
2006). This study obtained an average efflux ratio of 2.4 for glibenclamide, thereby 
confirming it as a P-gp substrate (Table 4.7). This is the first time glibenclamide is 
experimentally confirmed as a P-gp substrate in a bi-directional transport model. 
A typical P-gp inhibitor would decrease the efflux of the P-gp substrate, thereby decreasing 
the permeability in the efflux direction or secretory permeability or Papp (BL-AP) while 
increasing the absorptive permeability Papp (AP-BL). This change in the Papp of both 
directions would ultimately result in a decreased efflux ratio. As shown in table 4.7, 
verapamil the control P-gp inhibitor decreased the Papp (BL-AP) of glibenclamide from 6.3 
x 10
-5
 cm/s to 4.62 x 10
-5
 cm/s, and increased its Papp (AP-BL) from 2.65 x 10
-5
 cm/s to 
4.03 x 10
-5
 cm/s, thereby decreasing its efflux ratio from 2.38 to 1.13, thus confirming its 
effect in a bi-directional transport model as a P-gp inhibitor.  





Table 4-7: Tabular summary of the effects of extracts on the Papp values of glibenclamide and FD4 and the change in TEER values after 2 hours transport 
experiments in Caco-2 monolayers. 
Sample Direction of transport % of Initial TEER Papp Glib (x 10
-5
 cm/s) Efflux ratio (Glib) Papp FD4 (x 10
-6 
cm/s) 
 Glib only (10µM) AP-BL 
BL-AP 
67 ± 17 





Glib (10µM) + VP (20µM)   AP-BL 
BL-AP 
63 ± 38 





Glib 10µM + AS1(50µg/ml)  AP-BL 
BL-AP 
48 ± 13 





Glib (10µM) + BS1 (50µg/ml)  AP-BL 
BL-AP 
44 ± 13 





Glib (10µM) + CF1 (100µg/ml)  AP-BL 
BL-AP 
70 ± 28 





Glib (10µM) + DO1 (50µg/ml)  AP-BL 
BL-AP 
45 ± 31 





Glib (10µM) + KS1 (100µg/ml)  AP-BL 
BL-AP 
26 ± 9 





Glib (10µM) + SG1 (100µg/ml) AP-BL 
BL-AP 
53 ± 23 





Glib (10µM) + TA1 (100µg/ml) AP-BL 
BL-AP 
25 ± 17 





Glib (10µM) + XA1 (100µg/ml) AP-BL 
BL-AP 
28 ± 13 
25 ± 27 




ND- Not determined 
 





Contrary to expectation that all the modulated extracts would be identified as P-gp inhibitors 
since they increased intracellular Rh-123 concentration, only two of the extracts- SG1 and 
TA1 produced a similar effect as verapamil. They both increased the Papp (AP-BL) of 
glibenclamide to 3.38 and 3.06 x 10-5 cm/s respectively and decreased the Papp (AP-BL) of 
glibenclamide to 5.7 and 5.56 x 10-5 cm/s respectively. Asides for its possible P-gp 
inhibitory effect, TA1 also produced a greater effect on membrane permeability with 
possible opening of tight junctions, evidenced by its increased Papp (AP-BL) transport of 
FD4 and a higher change in TEER values compared to glibenclamide alone. This would in 
turn contribute to the increased Papp (AP-BL) seen with glibenclamide.  
Although it was assumed that an increase in intracellular Rh-123 concentration was possibly 
due to a P-gp modulatory effect, it has now been shown using the bidirectional transport 
assay that this may not necessarily be so. An increase in paracellular permeability due to an 
opening of tight junctions as evidenced by an increase in TEER values and/or increase in 
Papp (AP-BL) of a marker for paracellular transport such as FD4 could also result in 
increased intracellular concentration. This might be a possible explanation for the previously 
‘assumed’ P-gp modulatory effects for some of the extracts which were not confirmed in the 
bidirectional transport assay.  
For instance, although KS1 increased the Papp (AP-BL) of glibenclamide from 2.65– 5.6 x 
10
-5
 cm/s, the Papp (BL-AP) also increased very slightly from 6.13 x 10
-5
 cm/s to 6.6 x 10
-5
 
cm/s; and there was also a decrease in TEER values to approximately 20% of initial value 
with KS1 as opposed to approximately 60% of initial value with glibenclamide alone. 
However, these assumptions would need to be clarified using other appropriate assays. 
These studies have however highlighted the possibility of obtaining false positives in the 
identification of P-gp modulators simply based on in vitro intracellular accumulation assays. 
 





5 GENERAL DISCUSSION  
  






Despite increasing drug production by the pharmaceutical industry, the availability of 
conventional medicines continues to remain one of the challenges of healthcare provision all 
over the world. This is primarily because of the grave inequity in medicine access between 
countries due to cost-related factors, particularly for new medicines wherein the price of the 
drug is determined by the patent holder (Laing et al., 2003). At the same time, a large 
percentage of the world’s population including those living in urban areas with better access 
to modern healthcare systems do not consider conventional medicines as the ‘sole’ solution 
to their healthcare problems due to their cultural beliefs and values (van Andel and Westers, 
2010). In these contexts, the use of traditional systems of medicine in disease management 
will continue to flourish. 
Although there has been increasing advocacy for the integration of traditional medicine 
practice into modern healthcare systems, there are several identified dilemmas that make this 
very challenging, one of which is the selection of medicinal plants with the greatest potential 
as herbal medicines. A number of ethnobotanical surveys previously carried out in different 
parts of Nigeria have highlighted the availability of a large number of plants for diabetes 
management in Nigeria. The pharmacological and/or toxicological evidence available for 
these medicinal plants were however ‘scattered’ and not readily available to patients, 
healthcare practitioners and researchers to make a thorough assessment of their beneficial 
and toxic effects in diabetes management.  
A data-mining of a hundred and fifteen plants which met the criteria for either 
ethnobotanical and/or pharmacological evidence was carried out to provide a useful resource 
for harnessing the therapeutic benefits of these herbal medicines as a first step towards the 
possible integration of traditional medicine in the Nigerian healthcare system. This resource 
is freely available as an open access paper which would be beneficial in Nigeria but also in 
the wider continent because of the overlap between plant use within and outside Nigeria in 
the management of various diseases (as shown in Table 1, Appendix 1). 
In conventional systems of medicine, the risks of drug-drug interactions (DDIs) have 
become higher with the practice of poly-pharmacy. A prudent approach which is now 
routinely adopted in drug development is to obtain sufficient mechanistic knowledge about 
individual drugs that would in turn enable better prediction of these DDIs and forestall 
adverse reactions (Delgoda and Westlake, 2004). Similarly, for patients whose preference 
would be to integrate the use of herbal medicines alongside their conventional treatment, the 
risk of HDIs is an inevitable feature that should be considered. Just as the awareness of the 
potential risk of DDIs does not prohibit the practice of poly-pharmacy, the potential risk 





HDIs should also not preclude the co-administration of herbal medicines alongside 
prescription drugs by patients who choose to do so. On the other hand, a thorough 
assessment of the benefits and limitations of integrating both forms of treatment as it relates 
to the overall therapeutic goal needs to be considered. 
This PhD thesis is therefore a step forward to evaluate potential herb-drug interactions in 
Nigeria with a focus on diabetic patients, given that accurate prediction of HDIs is best done 
in the context of co-administered prescription drugs with a view to promoting their 
integration into the healthcare system. A thorough evaluation of herb-drug interactions in 
diabetes management in Nigeria will be incomplete if it only sought to identify their 
potential harmful risks, more so since the same herbal medicine could bring about a positive 
HDI with one drug and a negative HDI with another. The implications of the results of this 
PhD research will therefore be discussed both in the context of the beneficial outcomes of 
the identified HDIs as well as their possible risks.  
5.2 CLINICAL IMPLICATIONS OF IDENTIFIED HERB DRUG 
INTERACTIONS 
A number of in vivo and/or in vitro experimental evidence of the hypoglycaemic effects 
validating the use of most of the medicinal plants used in diabetes management in Nigeria 
are available. There are however much fewer reports about clinical studies on these plants 
which would be an important confirmatory evidence of its clinical benefit in humans.  
The clinical study of Phyllanthus amarus is a case in point whereby the expected 
hypoglycaemic effect was not observed in type-2 diabetic patients when extracts of the plant 
were administered as a substitute to their oral hypoglycaemic agents (Moshi et al., 2001). On 
the other hand, clinical evidence of improved glycaemic control in patients who co-
administered a hypoglycaemic herbal medicine alongside their oral hypoglycaemic drug 
compared to those on oral hypoglycaemic drugs alone have been observed for Momordica 
charanthia (Leatherdale et al., 1981); and a combination of Rauvolfia vomitoria and Citrus 
aurantium (Campbell-Tofte et al., 2011). It is therefore possible that better glycaemic 
control might also be observed in patients who co-administer Phyllanthus amarus with their 
oral hypoglycaemic agents, but this needs to be clinically evaluated. 
These two studies provide some evidence wherein a patient can obtain a beneficial HDI 
when a herbal medicine is co-administered with conventional drugs. It is important to 
emphasize that these would not necessarily be the case for all hypoglycaemic herb-drug 
combinations. On the other hand, while some might result in negative pharmacodynamic 
HDI due to hypoglycaemia, others may not even produce any improved glycaemia compared 





to the intake of oral hypoglycaemic drugs alone. It is on this basis that suggestions have been 
made in Chapter 2 that a concerted effort should be made to clinically validate the beneficial 
effects of these herbal medicines with particular focus on those commonly taken by patients 
as part of their diet. One strategy that can be employed in the design of such studies is to 
take into consideration the identified mechanism of action as a means of incorporating a 
possible synergistic effect. By doing this, untoward pharmacodynamic HDI can also be 
identified, which could be addressed with an appropriate dose adjustment. 
The assessment of potential pharmacokinetic herb-drug interactions that may arise from the 
combined use of herbal medicines and prescription drugs in diabetes management is equally 
as important as the evaluation of its clinical efficacy. Approximately forty of the plants 
assessed in Chapter 2 have in vitro interactions with known pharmacokinetic parameters, 
with some interacting with with more than one parameter. Morinda lucida in particular has 
been shown to inhibit P-gp efflux as well as cytochrome and GST enzymes. More 
importantly, some of these identified plants- Vernonia amygdalina, Mangifera indica and 
Phyllanthus amarus are currently being co-administered by diabetic patients with 
prescription drugs with overlapping pharmacokinetic effects as identified during the field 
work (Chapter 3). These brings to immediate attention those plants that would require 
further evaluation to confirm the presence or not of clinically relevant HDIs. 
The results of the field work also provide evidence that the use of more than one prescription 
drug in the therapeutic management of diabetes either for glycaemic control or the 
management of other diabetes-related co-morbidities is quite common. There are multiple 
implications of these- both for the additional burden that this could cause to these patients in 
the long term particularly in regard to prescription costs; as well as the associated risk of 
untoward HDIs for patients who co-administer herbal medicines alongside.  
This work also highlights the paucity of experimental evidence for potential 
pharmacokinetic HDIs for herbal medicines used in Nigeria as well as the high prevalence of 
use of unidentified herbal medicines, another factor that can hamper the identification and/or 
prediction of clinically relevant HDIs. One of the means undertaken in this PhD research to 
address this was to evaluate the effect of a number of medicinal plants collected during the 
field work in a number of in vitro assays that would provide information about potential 
pharmacokinetic interaction and/ or toxicological risks.  
The hypothesis of oxidative stress as the pathogenic mechanism linking insulin resistance 
with dysfunction of both beta cells and endothelium, and eventually leading to clinical 
diabetes and cardiovascular disease has been gaining credibility during the last decade. It has 
also been suggested as a possible reason wherein treating cardiovascular risk with drugs 





such as calcium channel blockers, ACE inhibitors, AT-1 receptor antagonists, and statins - 
compounds which show intracellular preventive antioxidant activity- have resulted in a 
decrease in the onset of new cases of diabetes (Ceriello and Motz, 2004, Robertson et al., 
2004).  
High glucose levels have been shown to increase nitric oxide (NO) synthesis and superoxide 
(O2
-
) production through the activation of protein kinase C both in vitro and in an in vivo 
experimental diabetes model (Hink et al., 2001). These two radicals (NO and O2
-
) react very 
quickly to form peroxynitrite resulting in nitrosative stress. The toxic effect of peroxynitrite 
is dependent on the presence of carbon dioxide (CO2) which is readily present in 
physiological conditions. Its rate of reaction with CO2 is so fast to prevent sufficient 
scavenging of the molecule itself. Therefore, it has been proposed that scavenging 
peroxynitrite is not realistic and a more rational approach would be to prevent superoxide 
and NO reacting in the first place (Squadrito and Pryor, 1998).  
It could therefore be proposed that extracts with specific NO (as identified in Table 4.3, such 
as the stem bark of Syzygium guineense) and/or superoxide scavenging effects could 
mitigate against this toxicological risk and be beneficial antioxidants in hyperglycaemic 
conditions. It is important to note that the benefits of nitric oxide scavengers would only be 
in conditions of oxidative stress whereby they readily react with superoxide to form 
peroxynitrite. This is because NO also known as endothelium derived relaxing factor 
(EDRF)- is an important biological messenger necessary for maintaining the integrity of 
blood vessels by vasodilatation (Hink et al., 2001). Thus NO scavenging in non-diabetic 
conditions may be counterproductive. Further work would also look at the ability of these 
plant extracts to scavenge superoxide as this has been proposed as a more suitable way to 
prevent peroxynitrite formation (Squadrito and Pryor, 1998). 
In addition, GSH in concert with GSH-dependent enzymes have been identified as one of the 
body’s mechanism of ensuring a regulated defence against oxidative stress (Hayes and 
McLellan, 1999). In this regard, although none of our extracts produced significant increase 
in intracellular GSH levels, the intake of those which decreased intracellular GSH levels 
should be discouraged (Table 4.5). Extracts of Khaya ivorensis (KS1 and KS3) is a case in 
point, which although identified as good NO scavengers also depleted intracellular GSH 
levels and would not be recommended as being beneficial for oxidative stress.  
Thus, the true benefit of extracts with good NO and/or O2
- 
scavenging effects in oxidative 
stress conditions in diabetic patients would need to be evaluated in the context of their 
effects on other physiologic antioxidant defence mechanisms. By doing this, the possible 
role of the co-administration of these herbal medicines not just to enhance glycaemic control 





in patients but also to limit the incidence of these vascular related complications can be 
assessed. This is particularly important in Nigeria since studies have shown that the high 
mortality amongst diabetic patients is largely due to poor blood glucose control and the 
associated vascular related complications (Chijioke et al., 2010). 
Furthermore, the potential pharmacokinetic interaction of the collected medicinal plants on 
the efflux activity of P-glycoprotein; as well as a further evaluation of their effects on 
intestinal glibenclamide transport, a known P-gp substrate and the second most prescribed 
anti-diabetic drug in Nigeria was undertaken. Nine extracts were originally identified as 
possible P-gp modulators based on the intracellular Rh-123 accumulation assay (Table 4.6, 
Figure 4.18). However, further evaluation in a bi-directional transport model across Caco-2 
monolayers indicates that only two of these- Syzygium guineense (SG1) and Terminalia 
avicennioides (TA1) could actually be modulating P-gp activity in an inhibitory capacity 
similar to verapamil.  
Although the clinical implication of the P-gp inhibitory effect of these two extracts on 
glibenclamide bioavailability can only best be assessed in an in vivo study in humans, it 
could be suggested that its effects on glibenclamide bioavailability is likely to be minimal. 
This is because the extracts only caused a slight increase in the absorptive apparent 
permeability of glibenclamide. With a borderline efflux ratio of 2.38, glibenclamide would 
only be considered as a moderate P-gp substrate such that the P-gp inhibition of the extracts 
did not bring about a significant change in its apparent permeability. As this is the first time 
the identity of glibenclamide as a P-gp substrate based on a bi-directional transport model is 
being carried out, a comparison of the effect of well known P-gp inhibitors on the Papp of 
glibenclamide alongside other P-gp substrates with higher efflux ratios would therefore need 
to be carried out to ensure a thorough assessment. 
Finally, although the other extracts did not exhibit the expected characteristics of P-gp 
modulators in the bi-directional transport, they could still modulate intestinal drug transport 
through their effects on tight junctions as monitored by TEER values and paracellular 
permeability of FD4. Ximenia americana (XA1) is a case in point which further decreased 
TEER to less than 30% of its initial value as well as increased the apparent permeability of 
the paracellular marker FD4 (Table 4.7). Further experiments would be needed to confirm 
this especially as decrease in TEER values have been identified as a cytotoxic mechanism 
that could potentially affect intestinal drug absorption (Narai et al., 1997).  





5.3 THE WAY FORWARD 
Given that only a small percentage of in vitro identified pharmacokinetic HDIs have so far 
produced a significant clinical effect, the evaluation carried out in this thesis is meant to 
serve as a guide for active therapeutic monitoring by healthcare practitioners in order to 
obtain clinical evidence of these HDIs when and if they occur. For this to be achieved, the 
extension of the pharmacovigilance monitoring system in Nigeria to herbal medicines, with 
the co-operation of both healthcare practitioners and traditional medicine practitioners 
(TMPs) is warranted (Shaw et al., 2012). 
A very detailed study investigating views about the safety of herbal medicines and hence the 
need for pharmacovigilance monitoring for herbal medicines amongst TMPs and those 
involved in the sale of herbal medicinal products in different parts of Lagos state was carried 
out. Unfortunately, almost 90% of the respondents (including Pharmacists) considered 
herbal medicines to be safe and without side effects (Awodele et al., 2013). This isn’t very 
surprising given that the highest percentage of herbal medicines used in Nigeria is 
preparations by the herbalists themselves and TMPs would be unlikely to attribute any 
harmful effects to their preparations.  
On the other hand, studies have shown that the increase in popularity or interest in 
alternative/herbal medicine for the prevention and treatment of various illnesses has also 
brought some concerns and fears over the professionalism of practitioners, as well as on the 
quality, efficacy and safety of the ‘natural’ formulations available in the market with reports 
of adulteration. There is therefore a need to not only promote the awareness but also 
improve channels of communication for pharmacovigilance reporting especially since the 
knowledge and practice of pharmacovigilance monitoring in Nigeria amongst healthcare 
providers in general is below average (Osakwe et al., 2013). Community pharmacists in 
particular can play a very useful role in this regard given that they are usually patients’ first 
point of contact as a cost- and time-saving alternative to visiting hospitals. 
Finally, there is an urgent need for better regulation of herbal medicines beyond the 
standards that are currently in practice in Nigeria. This would entail increased registration of 
herbal medicinal products as well as the regulation of the TMPs themselves especially with 
regards to their prepared formulations and the various channels of distribution. The 
verification of identified clinical evidence of HDIs can only be done alongside a qualitative 
and quantitative analysis of the phytochemical content of the herbal medicine in question. 
Thus, these aforementioned improved regulation steps would help to enhance the quality and 
safety of herbal medicines in circulation.  




It is well known that a large number of medicinal plants are available and are also being 
utilised as herbal medicines in Nigeria for diabetes management. This PhD research is 
however the first time that a data mining of all the experimental evidence available for these 
herbal medicines is being carried out to highlight not only their pharmacological benefits, 
but also their toxicological effects. This has been done to provide a useful resource for 
harnessing the therapeutic benefits of these herbal medicines as a first step towards the 
possible integration of traditional medicine in the Nigerian healthcare system. 
Secondly, this is the first time a field work study has been carried out in Nigeria specifically 
aimed at assessing the risks of pharmacokinetic herb-drug interactions amongst diabetic 
patients in Nigeria. By doing this, herbal medicines and prescription drugs with overlapping 
pharmacokinetic effects which are currently being co-administered by patients have been 
identified. Further monitoring would therefore be required to confirm the presence or not of 
clinically relevant HDIs. 
Thirdly, this work has also highlighted the paucity of experimental evidence for predicting 
potential pharmacokinetic herb-drug interactions in Nigeria; and to address this has 
evaluated for the first time the possible interaction of a select number of these medicinal 
plants on the efflux activity of P-glycoprotein with further evaluation of its effects on 
glibenclamide, a P-gp substrate commonly administered to diabetic patients. A lot more 
work is still required to fully evaluate medicinal plants used in Nigeria for potential risks of 
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APPENDIX 1:  
JOURNAL OF ETHNOPHARMACOLOGY PAPER 
APPENDIX 4:  
QUESTIONNAIRE USED TO INTERVIEW DIABETIC PATIENTS AND 
TRADITIONAL MEDICINE PRACTITIONERS 
 
GENERAL INFORMATION FROM ALL RESPONDENTS 
 
 Name of Individual:  
 Sex of Individual:  
 Town of birth/Tribe: 
 Town where they live:  
 Age of Individual (15-30, 30-45, 45-60, Above 60):  
 Languages spoken:  




 When did you start receiving treatment for diabetes?  
 How do you prefer to treat diabetes (with medications and/or remedies)?  
 What medications do you take?  
 How do you obtain the medications that you take?  
 What herbal remedies do you take?  
 How do you obtain the herbal remedies that you take?  
 Do you sometimes skip doses of any of the above mentioned means of 
treatment?  
 Why if at all do you skip doses?  
 What treatment do you consider more effective (or do you prefer)?  
 Have you (or someone you know) had any adverse reaction during diabetes 
treatment OR what is your most common complaint during diabetes 
treatment?  
 Any co-morbidity?  
 What is your average monthly cost of either treatment? 
GENERAL INFORMATION FROM ALL RESPONDENTS 
 
 Name of Individual:  
 Sex of Individual:  
 Town of birth:  
 Town where they live:  
 Age of Individual (15-30, 30-45, 45-60, Above 60):  
 Languages spoken:  
 Occupation (main and others):  
 
QUESTIONS FOR HERBALISTS 
 
 What is your understanding of diabetes?  
 What are the symptoms that you associate with diabetes or that you look out 
for before you consider an individual as a patient?  
 What are the plant parts effective against diabetes & How do you treat it (with 
plants, medications and/or rituals)?  
 What is the form of preparation for these anti-diabetic formulations (Raw, 
decoction, maceration, infusion, Toast/Roast, Fermentation, Others (specify)?  
 How is the preparation administered (oral, topical, injectable)?  
 Are there other measures/conditions that are important for the success of your 
treatment (such as diet, spiritual well-being etc)?  
 What is the duration of treatment on the average for each patient? What is the 
cost of treatment?  
 
APPENDIX 5: HPLC UV/VIS OF ANALYSED PLANT SAMPLES 
SHOWING THE FINGERPRINT CHROMATOGRAMS AND 
SPECTRA OF IDENTIFIED PHENOLIC COMPOUNDS 
 
Spectra of Quercitrin in AB1
Quercitrin standard
Annona senegalensis bark AS1










